Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific B4GALNT3 B4GalNac-T3, FLJ16224, FLJ40362 ENSG00000139044 Beta-1,4-N-acetyl-galactosaminyl transferase 3 12 460364-563509 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA011404 Approved Supported Golgi apparatus
Vesicles Endometrial cancer:1.69e-10 (favourable) Mixed Tissue enhanced stomach: 69.0 colon: 22.0 P2RX4 P2X4 ENSG00000135124 Purinergic receptor P2X, ligand gated ion channel, 4 12 121209857-121234106 Predicted membrane proteins, Transporters Evidence at protein level HPA039494 Approved Approved Actin filaments
Cytosol Endometrial cancer:6.30e-10 (favourable) Expressed in all Mixed placenta: 33.5 SPDEF bA375E1.3, PDEF ENSG00000124664 SAM pointed domain containing ETS transcription factor 6 34537802-34556333 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055707 Supported Nucleus
Nucleoli Endometrial cancer:9.26e-9 (favourable) Group enriched Tissue enhanced prostate: 154.8 breast,cervix, uterine: 42.1 SCGB2A1 LPHC, MGB2, MGC71973, UGB3 ENSG00000124939 Secretoglobin, family 2A, member 1 11 62208668-62213939 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA034584 Supported Endometrial cancer:1.54e-8 (favourable), Colorectal cancer:1.22e-4 (favourable), Renal cancer:6.36e-4 (favourable) Group enriched Group enriched 6 cervix, uterine: 2835.4;epididymis: 1634.2 fallopian tube: 376.7 DHRS7B CGI-93, DKFZp566O084, MGC8916, SDR32C1 ENSG00000109016 Dehydrogenase/reductase (SDR family) member 7B 17 21123364-21193265 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012132, HPA016873 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.4 PLPP2 LPP2, PAP-2c, PPAP2C ENSG00000141934 Phospholipid phosphatase 2 19 281040-291504 Enzymes, Predicted membrane proteins Evidence at protein level HPA055540 Uncertain Approved Mitochondria Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 126.8 cervix, uterine: 91.2 NXNL2 C9orf121 ENSG00000130045 Nucleoredoxin-like 2 9 88535101-88584274 Predicted intracellular proteins Evidence at transcript level HPA045526 Uncertain Approved Cytosol Endometrial cancer:3.83e-8 (favourable), Breast cancer:6.53e-4 (favourable), Renal cancer:9.60e-4 (favourable) Group enriched Mixed adipose tissue: 8.1 SMDT1 C22orf32, DDDD, dJ186O1.1, EMRE ENSG00000183172 Single-pass membrane protein with aspartate-rich tail 1 22 42079691-42084284 Predicted membrane proteins, Transporters Evidence at protein level HPA032117, HPA060340 Uncertain Supported Nucleus
Mitochondria Renal cancer:2.36e-9 (favourable), Endometrial cancer:5.32e-8 (favourable), Pancreatic cancer:5.87e-4 (favourable) Expressed in all Expressed in all thyroid gland: 7.8 SLC47A1 FLJ10847, MATE1 ENSG00000142494 Solute carrier family 47 (multidrug and toxin extrusion), member 1 17 19495385-19579034 Predicted membrane proteins, Transporters Evidence at protein level HPA021987 Supported Endometrial cancer:5.54e-8 (favourable), Renal cancer:1.06e-5 (favourable), Lung cancer:1.88e-5 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 139.0;kidney: 105.0 liver: 55.2 HEXA ENSG00000213614 Hexosaminidase A (alpha polypeptide) 15 72340919-72376476 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA054583 Supported Endometrial cancer:5.63e-8 (favourable) Expressed in all Expressed in all epididymis: 197.5 PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Supported Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 95.8;endometrium: 171.3;fallopian tube: 52.8;smooth muscle: 113.5 ovary: 19.4 STX18 Ufe1 ENSG00000168818 Syntaxin 18 4 4415742-4542346 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003019 Approved Approved Plasma membrane Endometrial cancer:6.33e-8 (favourable), Colorectal cancer:2.84e-4 (favourable), Urothelial cancer:4.69e-4 (favourable), Renal cancer:7.03e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 181.9 ATPIF1 ATPI, ATPIP, IP, MGC1167, MGC8898 ENSG00000130770 ATPase inhibitory factor 1 1 28236109-28246906 Predicted intracellular proteins Evidence at protein level HPA027999 Supported Validated Mitochondria Endometrial cancer:6.38e-8 (favourable), Ovarian cancer:8.20e-4 (favourable) Expressed in all Expressed in all heart muscle: 357.7 DRAM1 DRAM, FLJ11259 ENSG00000136048 DNA-damage regulated autophagy modulator 1 12 101877351-102012130 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:6.52e-8 (favourable), Renal cancer:3.91e-4 (unfavourable) Expressed in all Expressed in all lung: 133.6 SPAG4 CT127, SUN4 ENSG00000061656 Sperm associated antigen 4 20 35615892-35621049 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048393, HPA061789 Approved Endometrial cancer:9.52e-8 (favourable), Colorectal cancer:1.09e-5 (unfavourable), Glioma:8.89e-5 (unfavourable), Renal cancer:1.28e-4 (unfavourable), Urothelial cancer:6.66e-4 (favourable) Expressed in all Mixed testis: 22.6 SCGB2A2 MGB1, MGC71974, UGB2 ENSG00000110484 Secretoglobin, family 2A, member 2 11 62270155-62273156 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB026270 Supported Endometrial cancer:9.57e-8 (favourable) Tissue enriched Tissue enriched 7 breast: 3633.4 cervix, uterine: 504.4 ZAP70 SRK, STD, ZAP-70 ENSG00000115085 Zeta-chain (TCR) associated protein kinase 70kDa 2 97713560-97739862 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002625, HPA003134 Supported Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable) Mixed Tissue enhanced appendix: 37.7;lymph node: 65.2;spleen: 38.3 tonsil: 16.9 GPR108 LUSTR2 ENSG00000125734 G protein-coupled receptor 108 19 6729914-6737603 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041924, HPA041951, HPA063863 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 73.7 MSX1 HOX7, HYD1, OFC5 ENSG00000163132 Msh homeobox 1 4 4859666-4863936 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB026198, HPA063895, HPA073604 Supported Supported Nucleoplasm Endometrial cancer:1.64e-7 (favourable), Renal cancer:1.18e-5 (unfavourable) Tissue enriched Group enriched 6 cervix, uterine: 60.9;endometrium: 23.8 adipose tissue: 6.7 SERINC2 FKSG84, PRO0899, TDE2, TDE2L ENSG00000168528 Serine incorporator 2 1 31409565-31434680 Predicted membrane proteins Evidence at protein level HPA005974 Approved Endometrial cancer:1.69e-7 (favourable), Liver cancer:2.11e-4 (unfavourable), Lung cancer:5.70e-4 (unfavourable) Expressed in all Mixed urinary bladder: 138.8 HMG20B BRAF25, BRAF35, HMGX2, HMGXB2, SMARCE1r, SOXL ENSG00000064961 High mobility group 20B 19 3572777-3579088 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA050220, HPA053157, HPA069832 Approved Validated Nucleoplasm Endometrial cancer:1.72e-7 (favourable), Urothelial cancer:2.89e-5 (favourable) Expressed in all Expressed in all prostate: 64.9 CD3D T3D ENSG00000167286 CD3d molecule, delta (CD3-TCR complex) 11 118338954-118342744 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013055 Supported Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable) Expressed in all Tissue enhanced lymph node: 202.6;tonsil: 124.1 appendix: 90.4 CCDC159 ENSG00000183401 Coiled-coil domain containing 159 19 11344684-11354944 Predicted intracellular proteins Evidence at protein level HPA047126, HPA054655 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Endometrial cancer:1.87e-7 (favourable), Pancreatic cancer:1.42e-4 (favourable), Urothelial cancer:8.62e-4 (favourable), Ovarian cancer:9.46e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 64.3 KIAA1324 EIG121, maba1 ENSG00000116299 KIAA1324 1 109113679-109206781 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029869, HPA070749 Supported Supported Plasma membrane Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable) Mixed Mixed cervix, uterine: 128.0 CRELD2 MGC11256 ENSG00000184164 Cysteine-rich with EGF-like domains 2 22 49918167-49927540 Predicted secreted proteins Evidence at protein level HPA000603, CAB025604 Approved Renal cancer:1.34e-9 (unfavourable), Endometrial cancer:2.42e-7 (favourable) Expressed in all Expressed in all thyroid gland: 94.0 IER5 ENSG00000162783 Immediate early response 5 1 181088712-181092899 Predicted intracellular proteins Evidence at protein level HPA029894 Uncertain Approved Supported Nucleus
Nucleoli Endometrial cancer:2.42e-7 (favourable), Lung cancer:1.18e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable) Expressed in all Mixed bone marrow: 31.2 SAMM50 CGI-51, OMP85, SAM50, TOB55, TRG-3, YNL026W ENSG00000100347 SAMM50 sorting and assembly machinery component 22 43955421-44010531 Predicted intracellular proteins, Transporters Evidence at protein level HPA034537 Supported Validated Mitochondria Renal cancer:4.43e-8 (favourable), Endometrial cancer:2.63e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 237.7 TRPM4 FLJ20041 ENSG00000130529 Transient receptor potential cation channel, subfamily M, member 4 19 49157741-49211836 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA041169 Supported Supported Nucleoplasm
Plasma membrane Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable) Expressed in all Mixed colon: 27.5 C15orf65 FLJ27352 ENSG00000261652 Chromosome 15 open reading frame 65 15 55408548-55418764 Cancer-related genes, Predicted intracellular proteins Evidence at transcript level HPA067189 Approved Approved Nucleus
Cytosol Endometrial cancer:3.18e-7 (favourable) Expressed in all Mixed testis: 16.8 VPS39 KIAA0770, VAM6 ENSG00000166887 Vacuolar protein sorting 39 homolog (S. cerevisiae) 15 42158701-42208316 Plasma proteins, Predicted intracellular proteins Evidence at protein level Endometrial cancer:3.21e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 64.4 SLC25A35 FLJ40217 ENSG00000125434 Solute carrier family 25, member 35 17 8287763-8295343 Predicted membrane proteins, Transporters Evidence at protein level HPA051720 Uncertain Approved Vesicles
Mitochondria Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable) Expressed in all Mixed testis: 19.6 KDM4B JMJD2B, KIAA0876, TDRD14B ENSG00000127663 Lysine (K)-specific demethylase 4B 19 4969113-5153595 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062872 Supported Nucleus
Cytosol Endometrial cancer:4.25e-7 (favourable), Melanoma:2.13e-4 (unfavourable), Colorectal cancer:2.74e-4 (unfavourable), Breast cancer:7.39e-4 (favourable) Expressed in all Expressed in all thyroid gland: 19.8 MDM2 HDM2, MGC5370 ENSG00000135679 MDM2 proto-oncogene, E3 ubiquitin protein ligase 12 68808172-68850686 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB000086, CAB016303 Supported Supported Nucleus Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable) Expressed in all Expressed in all rectum: 44.3 FZD10 CD350 ENSG00000111432 Frizzled class receptor 10 12 130162459-130165740 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014484, HPA014485 Uncertain Supported Nucleoplasm Endometrial cancer:5.05e-7 (favourable) Mixed Tissue enhanced cervix, uterine: 9.3;esophagus: 8.8 skin: 5.6 RILPL2 FLJ30380, FLJ32372, MGC7036 ENSG00000150977 Rab interacting lysosomal protein-like 2 12 123410683-123436717 Predicted intracellular proteins Evidence at protein level HPA028958 Uncertain Supported Cytosol Endometrial cancer:5.24e-7 (favourable) Expressed in all Mixed bone marrow: 21.6 ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Supported Approved Nucleus
Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.4;cervix, uterine: 127.3;endometrium: 179.7;fallopian tube: 105.5;smooth muscle: 75.9 seminal vesicle: 13.5 ANAPC4 APC4 ENSG00000053900 Anaphase promoting complex subunit 4 4 25377213-25418498 Predicted intracellular proteins Evidence at protein level CAB032519, HPA038395, HPA038396 Approved Approved Intermediate filaments Endometrial cancer:5.73e-7 (favourable), Urothelial cancer:1.12e-6 (favourable), Renal cancer:1.17e-5 (unfavourable), Head and neck cancer:1.95e-4 (favourable) Expressed in all Expressed in all fallopian tube: 54.6 CEACAM1 BGP, BGP1, CD66a ENSG00000079385 Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 19 42507304-42561234 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002146, HPA011041 Supported Endometrial cancer:6.32e-7 (favourable) Mixed Tissue enhanced colon: 205.9;rectum: 132.8 esophagus: 46.7 MYDGF C19orf10, IL-25, IL-27, IL25, IL27, IL27w, R33729_1, SF20 ENSG00000074842 Myeloid-derived growth factor 19 4641374-4670370 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041872, HPA046744 Approved Renal cancer:4.99e-12 (unfavourable), Endometrial cancer:6.50e-7 (favourable) Expressed in all Expressed in all epididymis: 132.3 SYTL1 exophilin-7, FLJ14996, JFC1, SLP1 ENSG00000142765 Synaptotagmin-like 1 1 27342020-27353937 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037825 Approved Endometrial cancer:6.83e-7 (favourable), Renal cancer:1.12e-5 (unfavourable) Mixed Mixed skin: 69.1 B4GALT1 beta4Gal-T1, GGTB2 ENSG00000086062 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 9 33104082-33167356 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA010806, HPA010807 Supported Validated Golgi apparatus Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 138.8 RPS6KA1 HU-1, p90Rsk, RSK, RSK1 ENSG00000117676 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 1 26529761-26575030 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003852, HPA007981 Approved Supported Nucleus
Cytosol Endometrial cancer:7.20e-7 (favourable), Renal cancer:1.84e-4 (favourable), Stomach cancer:4.58e-4 (favourable), Urothelial cancer:8.33e-4 (favourable) Expressed in all Mixed small intestine: 39.7 LYRM1 A211C6.1 ENSG00000102897 LYR motif containing 1 16 20899868-20925006 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA059840 Supported Nucleoplasm
Midbody Endometrial cancer:7.48e-7 (favourable), Renal cancer:4.80e-4 (unfavourable), Urothelial cancer:9.50e-4 (favourable) Expressed in all Expressed in all testis: 70.0 CD8B CD8B1 ENSG00000172116 CD8b molecule 2 86815339-86861924 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004353, HPA029164 Approved Supported Plasma membrane Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable) Mixed Tissue enhanced cervix, uterine: 60.5;lymph node: 40.2 parathyroid gland: 22.4 GLYATL2 BXMAS2-10, MGC24009 ENSG00000156689 Glycine-N-acyltransferase-like 2 11 58834065-58904215 Enzymes, Predicted intracellular proteins Evidence at protein level HPA060292, HPA065454 Uncertain Approved Mitochondria Endometrial cancer:9.05e-7 (favourable) Tissue enhanced Group enriched 6 breast: 14.1;cervix, uterine: 27.3;gallbladder: 11.0 salivary gland: 3.0 TMEM62 FLJ23375 ENSG00000137842 Transmembrane protein 62 15 43123279-43185146 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044461, HPA062359 Approved Approved Nucleus
Nucleoli fibrillar center
Nuclear bodies
Cytoplasmic bodies Endometrial cancer:9.72e-7 (favourable) Expressed in all Expressed in all breast: 27.2 SIRPG bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma ENSG00000089012 Signal-regulatory protein gamma 20 1629152-1657779 CD markers, Predicted membrane proteins Evidence at protein level Melanoma:7.36e-7 (favourable), Endometrial cancer:1.05e-6 (favourable), Renal cancer:1.47e-6 (unfavourable), Head and neck cancer:2.24e-4 (favourable) Mixed Tissue enhanced lymph node: 39.4;tonsil: 26.8 appendix: 17.6 IDNK bA522I20.2, C9orf103 ENSG00000148057 IdnK, gluconokinase homolog (E. coli) 9 83623049-83644130 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA020378, HPA058429 Approved Approved Mitochondria
Cytosol Endometrial cancer:1.10e-6 (favourable) Expressed in all Mixed kidney: 50.2 WFS1 DFNA14, DFNA38, DFNA6, DIDMOAD, WFS ENSG00000109501 Wolfram syndrome 1 (wolframin) 4 6269849-6303265 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029128 Approved Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable) Expressed in all Mixed ovary: 61.4 FAM189A2 C9orf61, X123 ENSG00000135063 Family with sequence similarity 189, member A2 9 69324572-69392455 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029411, HPA057207 Approved Endometrial cancer:1.16e-6 (favourable), Renal cancer:1.75e-5 (favourable) Tissue enhanced Tissue enhanced thyroid gland: 100.5 cervix, uterine: 64.0 ZDHHC1 C16orf1, HSU90653, ZNF377 ENSG00000159714 Zinc finger, DHHC-type containing 1 16 67394419-67416833 Enzymes, Predicted membrane proteins Evidence at transcript level HPA042531, HPA048659 Uncertain Approved Cytosol Endometrial cancer:1.25e-6 (favourable), Renal cancer:1.55e-6 (favourable), Pancreatic cancer:5.99e-4 (favourable) Expressed in all Mixed fallopian tube: 31.4 PLEKHM1 KIAA0356 ENSG00000225190 Pleckstrin homology domain containing, family M (with RUN domain) member 1 17 45435900-45490749 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA025018, HPA039473 Approved Supported Nucleoli
Vesicles Endometrial cancer:1.28e-6 (favourable), Liver cancer:3.25e-4 (unfavourable) Expressed in all Mixed esophagus: 11.9 SEC16A KIAA0310, p250, Sec16L ENSG00000148396 SEC16 homolog A, endoplasmic reticulum export factor 9 136440096-136483759 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005684 Supported Supported Endoplasmic reticulum
Golgi apparatus Endometrial cancer:1.30e-6 (favourable), Renal cancer:4.47e-4 (favourable) Expressed in all Expressed in all stomach: 26.6 MOB3A MOB-LAK, MOB1C, MOBKL2A, moblak ENSG00000172081 MOB kinase activator 3A 19 2071038-2096673 Predicted intracellular proteins Evidence at protein level HPA057744 Uncertain Intermediate filaments
Cytosol Endometrial cancer:1.33e-6 (favourable), Renal cancer:1.93e-4 (unfavourable) Expressed in all Expressed in all lymph node: 86.5 IL20RA IL-20R1, ZCYTOR7 ENSG00000016402 Interleukin 20 receptor, alpha 6 136999971-137045180 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB024990, HPA042281 Approved Approved Cytosol Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable) Mixed Tissue enhanced skin: 45.1 breast: 33.2 KCNK6 K2p6.1, TWIK-2 ENSG00000099337 Potassium channel, two pore domain subfamily K, member 6 19 38319844-38332076 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022637, HPA040184 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Endometrial cancer:1.45e-6 (favourable), Renal cancer:1.04e-5 (unfavourable) Expressed in all Mixed endometrium: 22.8 GNB5 GB5 ENSG00000069966 Guanine nucleotide binding protein (G protein), beta 5 15 52115105-52191369 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB032353, HPA041942, HPA044198 Uncertain Approved Nuclear speckles
Centrosome
Rods & Rings Renal cancer:3.32e-11 (favourable), Endometrial cancer:1.47e-6 (favourable) Expressed in all Mixed parathyroid gland: 73.1 NFIC CTF, CTF5, NF-I, NFI ENSG00000141905 Nuclear factor I/C (CCAAT-binding transcription factor) 19 3359563-3469217 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004300, CAB004674, HPA052625 Supported Validated Nucleus
Nucleoli fibrillar center Endometrial cancer:1.52e-6 (favourable) Expressed in all Expressed in all skeletal muscle: 68.9 C1orf64 ERRF, MGC24047 ENSG00000183888 Chromosome 1 open reading frame 64 1 16004236-16008807 Predicted intracellular proteins Evidence at transcript level HPA026676 Uncertain Approved Nucleoplasm Endometrial cancer:1.68e-6 (favourable) Tissue enhanced Tissue enhanced breast: 7.0 cervix, uterine: 3.7 EEF2 EEF-2, EF2 ENSG00000167658 Eukaryotic translation elongation factor 2 19 3976056-3985469 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007795, HPA040534, HPA057351 Approved Validated Plasma membrane
Cytosol Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable) Expressed in all Expressed in all ovary: 1621.9 TJP3 ZO-3 ENSG00000105289 Tight junction protein 3 19 3708109-3750813 Predicted intracellular proteins Evidence at protein level CAB013244, HPA046863, HPA053337 Supported Validated Nucleoplasm
Cell Junctions Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable) Mixed Tissue enhanced duodenum: 42.7;small intestine: 42.1 colon: 31.1 SIT1 SIT ENSG00000137078 Signaling threshold regulating transmembrane adaptor 1 9 35649295-35650950 Predicted membrane proteins Evidence at protein level HPA018506 Supported Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable) Mixed Group enriched 5 appendix: 25.6;lymph node: 56.9;spleen: 22.3;tonsil: 30.9 urinary bladder: 6.3 GZMH CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2 ENSG00000100450 Granzyme H (cathepsin G-like 2, protein h-CCPX) 14 24606480-24609699 Enzymes, Predicted secreted proteins Evidence at protein level HPA029200 Supported Renal cancer:1.74e-6 (unfavourable), Endometrial cancer:2.00e-6 (favourable) Expressed in all Tissue enhanced spleen: 35.8 lymph node: 25.9 CCL22 A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1 ENSG00000102962 Chemokine (C-C motif) ligand 22 16 57358772-57366190 Predicted secreted proteins Evidence at protein level Endometrial cancer:2.23e-6 (favourable), Head and neck cancer:9.17e-5 (favourable), Colorectal cancer:2.98e-4 (favourable) Mixed Tissue enhanced appendix: 19.2;tonsil: 14.1 skin: 7.9 CD3E ENSG00000198851 CD3e molecule, epsilon (CD3-TCR complex) 11 118304545-118316175 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000010, HPA040957, HPA043955, CAB072863, CAB072864 Supported Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 203.4;tonsil: 118.2 appendix: 97.3 LTB p33, TNFC, TNFSF3 ENSG00000227507 Lymphotoxin beta (TNF superfamily, member 3) 6 31580525-31582522 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048884 Approved Approved Centrosome Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable) Expressed in all Group enriched 8 appendix: 19.4;lymph node: 22.5;spleen: 26.4;tonsil: 10.6 bone marrow: 2.6 NUDT18 FLJ22494, MTH3 ENSG00000275074 Nudix (nucleoside diphosphate linked moiety X)-type motif 18 8 22106872-22109419 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028581, HPA030125 Approved Supported Nucleoplasm
Golgi apparatus Endometrial cancer:2.49e-6 (favourable), Cervical cancer:1.43e-4 (favourable), Pancreatic cancer:2.47e-4 (favourable), Renal cancer:8.30e-4 (favourable) Expressed in all Mixed epididymis: 16.0 FAM149A DKFZP564J102, MST119, MSTP119 ENSG00000109794 Family with sequence similarity 149, member A 4 186104419-186172667 Predicted intracellular proteins Evidence at protein level HPA055004 Uncertain Approved Nucleus Endometrial cancer:2.67e-6 (favourable) Mixed Mixed kidney: 36.8 RHBDD3 C22orf3, PTAG ENSG00000100263 Rhomboid domain containing 3 22 29259852-29268209 Predicted membrane proteins Evidence at protein level HPA043979 Approved Approved Microtubules Endometrial cancer:2.67e-6 (favourable), Renal cancer:2.24e-4 (unfavourable) Expressed in all Mixed testis: 10.5 NCMAP C1orf130, FLJ42528, MP11 ENSG00000184454 Noncompact myelin associated protein 1 24556111-24609328 Predicted membrane proteins Evidence at transcript level HPA013656 Uncertain Endometrial cancer:2.83e-6 (favourable) Mixed Tissue enhanced gallbladder: 11.5 thyroid gland: 7.1 LCK ENSG00000182866 LCK proto-oncogene, Src family tyrosine kinase 1 32251239-32286165 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003494, CAB003816 Supported Approved Golgi apparatus Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable) Mixed Tissue enhanced appendix: 68.8;lymph node: 127.7;tonsil: 75.1 spleen: 55.2 TTC38 FLJ20699 ENSG00000075234 Tetratricopeptide repeat domain 38 22 46267961-46294008 Predicted intracellular proteins Evidence at protein level HPA029302 Approved Approved Cytosol Endometrial cancer:3.21e-6 (favourable) Expressed in all Expressed in all small intestine: 90.1 ELAC2 FLJ10530, HPC2 ENSG00000006744 ElaC ribonuclease Z 2 17 12992391-13018187 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019535 Approved Validated Nucleoplasm Endometrial cancer:3.24e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 53.9 PAFAH2 HSD-PLA2 ENSG00000158006 Platelet-activating factor acetylhydrolase 2, 40kDa 1 25959767-25998157 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018157 Approved Renal cancer:0.00e+0 (favourable), Endometrial cancer:3.28e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 28.6 GALNT10 GalNAc-T10 ENSG00000164574 Polypeptide N-acetylgalactosaminyltransferase 10 5 154190730-154420984 Enzymes, Predicted secreted proteins Evidence at protein level HPA007525 Approved Approved Nucleoplasm
Golgi apparatus
Plasma membrane Endometrial cancer:3.33e-6 (favourable), Ovarian cancer:5.69e-4 (unfavourable) Expressed in all Expressed in all ovary: 81.4 TXN TRX ENSG00000136810 Thioredoxin 9 110243811-110256640 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008678, HPA047478, HPA055752 Supported Validated Nucleus
Nucleoli
Cytosol Endometrial cancer:3.40e-6 (favourable) Expressed in all Expressed in all esophagus: 705.8 EXPH5 SLAC2-B ENSG00000110723 Exophilin 5 11 108505431-108593738 Disease related genes, Predicted intracellular proteins Evidence at protein level Endometrial cancer:3.42e-6 (favourable), Head and neck cancer:1.46e-4 (favourable), Renal cancer:2.43e-4 (favourable), Lung cancer:5.12e-4 (favourable) Mixed Tissue enhanced skin: 31.3 parathyroid gland: 15.9 CXCR3 CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR ENSG00000186810 Chemokine (C-X-C motif) receptor 3 X 71615916-71618517 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA045942 Supported Renal cancer:1.67e-6 (unfavourable), Endometrial cancer:3.44e-6 (favourable), Melanoma:2.90e-4 (favourable), Head and neck cancer:3.35e-4 (favourable) Mixed Tissue enhanced lymph node: 18.1 spleen: 8.9 SCGB1D2 LIPB, LPHB ENSG00000124935 Secretoglobin, family 1D, member 2 11 62242210-62244808 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA035318 Approved Endometrial cancer:3.46e-6 (favourable), Renal cancer:8.03e-6 (favourable) Group enriched Group enriched 9 breast: 1426.3;cervix, uterine: 5141.6 epididymis: 377.9 ZG16B HRPE773, JCLN2, PRO1567 ENSG00000162078 Zymogen granule protein 16B 16 2830169-2839585 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041125, HPA053549 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:3.48e-6 (favourable) Tissue enhanced Tissue enriched 210 salivary gland: 19669.3 prostate: 93.6 FAM57A CT120, FLJ22282 ENSG00000167695 Family with sequence similarity 57, member A 17 732412-742972 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:3.53e-6 (favourable), Renal cancer:1.44e-4 (unfavourable) Expressed in all Tissue enhanced skin: 82.8 esophagus: 26.0 ASB2 ASB-2 ENSG00000100628 Ankyrin repeat and SOCS box containing 2 14 93934153-93976791 Predicted intracellular proteins Evidence at protein level Endometrial cancer:3.62e-6 (favourable) Mixed Tissue enhanced skeletal muscle: 85.9 smooth muscle: 25.3 IHH BDA1, HHG2 ENSG00000163501 Indian hedgehog 2 219054420-219060467 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:3.67e-6 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 8.8;colon: 21.4;duodenum: 15.3;endometrium: 31.4;rectum: 16.9;small intestine: 16.8;stomach: 15.6 appendix,prostate: 3.1 NMRK1 bA235O14.2, C9orf95, FLJ20559, NRK1 ENSG00000106733 Nicotinamide riboside kinase 1 9 75060573-75088217 Enzymes, Predicted intracellular proteins Evidence at protein level HPA049795 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:3.70e-6 (favourable), Renal cancer:5.60e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 118.5 GBP5 ENSG00000154451 Guanylate binding protein 5 1 89258950-89272804 Predicted intracellular proteins Evidence at protein level HPA028656 Approved Approved Endoplasmic reticulum Renal cancer:5.53e-8 (unfavourable), Endometrial cancer:3.73e-6 (favourable), Ovarian cancer:1.24e-4 (favourable), Colorectal cancer:9.54e-4 (favourable) Expressed in all Tissue enhanced appendix: 103.3 lymph node: 61.2 SCAMP4 FLJ33847 ENSG00000227500 Secretory carrier membrane protein 4 19 1905214-1926013 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043284 Approved Approved Golgi apparatus
Vesicles
Lipid droplets
Plasma membrane Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable) Expressed in all Expressed in all fallopian tube: 58.6 PARVG ENSG00000138964 Parvin, gamma 22 44172956-44219533 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031833, HPA031834 Uncertain Renal cancer:3.43e-6 (unfavourable), Endometrial cancer:4.44e-6 (favourable) Expressed in all Tissue enhanced spleen: 39.1 appendix: 36.8 ANO1 DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A ENSG00000131620 Anoctamin 1, calcium activated chloride channel 11 70078302-70189528 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032148 Supported Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 217.7;seminal vesicle: 295.7 skin: 116.0 DIO2 SelY, TXDI2 ENSG00000211448 Deiodinase, iodothyronine, type II 14 80197527-80387757 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029544, HPA048002 Supported Nucleoplasm
Cytosol Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 268.3;thyroid gland: 599.1 esophagus: 70.6 LRRC26 bA350O14.10 ENSG00000184709 Leucine rich repeat containing 26 9 137168758-137170051 Predicted membrane proteins Evidence at protein level HPA056312 Approved Supported Plasma membrane Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable) Tissue enriched Group enriched 6 colon: 10.5;prostate: 29.3;salivary gland: 26.7 small intestine: 3.6 KLHL22 FLJ14360, KELCHL ENSG00000099910 Kelch-like family member 22 22 20441519-20495883 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.34e-8 (favourable), Pancreatic cancer:3.85e-6 (favourable), Endometrial cancer:4.88e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 34.9 COQ4 CGI-92 ENSG00000167113 Coenzyme Q4 9 128322536-128334072 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA021406, HPA042945 Supported Supported Mitochondria Endometrial cancer:4.93e-6 (favourable), Renal cancer:5.76e-6 (favourable), Cervical cancer:2.97e-5 (favourable) Expressed in all Expressed in all fallopian tube: 64.1 DNMBP ARHGEF36, KIAA1010, Tuba ENSG00000107554 Dynamin binding protein 10 99875577-100009919 Predicted intracellular proteins Evidence at protein level HPA037878, HPA058216 Uncertain Approved Nucleoli
Nuclear bodies
Golgi apparatus
Cytosol Endometrial cancer:4.95e-6 (favourable), Urothelial cancer:6.15e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 56.8 MLPH exophilin-3, l(1)-3Rk, l1Rk3, ln, Slac-2a ENSG00000115648 Melanophilin 2 237485428-237555318 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA014685 Uncertain Endometrial cancer:5.14e-6 (favourable), Renal cancer:1.50e-4 (unfavourable) Mixed Mixed prostate: 102.1 REEP5 C5orf18, D5S346, DP1, TB2 ENSG00000129625 Receptor accessory protein 5 5 112876379-112922539 Predicted membrane proteins Evidence at protein level HPA003895, HPA069960 Approved Approved Endoplasmic reticulum Endometrial cancer:5.23e-6 (favourable), Renal cancer:2.05e-5 (favourable) Expressed in all Expressed in all thyroid gland: 341.6 BATF B-ATF, BATF1, SFA-2 ENSG00000156127 Basic leucine zipper transcription factor, ATF-like 14 75522425-75547015 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059588, HPA064962 Approved Validated Nucleoplasm Renal cancer:3.74e-9 (unfavourable), Endometrial cancer:5.35e-6 (favourable), Head and neck cancer:7.91e-5 (favourable), Urothelial cancer:4.30e-4 (favourable), Colorectal cancer:8.30e-4 (unfavourable) Expressed in all Tissue enhanced lymph node: 31.9 appendix: 27.3 TFF3 HITF, ITF ENSG00000160180 Trefoil factor 3 (intestinal) 21 42311667-42315651 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB020681, HPA035464 Supported Approved Nucleus
Nucleoli Endometrial cancer:5.60e-6 (favourable) Expressed in all Tissue enhanced cervix, uterine: 467.4;colon: 507.1;rectum: 511.3;thyroid gland: 618.6 small intestine: 466.0 MFSD12 C19orf28, MGC20700, PP3501 ENSG00000161091 Major facilitator superfamily domain containing 12 19 3538261-3574290 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042149, HPA043088 Uncertain Approved Nucleoplasm
Mitochondria Endometrial cancer:5.66e-6 (favourable), Lung cancer:2.34e-4 (unfavourable), Liver cancer:6.61e-4 (unfavourable), Stomach cancer:7.70e-4 (favourable) Tissue enriched Expressed in all skin: 64.2 VMAC ENSG00000187650 Vimentin-type intermediate filament associated coiled-coil protein 19 5904858-5910853 Predicted intracellular proteins Evidence at protein level Endometrial cancer:5.67e-6 (favourable), Urothelial cancer:7.24e-4 (favourable), Head and neck cancer:8.20e-4 (favourable) Expressed in all Mixed spleen: 7.8 CTNNBIP1 ICAT, MGC15093 ENSG00000178585 Catenin, beta interacting protein 1 1 9848276-9910336 Predicted intracellular proteins Evidence at protein level HPA042617 Approved Plasma membrane
Cell Junctions
Mitochondria Endometrial cancer:5.68e-6 (favourable) Expressed in all Expressed in all skin: 288.8 ARHGAP26 GRAF, KIAA0621, OPHN1L, OPHN1L1 ENSG00000145819 Rho GTPase activating protein 26 5 142770384-143229011 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035106, HPA035107 Approved Approved Cytosol Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable) Expressed in all Mixed cerebral cortex: 30.9 PMM1 Sec53 ENSG00000100417 Phosphomannomutase 1 22 41576894-41589890 Enzymes, Predicted intracellular proteins Evidence at protein level HPA030712 Uncertain Endometrial cancer:6.09e-6 (favourable), Pancreatic cancer:2.05e-4 (favourable), Cervical cancer:5.92e-4 (favourable) Expressed in all Expressed in all ovary: 54.9 RASGRF1 CDC25, CDC25L, GNRP, GRF1, GRF55, H-GRF55, PP13187 ENSG00000058335 Ras protein-specific guanine nucleotide-releasing factor 1 15 78959947-79090773 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010413, HPA041965 Approved Supported Golgi apparatus Endometrial cancer:6.14e-6 (favourable) Mixed Group enriched 14 cerebral cortex: 30.6;lung: 11.7 lymph node: 1.5 CD8A CD8 ENSG00000153563 CD8a molecule 2 86784610-86808396 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000012, HPA037756, CAB075722 Supported Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable) Expressed in all Tissue enhanced spleen: 164.7 lymph node: 47.7 GMPPB KIAA1851 ENSG00000173540 GDP-mannose pyrophosphorylase B 3 49716844-49723951 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA014657 Uncertain Supported Nucleus Endometrial cancer:6.19e-6 (favourable), Renal cancer:3.17e-4 (favourable) Expressed in all Expressed in all thyroid gland: 41.9 ATP2C2 KIAA0703, SPCA2 ENSG00000064270 ATPase, Ca++ transporting, type 2C, member 2 16 84368527-84464187 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA052262, HPA075812 Approved Approved Plasma membrane
Focal adhesion sites Endometrial cancer:6.20e-6 (favourable) Mixed Tissue enhanced rectum: 39.0 skin: 30.1 GZMA CTLA3, HFSP ENSG00000145649 Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 5 55102648-55110252 Enzymes, Predicted secreted proteins Evidence at protein level HPA054134 Uncertain Renal cancer:1.26e-6 (unfavourable), Endometrial cancer:6.44e-6 (favourable), Breast cancer:7.27e-4 (favourable) Expressed in all Mixed spleen: 72.0 YWHAE FLJ45465 ENSG00000108953 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon 17 1344272-1400378 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008445, CAB016200, CAB021109, CAB047350 Approved Uncertain Cytosol Endometrial cancer:6.48e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 452.9 ZBTB7A DKFZp547O146, FBI-1, LRF, pokemon, ZBTB7, ZNF857A ENSG00000178951 Zinc finger and BTB domain containing 7A 19 4044364-4066945 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB037214, CAB037285, HPA046387 Supported Approved Nucleoplasm Renal cancer:1.34e-6 (favourable), Endometrial cancer:6.50e-6 (favourable), Stomach cancer:1.79e-4 (favourable), Pancreatic cancer:2.99e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 23.9 CD74 DHLAG ENSG00000019582 CD74 molecule, major histocompatibility complex, class II invariant chain 5 150401637-150412929 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB002506, HPA010592 Supported Supported Golgi apparatus Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable) Expressed in all Expressed in all spleen: 6665.5 CXCR6 BONZO, CD186, STRL33, TYMSTR ENSG00000172215 Chemokine (C-X-C motif) receptor 6 3 45940933-45948353 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA047591 Uncertain Endometrial cancer:6.74e-6 (favourable), Renal cancer:2.42e-5 (unfavourable), Head and neck cancer:2.16e-4 (favourable), Cervical cancer:4.92e-4 (favourable) Mixed Mixed lymph node: 17.6 PEMT PEMPT, PEMT2 ENSG00000133027 Phosphatidylethanolamine N-methyltransferase 17 17505563-17591708 Enzymes, Predicted membrane proteins Evidence at protein level HPA042375 Approved Approved Cytosol Endometrial cancer:6.77e-6 (favourable) Expressed in all Expressed in all epididymis: 205.4 GORASP1 FLJ23443, GOLPH5, GRASP65, P65 ENSG00000114745 Golgi reassembly stacking protein 1, 65kDa 3 39096659-39108363 Predicted intracellular proteins Evidence at protein level HPA056283 Supported Supported Golgi apparatus Renal cancer:1.91e-6 (favourable), Endometrial cancer:6.92e-6 (favourable), Liver cancer:5.13e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 36.7 ERMN ERMIN, JN, KIAA1189 ENSG00000136541 Ermin, ERM-like protein 2 157318625-157327713 Predicted intracellular proteins Evidence at protein level HPA038295, HPA038296 Supported Endometrial cancer:6.93e-6 (favourable) Group enriched Tissue enriched 27 cerebral cortex: 228.3 bone marrow: 8.4 DCAKD FLJ22955 ENSG00000172992 Dephospho-CoA kinase domain containing 17 45023340-45061109 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060997 Approved Nucleus Endometrial cancer:7.16e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 47.2 FAM214A FLJ10980, KIAA1370 ENSG00000047346 Family with sequence similarity 214, member A 15 52581317-52709817 Predicted intracellular proteins Evidence at protein level HPA039369, HPA040180 Approved Approved Nucleoplasm Endometrial cancer:7.27e-6 (favourable), Lung cancer:8.68e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 56.9 R3HDM4 C19orf22, MGC16353 ENSG00000198858 R3H domain containing 4 19 896503-913245 Predicted intracellular proteins Evidence at protein level HPA043025, HPA048638 Uncertain Approved Nucleus
Cytosol Endometrial cancer:7.33e-6 (favourable) Expressed in all Expressed in all appendix: 69.6 NKG7 GIG1, GMP-17 ENSG00000105374 Natural killer cell granule protein 7 19 51371606-51372715 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071454 Approved Vesicles Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable) Expressed in all Tissue enhanced bone marrow: 352.2;spleen: 153.8 lymph node: 124.8 FOXA2 HNF3B ENSG00000125798 Forkhead box A2 20 22581005-22585455 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB001388, HPA066846 Approved Supported Nucleoplasm
Cell Junctions Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 21.3;lung: 20.6;stomach: 31.3 liver: 11.5 TNFRSF18 AITR, CD357, GITR ENSG00000186891 Tumor necrosis factor receptor superfamily, member 18 1 1203508-1206691 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008025 Approved Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable) Expressed in all Tissue enhanced skin: 43.3 parathyroid gland: 17.6 RNF183 MGC4734 ENSG00000165188 Ring finger protein 183 9 113297093-113303376 Predicted membrane proteins Evidence at protein level HPA057675 Uncertain Endometrial cancer:7.95e-6 (favourable), Renal cancer:3.51e-4 (favourable) Tissue enhanced Tissue enhanced epididymis: 19.6;gallbladder: 9.0 kidney: 4.3 PHF11 BCAP, IGER, NY-REN-34 ENSG00000136147 PHD finger protein 11 13 49495610-49528987 Predicted intracellular proteins Evidence at protein level HPA016566, HPA016708 Uncertain Supported Nucleoplasm
Nuclear membrane Renal cancer:4.46e-7 (unfavourable), Endometrial cancer:7.98e-6 (favourable), Urothelial cancer:3.46e-4 (favourable) Expressed in all Expressed in all thyroid gland: 57.4 SRA1 SRA, STRAA1 ENSG00000213523 Steroid receptor RNA activator 1 5 140537340-140558310 Predicted intracellular proteins Evidence at protein level HPA044598, HPA050153 Approved Supported Nucleoplasm
Microtubules
Cytosol Endometrial cancer:8.01e-6 (favourable) Expressed in all Mixed adrenal gland: 16.7 TNFRSF14 ATAR, CD270, HVEA, HVEM, LIGHTR, TR2 ENSG00000157873 Tumor necrosis factor receptor superfamily, member 14 1 2555639-2565382 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006404, CAB026150, CAB030007 Approved Approved Cytosol
Rods & Rings Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable) Expressed in all Expressed in all duodenum: 46.7 LPCAT2 AGPAT11, AYTL1, FLJ20481, LysoPAFAT ENSG00000087253 Lysophosphatidylcholine acyltransferase 2 16 55508998-55586670 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007891, HPA008433 Supported Supported Validated Endoplasmic reticulum
Lipid droplets Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 141.9 bone marrow: 56.6 NUCB2 NEFA ENSG00000070081 Nucleobindin 2 11 17208153-17349974 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008395, CAB015931 Approved Validated Golgi apparatus Endometrial cancer:8.27e-6 (favourable), Renal cancer:3.94e-5 (unfavourable), Ovarian cancer:1.98e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 719.8 CTSW ENSG00000172543 Cathepsin W 11 65879809-65883741 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016345 Supported Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 70.8;spleen: 61.4 lung: 36.5 CD247 CD3H, CD3Q, CD3Z ENSG00000198821 CD247 molecule 1 167430640-167518610 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004651, HPA008750 Supported Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable) Mixed Tissue enhanced lymph node: 66.0;spleen: 49.4 tonsil: 34.9 ANKRD22 MGC22805 ENSG00000152766 Ankyrin repeat domain 22 10 88822132-88851818 Predicted intracellular proteins Evidence at protein level HPA012922 Approved Approved Nucleus Endometrial cancer:8.73e-6 (favourable), Pancreatic cancer:6.15e-4 (unfavourable) Expressed in all Tissue enhanced skin: 38.6;stomach: 48.9 esophagus: 27.1 SAT2 SSAT2 ENSG00000141504 Spermidine/spermine N1-acetyltransferase family member 2 17 7626234-7627876 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022136, HPA057096 Supported Endometrial cancer:8.76e-6 (favourable), Pancreatic cancer:6.05e-5 (favourable), Lung cancer:6.71e-4 (favourable) Expressed in all Expressed in all duodenum: 93.5 SPCS3 FLJ22649, PRO3567, SPC22/23, SPC3, YLR066W ENSG00000129128 Signal peptidase complex subunit 3 4 176319964-176332245 Predicted intracellular proteins Evidence at protein level HPA053180 Approved Endometrial cancer:8.89e-6 (favourable), Pancreatic cancer:1.87e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 103.8 ARFGAP3 ARFGAP1 ENSG00000242247 ADP-ribosylation factor GTPase activating protein 3 22 42796502-42858106 Predicted intracellular proteins Evidence at protein level HPA000638 Approved Supported Golgi apparatus
Cytosol Endometrial cancer:8.97e-6 (favourable), Thyroid cancer:2.65e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 113.0 RPS27L ENSG00000185088 Ribosomal protein S27-like 15 63125872-63158021 Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins Evidence at protein level HPA066851 Supported Nucleoli
Endoplasmic reticulum
Cytosol Endometrial cancer:9.08e-6 (favourable) Expressed in all Expressed in all adrenal gland: 223.3 CST7 ENSG00000077984 Cystatin F (leukocystatin) 20 24949230-24959928 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA040442 Supported Renal cancer:4.37e-6 (unfavourable), Endometrial cancer:9.17e-6 (favourable), Head and neck cancer:5.85e-5 (favourable), Breast cancer:6.55e-4 (favourable), Cervical cancer:7.90e-4 (favourable) Expressed in all Tissue enriched 9 bone marrow: 644.5 spleen: 75.4 HSDL2 C9orf99, SDR13C1 ENSG00000119471 Hydroxysteroid dehydrogenase like 2 9 112379937-112472410 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042890, HPA050453 Supported Supported Mitochondria Renal cancer:9.29e-7 (favourable), Endometrial cancer:9.23e-6 (favourable) Expressed in all Expressed in all adrenal gland: 79.7 MLEC KIAA0152 ENSG00000110917 Malectin 12 120686869-120701864 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:9.60e-6 (favourable), Stomach cancer:8.77e-4 (favourable) Expressed in all Expressed in all thyroid gland: 161.6 VIM ENSG00000026025 Vimentin 10 17228259-17237593 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000080, HPA001762, CAB058687 Supported Supported Intermediate filaments Renal cancer:8.69e-8 (unfavourable), Endometrial cancer:9.75e-6 (favourable) Expressed in all Expressed in all ovary: 4341.9 MARCH2 HSPC240, MARCH-II, RNF172 ENSG00000099785 Membrane-associated ring finger (C3HC4) 2, E3 ubiquitin protein ligase 19 8413270-8439017 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014063 Approved Uncertain Cytosol Endometrial cancer:1.05e-5 (favourable), Pancreatic cancer:6.21e-4 (favourable), Colorectal cancer:6.48e-4 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Expressed in all Expressed in all epididymis: 63.9 DACT2 bA503C24.7, C6orf116, DAPPER2 ENSG00000164488 Dishevelled-binding antagonist of beta-catenin 2 6 168292830-168319754 Predicted intracellular proteins Evidence at transcript level HPA030251, HPA030252 Approved Endometrial cancer:1.07e-5 (favourable), Renal cancer:5.76e-5 (favourable) Tissue enhanced Tissue enhanced placenta: 18.7 prostate: 6.7 VPS53 FLJ10979, HCCS1 ENSG00000141252 Vacuolar protein sorting 53 homolog (S. cerevisiae) 17 508668-721717 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA022988, HPA024446 Approved Approved Golgi apparatus
Cytosol Endometrial cancer:1.08e-5 (favourable), Pancreatic cancer:1.56e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 18.7 CISH CIS, CIS-1, G18, SOCS ENSG00000114737 Cytokine inducible SH2-containing protein 3 50606490-50611831 Predicted intracellular proteins Evidence at protein level CAB034039, HPA040812 Approved Approved Microtubules
Cytokinetic bridge Renal cancer:3.53e-12 (favourable), Endometrial cancer:1.13e-5 (favourable), Liver cancer:6.98e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable) Expressed in all Mixed thyroid gland: 42.9 TCTN1 FLJ21127, JBTS13, TECT1 ENSG00000204852 Tectonic family member 1 12 110614027-110649430 Disease related genes, Predicted secreted proteins Evidence at protein level HPA039687, HPA040036 Approved Approved Nucleoplasm
Actin filaments Endometrial cancer:1.13e-5 (favourable) Expressed in all Mixed fallopian tube: 43.7 PDLIM1 CLIM1, CLP-36, CLP36, hCLIM1 ENSG00000107438 PDZ and LIM domain 1 10 95237572-95291024 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017010, CAB072838, CAB072840 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Endometrial cancer:1.14e-5 (favourable) Expressed in all Expressed in all small intestine: 278.6 ARL4D ARF4L ENSG00000175906 ADP-ribosylation factor-like 4D 17 43398959-43401137 Predicted intracellular proteins Evidence at protein level HPA060379 Uncertain Approved Golgi apparatus
Vesicles Endometrial cancer:1.16e-5 (favourable), Head and neck cancer:6.66e-4 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable) Expressed in all Mixed thyroid gland: 62.4 PIAS4 FLJ12419, Piasg, PIASY, ZMIZ6 ENSG00000105229 Protein inhibitor of activated STAT, 4 19 4007646-4039386 Predicted intracellular proteins Evidence at protein level HPA010598 Approved Approved Nucleoplasm Endometrial cancer:1.18e-5 (favourable), Pancreatic cancer:7.04e-4 (favourable) Expressed in all Expressed in all testis: 29.3 TRABD PP2447 ENSG00000170638 TraB domain containing 22 50185915-50199598 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA000822 Approved Approved Nucleus
Mitochondria Endometrial cancer:1.19e-5 (favourable), Renal cancer:1.85e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 38.6 TMEM229B C14orf83, FLJ33387 ENSG00000198133 Transmembrane protein 229B 14 67447084-67533739 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA046562 Approved Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable) Expressed in all Mixed duodenum: 16.2 RANBP3 ENSG00000031823 RAN binding protein 3 19 5916139-5978142 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA043375, HPA043389 Supported Validated Nucleoplasm Endometrial cancer:1.22e-5 (favourable), Pancreatic cancer:4.14e-4 (favourable), Thyroid cancer:8.14e-4 (favourable) Expressed in all Expressed in all testis: 60.1 SEC61B ENSG00000106803 Sec61 translocon beta subunit 9 99222064-99230615 Predicted membrane proteins, Transporters Evidence at protein level HPA049407 Approved Validated Endoplasmic reticulum Endometrial cancer:1.26e-5 (favourable) Expressed in all Expressed in all epididymis: 333.0 ID3 bHLHb25, HEIR-1 ENSG00000117318 Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1 23557918-23559794 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB021353, HPA024677 Approved Supported Nucleoplasm Endometrial cancer:1.27e-5 (favourable) Expressed in all Mixed seminal vesicle: 90.6 SPATA18 FLJ32906 ENSG00000163071 Spermatogenesis associated 18 4 52051331-52097292 Predicted intracellular proteins Evidence at protein level HPA036854, HPA036855 Supported Renal cancer:3.73e-9 (favourable), Endometrial cancer:1.32e-5 (favourable) Expressed in all Tissue enhanced fallopian tube: 108.1;testis: 42.4 cervix, uterine: 16.1 TKFC DAK, DKFZP586B1621, NET45 ENSG00000149476 Triokinase/FMN cyclase 11 61333210-61353295 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039486, HPA048186 Supported Approved Nucleus
Cytosol Endometrial cancer:1.32e-5 (favourable), Renal cancer:8.38e-5 (favourable) Expressed in all Expressed in all duodenum: 205.9 SIGIRR TIR8 ENSG00000185187 Single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 11 405716-417455 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023188 Approved Approved Nucleoli fibrillar center
Cytosol Renal cancer:7.61e-6 (favourable), Endometrial cancer:1.34e-5 (favourable), Urothelial cancer:1.54e-5 (favourable), Cervical cancer:7.44e-5 (favourable), Head and neck cancer:9.08e-4 (favourable) Expressed in all Expressed in all spleen: 65.9 CCL5 D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228 ENSG00000271503 Chemokine (C-C motif) ligand 5 17 35871491-35880793 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable) Expressed in all Tissue enhanced spleen: 81.8 lymph node: 69.9 LEF1 TCF10, TCF1ALPHA, TCF7L3 ENSG00000138795 Lymphoid enhancer-binding factor 1 4 108047545-108168956 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002087, CAB019405 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:2.47e-6 (unfavourable), Endometrial cancer:1.37e-5 (favourable) Expressed in all Tissue enhanced lymph node: 42.2 tonsil: 29.3 KLRB1 CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A ENSG00000111796 Killer cell lectin-like receptor subfamily B, member 1 12 9594551-9607886 CD markers, Predicted membrane proteins Evidence at protein level HPA039113 Approved Uncertain Nucleoplasm
Cytosol Endometrial cancer:1.42e-5 (favourable), Breast cancer:3.51e-5 (favourable), Head and neck cancer:6.99e-5 (favourable), Thyroid cancer:5.61e-4 (favourable) Mixed Mixed spleen: 41.3 PLPP5 DPPL1, HTPAP, PPAPDC1B ENSG00000147535 Phospholipid phosphatase 5 8 38263130-38269243 Enzymes, Predicted membrane proteins Evidence at protein level HPA055777 Approved Vesicles Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable) Expressed in all Expressed in all prostate: 123.7 NOP10 MGC70651, NOLA3, NOP10P ENSG00000182117 NOP10 ribonucleoprotein 15 34341713-34343177 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA059198 Supported Supported Nuclear bodies Endometrial cancer:1.48e-5 (favourable) Expressed in all Expressed in all epididymis: 284.1 IGSF6 DORA ENSG00000140749 Immunoglobulin superfamily, member 6 16 21639537-21652660 Predicted membrane proteins Evidence at protein level HPA041023, HPA041072 Uncertain Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable) Expressed in all Tissue enhanced spleen: 64.7 appendix: 37.2 ASRGL1 ALP, ALP1, FLJ22316 ENSG00000162174 Asparaginase like 1 11 62337448-62393412 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029725, HPA055572, CAB070192 Supported Approved Nucleoplasm
Microtubules Renal cancer:4.32e-7 (favourable), Endometrial cancer:1.56e-5 (favourable), Colorectal cancer:6.14e-4 (favourable), Liver cancer:9.46e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 180.8 ERICH3 C1orf173, DKFZp547I048, RP11-653A5.1 ENSG00000178965 Glutamate-rich 3 1 74568111-74673738 Predicted intracellular proteins Evidence at protein level HPA028655 Approved Endometrial cancer:1.56e-5 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 18.9;fallopian tube: 27.5;testis: 44.0 cervix, uterine: 8.6 PPIB CYPB, OI9 ENSG00000166794 Peptidylprolyl isomerase B (cyclophilin B) 15 64155812-64163205 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level CAB011487, HPA012720 Supported Supported Nucleus
Endoplasmic reticulum Renal cancer:2.02e-11 (unfavourable), Endometrial cancer:1.56e-5 (favourable) Expressed in all Expressed in all thyroid gland: 852.0 GZMB CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT ENSG00000100453 Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) 14 24630954-24634267 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000376, HPA003418 Supported Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable) Expressed in all Tissue enhanced lymph node: 40.7 spleen: 36.7 TTLL10 FLJ36119, TTLL5 ENSG00000162571 Tubulin tyrosine ligase-like family member 10 1 1173884-1197935 Predicted intracellular proteins Evidence at protein level HPA042712 Uncertain Endometrial cancer:1.61e-5 (favourable) Mixed Group enriched 7 fallopian tube: 14.1;testis: 28.0 lung: 2.8 CD2 SRBC ENSG00000116824 CD2 molecule 1 116754385-116769228 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002430, HPA003883 Supported Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 132.9 tonsil: 73.5 TTC8 BBS8, RP51 ENSG00000165533 Tetratricopeptide repeat domain 8 14 88824153-88881078 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003310 Uncertain Endometrial cancer:1.69e-5 (favourable), Renal cancer:4.89e-4 (favourable), Ovarian cancer:7.77e-4 (favourable) Expressed in all Expressed in all ovary: 90.7 PPP6R2 dJ579N16.1, KIAA0685, SAP190, SAPS2 ENSG00000100239 Protein phosphatase 6, regulatory subunit 2 22 50343304-50445090 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030656, CAB034919 Uncertain Supported Vesicles
Cytosol Endometrial cancer:1.70e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable) Expressed in all Expressed in all testis: 65.3 MIER2 KIAA1193 ENSG00000105556 Mesoderm induction early response 1, family member 2 19 301444-344807 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA041439 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:7.22e-6 (unfavourable), Endometrial cancer:1.72e-5 (favourable), Colorectal cancer:2.89e-4 (unfavourable) Expressed in all Mixed testis: 12.8 CRYL1 GDH, lambda-CRY, MGC149525, MGC149526 ENSG00000165475 Crystallin, lambda 1 13 20403667-20525857 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040403 Supported Approved Nucleus
Nucleoli
Golgi apparatus
Plasma membrane Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable) Expressed in all Expressed in all kidney: 335.8 TTC9 KIAA0227, TTC9A ENSG00000133985 Tetratricopeptide repeat domain 9 14 70641787-70675360 Predicted intracellular proteins Evidence at protein level Renal cancer:2.10e-8 (favourable), Endometrial cancer:1.82e-5 (favourable) Expressed in all Tissue enhanced esophagus: 44.8 fallopian tube: 15.7 GPX4 MCSP, PHGPx ENSG00000167468 Glutathione peroxidase 4 19 1103926-1106791 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB008630, HPA047224, HPA058546 Supported Supported Nucleoplasm
Mitochondria Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable) Expressed in all Expressed in all testis: 1137.7 MED11 HSPC296, MGC88387 ENSG00000161920 Mediator complex subunit 11 17 4731428-4733610 Predicted intracellular proteins Evidence at protein level HPA056669 Uncertain Approved Nucleoplasm
Nuclear bodies Endometrial cancer:1.86e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.1 CEACAM21 FLJ13540, R29124_1 ENSG00000007129 Carcinoembryonic antigen-related cell adhesion molecule 21 19 41549518-41586844 Predicted membrane proteins Evidence at transcript level HPA043411 Uncertain Endometrial cancer:1.89e-5 (favourable) Mixed Tissue enhanced bone marrow: 11.0 spleen: 6.6 SEC11A SEC11L1, sid2895, SPC18, SPCS4A ENSG00000140612 SEC11 homolog A, signal peptidase complex subunit 15 84669538-84716716 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047533 Approved Nuclear membrane
Golgi apparatus Endometrial cancer:1.94e-5 (favourable), Head and neck cancer:5.99e-5 (unfavourable), Thyroid cancer:2.95e-4 (favourable) Expressed in all Expressed in all thyroid gland: 211.4 CCL4 Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4 ENSG00000275302 Chemokine (C-C motif) ligand 4 17 36103590-36105621 Cancer-related genes, Predicted secreted proteins Evidence at protein level CAB007805 Approved Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable) Expressed in all Tissue enhanced spleen: 25.2 lymph node: 17.9 BPIFB2 BPIL1, C20orf184, dJ726C3.2, LPLUNC2 ENSG00000078898 BPI fold containing family B, member 2 20 33007600-33023709 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA049491, HPA060121 Supported Approved Vesicles Endometrial cancer:1.97e-5 (favourable) Group enriched Group enriched 23 esophagus: 99.0;salivary gland: 91.0 cervix, uterine: 4.0 TMEM132A FLJ20539, GBP, HSPA5BP1 ENSG00000006118 Transmembrane protein 132A 11 60924463-60937159 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051979, HPA060492 Supported Approved Mitochondria Renal cancer:1.55e-9 (unfavourable), Endometrial cancer:1.98e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 94.5 placenta: 24.9 ARFIP2 POR1 ENSG00000132254 ADP-ribosylation factor interacting protein 2 11 6474683-6481479 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB032985, HPA038156 Approved Approved Nucleus
Nucleoli fibrillar center
Golgi apparatus Endometrial cancer:2.00e-5 (favourable), Renal cancer:9.53e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 81.1 DAPK3 ZIP, ZIPK ENSG00000167657 Death-associated protein kinase 3 19 3958453-3971123 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028569, HPA064809 Approved Approved Nucleus Endometrial cancer:2.01e-5 (favourable), Renal cancer:6.49e-4 (unfavourable) Expressed in all Expressed in all endometrium: 76.1 CD7 GP40, LEU-9, Tp40, TP41 ENSG00000173762 CD7 molecule 17 82314868-82317602 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002594, HPA039079 Supported Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable) Expressed in all Tissue enhanced appendix: 44.8;lymph node: 42.1;spleen: 44.0 small intestine: 17.4 TXNDC11 EFP1 ENSG00000153066 Thioredoxin domain containing 11 16 11679080-11742878 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041174, HPA041390 Supported Supported Plasma membrane
Cytosol Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 83.0 AKNA KIAA1968 ENSG00000106948 AT-hook transcription factor 9 114334156-114394405 Predicted intracellular proteins Evidence at protein level HPA052367, HPA063993 Supported Nucleoplasm
Centrosome Endometrial cancer:2.14e-5 (favourable), Renal cancer:2.55e-5 (unfavourable), Cervical cancer:1.22e-4 (favourable), Head and neck cancer:1.25e-4 (favourable), Urothelial cancer:2.29e-4 (favourable) Expressed in all Mixed spleen: 97.3 TOM1 ENSG00000100284 Target of myb1 membrane trafficking protein 22 35299275-35347994 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000818, HPA001749 Approved Approved Plasma membrane
Microtubule organizing center
Cytosol Endometrial cancer:2.20e-5 (favourable), Renal cancer:3.72e-5 (favourable) Expressed in all Expressed in all esophagus: 54.8 CIB1 CALMYRIN, CIB, KIP, SIP2-28 ENSG00000185043 Calcium and integrin binding 1 (calmyrin) 15 90229975-90234047 Predicted intracellular proteins Evidence at protein level CAB012991, HPA048825 Approved Supported Nucleoplasm
Plasma membrane Endometrial cancer:2.26e-5 (favourable) Expressed in all Expressed in all fallopian tube: 204.7 PRMT7 FLJ10640, KIAA1933 ENSG00000132600 Protein arginine methyltransferase 7 16 68310974-68358563 Enzymes, Predicted intracellular proteins Evidence at protein level HPA044241 Supported Supported Nucleoplasm
Nucleoli fibrillar center Endometrial cancer:2.31e-5 (favourable) Expressed in all Expressed in all fallopian tube: 24.8 INPP5K SKIP ENSG00000132376 Inositol polyphosphate-5-phosphatase K 17 1494571-1516888 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031044 Uncertain Pancreatic cancer:1.47e-6 (favourable), Endometrial cancer:2.33e-5 (favourable), Cervical cancer:3.91e-4 (favourable) Expressed in all Expressed in all adipose tissue: 32.1 LGALS1 GBP ENSG00000100097 Lectin, galactoside-binding, soluble, 1 22 37675608-37679806 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000646, HPA000687, HPA001130, CAB002157 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.18e-10 (unfavourable), Endometrial cancer:2.36e-5 (favourable), Liver cancer:3.06e-4 (unfavourable), Urothelial cancer:5.10e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1705.8 ADPRM C17orf48, MDS006 ENSG00000170222 ADP-ribose/CDP-alcohol diphosphatase, manganese-dependent 17 10697594-10711233 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023265, HPA023820 Approved Endometrial cancer:2.38e-5 (favourable), Cervical cancer:1.69e-4 (favourable) Expressed in all Expressed in all prostate: 18.1 HDAC10 DKFZP761B039 ENSG00000100429 Histone deacetylase 10 22 50245183-50251405 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB045977, HPA056514 Supported Approved Nucleoli fibrillar center Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable) Expressed in all Mixed spleen: 9.9 PRR5 FLJ20185k, PP610, Protor-1 ENSG00000186654 Proline rich 5 (renal) 22 44668547-44737681 Predicted intracellular proteins Evidence at protein level HPA054072 Approved Endometrial cancer:2.47e-5 (favourable) Expressed in all Mixed spleen: 17.9 NLRX1 CLR11.3, NOD9 ENSG00000160703 NLR family member X1 11 119166568-119184016 Predicted intracellular proteins Evidence at protein level HPA061516 Supported Supported Plasma membrane
Cell Junctions
Mitochondria Renal cancer:2.59e-6 (favourable), Endometrial cancer:2.47e-5 (favourable) Expressed in all Expressed in all esophagus: 37.9 TTC12 FLJ13859, FLJ20535, TPARM ENSG00000149292 Tetratricopeptide repeat domain 12 11 113314529-113383544 Predicted intracellular proteins Evidence at protein level HPA038542, HPA038543, HPA061364 Approved Approved Nucleoplasm Endometrial cancer:2.48e-5 (favourable), Renal cancer:5.95e-5 (favourable), Colorectal cancer:3.14e-4 (favourable) Expressed in all Expressed in all testis: 91.9 CYGB HGB, STAP ENSG00000161544 Cytoglobin 17 76527356-76551175 Predicted intracellular proteins Evidence at protein level HPA017757, HPA061642 Approved Validated Nuclear speckles Endometrial cancer:2.55e-5 (favourable), Glioma:1.63e-4 (unfavourable), Renal cancer:2.13e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 46.6 KCNRG ENSG00000198553 Potassium channel regulator 13 50015254-50020922 Predicted intracellular proteins Evidence at protein level HPA001027 Uncertain Vesicles Endometrial cancer:2.61e-5 (favourable) Mixed Tissue enriched 11 fallopian tube: 51.5 lung: 4.5 FAM166B ENSG00000215187 Family with sequence similarity 166, member B 9 35561831-35563899 Predicted intracellular proteins Evidence at protein level HPA045540 Uncertain Ovarian cancer:6.20e-6 (favourable), Endometrial cancer:2.61e-5 (favourable) Group enriched Group enriched 13 adrenal gland: 371.3;fallopian tube: 157.1;skeletal muscle: 82.6 epididymis: 15.9 RPL34 L34 ENSG00000109475 Ribosomal protein L34 4 108620566-108630412 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA035139 Uncertain Supported Nucleoli
Endoplasmic reticulum
Cytosol Endometrial cancer:2.76e-5 (favourable) Expressed in all Expressed in all breast: 4590.2 MPG MDG ENSG00000103152 N-methylpurine DNA glycosylase 16 77007-85853 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006531 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:2.82e-5 (favourable) Expressed in all Expressed in all thyroid gland: 48.9 SLC22A5 CDSP, OCTN2, SCD ENSG00000197375 Solute carrier family 22 (organic cation/carnitine transporter), member 5 5 132369752-132395614 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA063062 Approved Mitochondria Endometrial cancer:2.87e-5 (favourable), Pancreatic cancer:7.36e-4 (favourable), Renal cancer:8.36e-4 (favourable) Expressed in all Mixed parathyroid gland: 31.4 ZNF683 Hobit, MGC33414 ENSG00000176083 Zinc finger protein 683 1 26361634-26374522 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA023865 Uncertain Endometrial cancer:2.90e-5 (favourable), Urothelial cancer:3.45e-5 (favourable) Mixed Tissue enriched 11 testis: 78.7 lung: 7.1 HPS1 BLOC3S1, HPS ENSG00000107521 Hermansky-Pudlak syndrome 1 10 98416198-98446947 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA061260 Approved Endometrial cancer:2.93e-5 (favourable), Cervical cancer:3.37e-5 (favourable), Lung cancer:1.26e-4 (favourable), Glioma:5.53e-4 (unfavourable) Expressed in all Expressed in all lymph node: 24.6 CYB561 CYB561A1, FRRS2 ENSG00000008283 Cytochrome b561 17 63432304-63446378 Predicted membrane proteins, Transporters Evidence at protein level HPA014753 Approved Endometrial cancer:2.95e-5 (favourable), Breast cancer:8.89e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 164.3 ARSA ENSG00000100299 Arylsulfatase A 22 50622754-50628173 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005554, CAB025183 Supported Uncertain Golgi apparatus
Cytosol Endometrial cancer:2.96e-5 (favourable) Expressed in all Expressed in all testis: 37.4 ACAP1 CENTB1, KIAA0050 ENSG00000072818 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 17 7336529-7351478 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062130 Approved Vesicles Renal cancer:1.65e-10 (unfavourable), Endometrial cancer:2.97e-5 (favourable), Head and neck cancer:4.17e-5 (favourable), Cervical cancer:3.66e-4 (favourable) Expressed in all Tissue enhanced lymph node: 95.5 spleen: 71.2 STAP2 BKS, STAP-2 ENSG00000178078 Signal transducing adaptor family member 2 19 4324043-4342786 Predicted intracellular proteins Evidence at protein level HPA002375, HPA027761 Approved Endometrial cancer:3.03e-5 (favourable), Cervical cancer:2.76e-4 (favourable), Urothelial cancer:4.13e-4 (favourable) Expressed in all Mixed duodenum: 81.7 SEPT1 DIFF6, PNUTL3 ENSG00000180096 Septin 1 16 30378133-30395991 Predicted intracellular proteins Evidence at protein level HPA041566, HPA060339 Supported Uncertain Actin filaments Renal cancer:2.40e-7 (unfavourable), Endometrial cancer:3.04e-5 (favourable), Lung cancer:7.24e-5 (favourable), Cervical cancer:9.72e-5 (favourable), Pancreatic cancer:2.22e-4 (favourable), Head and neck cancer:6.63e-4 (favourable) Expressed in all Tissue enhanced lymph node: 16.5;spleen: 11.5 tonsil: 6.2 GPR68 OGR1 ENSG00000119714 G protein-coupled receptor 68 14 91232532-91253925 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:3.06e-5 (favourable) Mixed Mixed appendix: 8.4 SPN CD43, GPL115, LSN ENSG00000197471 Sialophorin 16 29662979-29670876 CD markers, Predicted membrane proteins Evidence at protein level CAB002666, HPA055244 Supported Uncertain Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 38.7;lung: 33.4 lymph node: 25.8 TOB2 bK223H9, TOB4, TOBL, TROB2 ENSG00000183864 Transducer of ERBB2, 2 22 41433492-41447023 Predicted intracellular proteins Evidence at protein level HPA016603, HPA054112 Approved Approved Cytosol Renal cancer:1.18e-6 (favourable), Endometrial cancer:3.08e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 59.1 CDPF1 C22orf40, LOC150383 ENSG00000205643 Cysteine-rich, DPF motif domain containing 1 22 46244011-46250679 Predicted intracellular proteins Evidence at protein level HPA018823 Uncertain Approved Nucleus
Cytosol Endometrial cancer:3.13e-5 (favourable) Expressed in all Mixed fallopian tube: 7.0 CDKN1A CAP20, CDKN1, CIP1, P21, p21CIP1, p21Cip1/Waf1, SDI1, WAF1 ENSG00000124762 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 6 36676460-36687339 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000064, HPA005946, CAB069401 Supported Supported Nucleoplasm
Nuclear bodies Endometrial cancer:3.14e-5 (favourable), Renal cancer:4.95e-5 (favourable), Lung cancer:7.05e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 205.5 IL2RB CD122, IL15RB ENSG00000100385 Interleukin 2 receptor, beta 22 37125838-37175054 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062657 Supported Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable) Expressed in all Tissue enhanced spleen: 68.3 placenta: 52.4 C9orf24 bA573M23.4, CBE1, MGC32921, MGC33614, NYD-SP22, SMRP1 ENSG00000164972 Chromosome 9 open reading frame 24 9 34379019-34397832 Predicted intracellular proteins Evidence at protein level HPA053008 Uncertain Endometrial cancer:3.23e-5 (favourable), Pancreatic cancer:1.75e-4 (favourable) Tissue enhanced Group enriched 11 fallopian tube: 172.5;testis: 65.1 lung: 11.0 ORMDL2 adoplin-2, HSPC160, MST095, MSTP095 ENSG00000123353 ORMDL sphingolipid biosynthesis regulator 2 12 55817919-55821879 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Endometrial cancer:3.30e-5 (favourable), Liver cancer:9.75e-4 (unfavourable) Expressed in all Expressed in all epididymis: 62.1 PIDD1 DKFZp434D229, LRDD, MGC16925, PIDD ENSG00000177595 P53-induced death domain protein 1 11 799179-809753 Enzymes, Predicted intracellular proteins Evidence at protein level CAB012647, HPA055473 Supported Approved Golgi apparatus
Cytosol Endometrial cancer:3.32e-5 (favourable), Cervical cancer:8.19e-5 (favourable), Renal cancer:1.52e-4 (unfavourable), Head and neck cancer:3.91e-4 (favourable) Expressed in all Mixed bone marrow: 4.7 PDZRN3 KIAA1095, LNX3, SEMACAP3 ENSG00000121440 PDZ domain containing ring finger 3 3 73382433-73624940 Predicted intracellular proteins Evidence at protein level HPA038822, HPA061420 Approved Supported Nucleus
Cytosol Renal cancer:3.65e-7 (favourable), Endometrial cancer:3.35e-5 (favourable), Pancreatic cancer:4.93e-4 (favourable) Mixed Mixed ovary: 85.8 NDUFA11 B14.7 ENSG00000174886 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa 19 5891276-5904006 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072209 Uncertain Mitochondria Endometrial cancer:3.38e-5 (favourable), Cervical cancer:4.54e-5 (favourable) Expressed in all Expressed in all heart muscle: 298.5 IRAK4 NY-REN-64 ENSG00000198001 Interleukin-1 receptor-associated kinase 4 12 43758944-43789543 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB016685, CAB022077 Uncertain Approved Nucleoli
Microtubules
Cytosol Endometrial cancer:3.46e-5 (favourable), Urothelial cancer:4.42e-5 (favourable) Expressed in all Mixed lymph node: 20.6 DNAJC3 HP58, P58, P58IPK, PRKRI ENSG00000102580 DnaJ (Hsp40) homolog, subfamily C, member 3 13 95677139-95794989 Disease related genes, Predicted secreted proteins Evidence at protein level HPA039336, HPA041326 Uncertain Approved Endoplasmic reticulum Endometrial cancer:3.47e-5 (favourable) Expressed in all Expressed in all thyroid gland: 88.1 GNLY D2S69E, LAG-2, LAG2, NKG5, TLA519 ENSG00000115523 Granulysin 2 85685175-85698854 Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB025186, HPA058021 Supported Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 153.1;endometrium: 113.5;spleen: 114.5 lung: 51.2 C9orf116 MGC29761, PIERCE1, RbEST47 ENSG00000160345 Chromosome 9 open reading frame 116 9 135495181-135501734 Predicted intracellular proteins Evidence at protein level HPA021439 Uncertain Approved Nucleoplasm
Cytosol Endometrial cancer:3.53e-5 (favourable) Expressed in all Group enriched 6 epididymis: 30.7;fallopian tube: 152.6;testis: 63.0 thyroid gland: 13.6 ZSWIM7 SWS1 ENSG00000214941 Zinc finger, SWIM-type containing 7 17 15976560-15999717 Predicted intracellular proteins Evidence at protein level HPA054681 Uncertain Uncertain Cytosol Endometrial cancer:3.54e-5 (favourable), Pancreatic cancer:1.77e-4 (favourable) Expressed in all Mixed cerebral cortex: 11.9 RASAL3 FLJ21438 ENSG00000105122 RAS protein activator like 3 19 15451624-15464571 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA043417 Approved Renal cancer:1.16e-6 (unfavourable), Endometrial cancer:3.58e-5 (favourable), Head and neck cancer:3.07e-4 (favourable), Cervical cancer:8.75e-4 (favourable) Expressed in all Tissue enhanced lymph node: 38.0 spleen: 25.0 TBC1D30 KIAA0984 ENSG00000111490 TBC1 domain family, member 30 12 64781193-64881032 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039772, HPA040043 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-5 (favourable), Lung cancer:5.08e-4 (favourable) Mixed Mixed parathyroid gland: 12.3 OSTF1 bA235O14.1, OSF, SH3P2 ENSG00000134996 Osteoclast stimulating factor 1 9 75088543-75147265 Predicted intracellular proteins Evidence at protein level HPA020514 Approved Supported Cytosol Endometrial cancer:3.67e-5 (favourable) Expressed in all Expressed in all spleen: 124.6 STK11 LKB1, PJS ENSG00000118046 Serine/threonine kinase 11 19 1177558-1228435 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB016231, HPA017254, CAB022105, HPA067481 Approved Supported Nucleoplasm
Cytosol Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable) Expressed in all Expressed in all testis: 70.3 CACTIN C19orf29, cactin, fSAPc, NY-REN-24 ENSG00000105298 Cactin, spliceosome C complex subunit 19 3610641-3626815 Predicted intracellular proteins Evidence at protein level HPA042504, HPA042548 Approved Supported Nucleoplasm
Nuclear speckles
Cytosol Endometrial cancer:3.69e-5 (favourable) Expressed in all Expressed in all spleen: 14.7 FAM46C FLJ20202 ENSG00000183508 Family with sequence similarity 46, member C 1 117605934-117628372 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA054049 Uncertain Approved Nucleoplasm Renal cancer:2.77e-5 (favourable), Endometrial cancer:3.75e-5 (favourable) Expressed in all Mixed testis: 58.4 KIAA0226L C13orf18, FLJ21562 ENSG00000102445 KIAA0226-like 13 46342000-46438190 Predicted intracellular proteins Evidence at protein level HPA026614 Approved Supported Cytosol Endometrial cancer:3.76e-5 (favourable) Tissue enriched Mixed lymph node: 35.4 UPK1B TSPAN20, UPK1 ENSG00000114638 Uroplakin 1B 3 119173517-119205153 Predicted membrane proteins Evidence at protein level HPA031799, HPA031800 Supported Endometrial cancer:3.87e-5 (favourable), Stomach cancer:7.76e-4 (unfavourable) Tissue enhanced Tissue enhanced stomach: 33.2;urinary bladder: 37.5 tonsil: 16.0 TAOK2 KIAA0881, MAP3K17, PSK, PSK1, TAO1, TAO2 ENSG00000149930 TAO kinase 2 16 29973641-29992261 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010650 Approved Supported Nucleus
Nucleoli
Cytosol Endometrial cancer:3.87e-5 (favourable), Colorectal cancer:2.51e-4 (unfavourable), Renal cancer:3.66e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable) Expressed in all Expressed in all testis: 36.9 HLA-DMB D6S221E, RING7 ENSG00000242574 Major histocompatibility complex, class II, DM beta 6 32934629-32941070 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012298 Supported Endometrial cancer:3.89e-5 (favourable) Expressed in all Tissue enhanced thyroid gland: 29.3 spleen: 12.0 DYNLRB2 DNCL2B, DNLC2B, ROBLD2 ENSG00000168589 Dynein, light chain, roadblock-type 2 16 80540734-80550760 Predicted intracellular proteins Evidence at protein level Endometrial cancer:3.91e-5 (favourable) Mixed Group enriched 8 fallopian tube: 133.1;testis: 323.7 epididymis: 27.0 DGKE DAGK6, DGK ENSG00000153933 Diacylglycerol kinase, epsilon 64kDa 17 56834099-56869567 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017167 Approved Approved Nucleus
Cytosol Endometrial cancer:3.92e-5 (favourable) Mixed Mixed testis: 12.1 DRC3 CFAP134, DKFZP586M1120, LRRC48 ENSG00000171962 Dynein regulatory complex subunit 3 17 17972813-18016889 Predicted intracellular proteins Evidence at transcript level HPA036040, HPA036041 Approved Endometrial cancer:4.05e-5 (favourable), Breast cancer:1.51e-4 (favourable) Mixed Tissue enhanced fallopian tube: 98.0 testis: 21.8 LSM7 YNL147W ENSG00000130332 LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated 19 2321517-2328620 Predicted intracellular proteins Evidence at protein level HPA041850 Uncertain Approved Nucleoli fibrillar center Endometrial cancer:4.19e-5 (favourable), Cervical cancer:3.28e-4 (favourable), Urothelial cancer:6.96e-4 (favourable) Expressed in all Expressed in all lymph node: 72.1 C2orf81 hCG40743, LOC388963 ENSG00000159239 Chromosome 2 open reading frame 81 2 74414176-74421591 Predicted intracellular proteins Evidence at transcript level HPA054835 Approved Approved Nucleus
Nucleoli Endometrial cancer:4.22e-5 (favourable), Pancreatic cancer:9.42e-5 (favourable) Mixed Tissue enhanced fallopian tube: 31.9;testis: 26.6 parathyroid gland: 9.8 EYA2 EAB1 ENSG00000064655 EYA transcriptional coactivator and phosphatase 2 20 46894624-47188844 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027024, HPA059291 Uncertain Supported Cytosol Endometrial cancer:4.30e-5 (favourable) Tissue enhanced Tissue enhanced cervix, uterine: 75.8 fallopian tube: 49.5 TYMP ECGF1, MNGIE ENSG00000025708 Thymidine phosphorylase 22 50525752-50530056 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000530, HPA001072, CAB002518 Approved Approved Nuclear bodies
Golgi apparatus Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable) Expressed in all Tissue enhanced appendix: 103.2 spleen: 54.0 CITED4 ENSG00000179862 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 1 40861051-40862366 Predicted intracellular proteins Evidence at protein level HPA056434 Approved Approved Vesicles Endometrial cancer:4.38e-5 (favourable) Expressed in all Mixed breast: 20.5 UGCG GCS ENSG00000148154 UDP-glucose ceramide glucosyltransferase 9 111896766-111935369 Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024124 Approved Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable) Expressed in all Expressed in all adrenal gland: 84.4 SGSM3 DJ1042K10.2, RabGAP-5, RABGAP5, RUSC3, RUTBC3 ENSG00000100359 Small G protein signaling modulator 3 22 40370591-40410289 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048980 Approved Supported Golgi apparatus Endometrial cancer:4.47e-5 (favourable) Expressed in all Expressed in all stomach: 76.7 DNAJC22 FLJ13236, wus ENSG00000178401 DnaJ (Hsp40) homolog, subfamily C, member 22 12 49346917-49357546 Predicted membrane proteins Evidence at protein level HPA039953 Approved Vesicles Endometrial cancer:4.56e-5 (favourable), Melanoma:7.54e-4 (unfavourable) Mixed Mixed thyroid gland: 17.9 ZNF688 ENSG00000229809 Zinc finger protein 688 16 30569346-30572734 Predicted intracellular proteins Evidence at transcript level HPA048922 Uncertain Approved Nucleoplasm
Plasma membrane
Cell Junctions Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable) Expressed in all Expressed in all testis: 23.9 FICD HIP13, HYPE ENSG00000198855 FIC domain containing 12 108515185-108525837 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021390, HPA071134 Approved Approved Nucleus Endometrial cancer:4.61e-5 (favourable) Expressed in all Mixed thyroid gland: 17.6 HLA-DMA D6S222E, RING6 ENSG00000204257 Major histocompatibility complex, class II, DM alpha 6 32948613-32969094 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012750, HPA017295 Supported Approved Vesicles Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable) Expressed in all Tissue enhanced lung: 64.8 fallopian tube: 41.3 SIAE CSE-C, LSE, MGC87009, YSG2 ENSG00000110013 Sialic acid acetylesterase 11 124633113-124695707 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038052, HPA038053 Approved Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable) Expressed in all Expressed in all rectum: 116.8 TIMM13 Tim13, TIMM13B ENSG00000099800 Translocase of inner mitochondrial membrane 13 homolog (yeast) 19 2425624-2427894 Predicted intracellular proteins Evidence at protein level HPA048985 Uncertain Supported Nucleoli fibrillar center
Mitochondria Renal cancer:3.88e-5 (favourable), Endometrial cancer:4.68e-5 (favourable), Pancreatic cancer:9.77e-4 (favourable) Expressed in all Expressed in all adrenal gland: 53.3 EMC7 C11orf3, C15orf24 ENSG00000134153 ER membrane protein complex subunit 7 15 34084017-34101948 Predicted membrane proteins Evidence at protein level HPA010029, HPA047572 Approved Approved Nucleoplasm Endometrial cancer:4.68e-5 (favourable), Head and neck cancer:9.25e-5 (unfavourable) Expressed in all Expressed in all testis: 129.1 TRAF3IP2 ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CIKS, DKFZP586G0522 ENSG00000056972 TRAF3 interacting protein 2 6 111556454-111606278 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA036352 Approved Approved Golgi apparatus
Vesicles Endometrial cancer:4.73e-5 (favourable), Renal cancer:5.16e-5 (unfavourable), Cervical cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 49.4 PSTPIP1 CD2BP1, CD2BP1L, CD2BP1S, H-PIP, PAPAS, PSTPIP ENSG00000140368 Proline-serine-threonine phosphatase interacting protein 1 15 76993359-77037332 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA010600 Supported Renal cancer:7.36e-9 (unfavourable), Endometrial cancer:4.74e-5 (favourable) Expressed in all Tissue enhanced bone marrow: 37.7 appendix: 16.8 CYBA p22-PHOX ENSG00000051523 Cytochrome b-245, alpha polypeptide 16 88643283-88651152 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009492 Supported Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable) Expressed in all Expressed in all spleen: 476.3 MKNK2 GPRK7, MNK2 ENSG00000099875 MAP kinase interacting serine/threonine kinase 2 19 2037465-2051244 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021875, CAB037253, HPA053989 Supported Supported Nucleus
Nucleoli
Nuclear bodies Endometrial cancer:4.86e-5 (favourable), Stomach cancer:4.01e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 174.4 OSGIN1 BDGI, OKL38 ENSG00000140961 Oxidative stress induced growth inhibitor 1 16 83948282-83966332 Predicted intracellular proteins Evidence at protein level HPA019239 Approved Nucleoplasm
Cytosol Endometrial cancer:4.89e-5 (favourable) Tissue enriched Tissue enhanced liver: 57.4 duodenum: 32.2 SDF2L1 AP000553.C22.4, OTTHUMT00000075032 ENSG00000128228 Stromal cell-derived factor 2-like 1 22 21642261-21644298 Predicted secreted proteins Evidence at protein level HPA005638 Approved Endometrial cancer:4.98e-5 (favourable) Expressed in all Expressed in all thyroid gland: 45.2 SPPL2B IMP4, KIAA1532, PSL1 ENSG00000005206 Signal peptide peptidase like 2B 19 2328615-2354806 Enzymes, Predicted membrane proteins Evidence at protein level HPA039292 Approved Nucleoplasm
Plasma membrane
Centrosome Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable) Expressed in all Expressed in all testis: 49.2 MYO5C MGC74969 ENSG00000128833 Myosin VC 15 52192322-52295798 Predicted intracellular proteins Evidence at protein level CAB020790, HPA032115, HPA032116 Supported Supported Nucleus
Cytosol Renal cancer:2.47e-5 (favourable), Endometrial cancer:5.18e-5 (favourable), Stomach cancer:5.82e-4 (favourable) Expressed in all Mixed parathyroid gland: 38.0 ATP1B3 CD298, FLJ29027 ENSG00000069849 ATPase, Na+/K+ transporting, beta 3 polypeptide 3 141876124-141926514 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB020697, HPA048963 Supported Supported Plasma membrane Liver cancer:6.32e-6 (unfavourable), Renal cancer:1.29e-5 (unfavourable), Endometrial cancer:5.19e-5 (favourable) Expressed in all Expressed in all skin: 310.5 NUP188 KIAA0169 ENSG00000095319 Nucleoporin 188kDa 9 128947699-129007096 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA061750, HPA063942 Approved Supported Nucleus Endometrial cancer:5.20e-5 (favourable) Expressed in all Expressed in all testis: 104.4 CBY1 C22orf2, Cby, Chibby, PGEA1, PIGEA-14, PIGEA14 ENSG00000100211 Chibby homolog 1 (Drosophila) 22 38656636-38673854 Predicted intracellular proteins Evidence at protein level Endometrial cancer:5.22e-5 (favourable) Expressed in all Expressed in all fallopian tube: 95.4 SLC6A6 TAUT ENSG00000131389 Solute carrier family 6 (neurotransmitter transporter), member 6 3 14402576-14489349 Predicted membrane proteins, Transporters Evidence at protein level HPA015028, HPA016488 Supported Approved Cell Junctions
Cytosol Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Mixed ovary: 50.7 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 MGST2 MGST-II ENSG00000085871 Microsomal glutathione S-transferase 2 4 139665768-139740745 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010707 Approved Approved Nucleoplasm Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable) Expressed in all Expressed in all liver: 177.4 RAD51D HsTRAD, R51H3, RAD51L3, Trad ENSG00000185379 RAD51 paralog D 17 35092208-35121522 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:7.20e-9 (unfavourable), Pancreatic cancer:3.35e-6 (favourable), Endometrial cancer:5.37e-5 (favourable) Expressed in all Mixed cerebral cortex: 9.6 ABHD14B CIB, MGC15429 ENSG00000114779 Abhydrolase domain containing 14B 3 51968510-51983409 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036444, HPA036642 Supported Supported Nucleus
Nucleoli
Cytosol Renal cancer:2.93e-5 (favourable), Endometrial cancer:5.42e-5 (favourable), Cervical cancer:6.92e-5 (favourable) Expressed in all Expressed in all thyroid gland: 90.5 ITGAL CD11A, LFA-1 ENSG00000005844 Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) 16 30472658-30523185 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025011 Supported Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable) Expressed in all Tissue enhanced lymph node: 80.1;spleen: 82.2 appendix: 54.3 UBXN6 UBXD1, UBXDC2 ENSG00000167671 UBX domain protein 6 19 4444999-4457822 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040906, HPA041313, HPA061872 Approved Approved Golgi apparatus
Cytosol Renal cancer:2.78e-5 (favourable), Endometrial cancer:5.68e-5 (favourable), Pancreatic cancer:6.95e-4 (favourable) Expressed in all Expressed in all testis: 139.2 TNFSF12 APO3L, DR3LG, TWEAK ENSG00000239697 Tumor necrosis factor (ligand) superfamily, member 12 17 7548891-7557890 Predicted secreted proteins Evidence at protein level HPA052967 Uncertain Endometrial cancer:5.70e-5 (favourable) Expressed in all Mixed seminal vesicle: 26.9 ANXA1 ANX1, LPC1 ENSG00000135046 Annexin A1 9 73151757-73170393 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA011271, HPA011272, CAB013023, CAB035987, CAB058693 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable) Expressed in all Tissue enriched 6 esophagus: 7577.8 tonsil: 1266.5 PLA2G10 GXPLA2 ENSG00000069764 Phospholipase A2, group X 16 14672545-14694669 Enzymes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA041893 Uncertain Endometrial cancer:5.74e-5 (favourable) Mixed Tissue enhanced colon: 7.1;rectum: 6.7;stomach: 10.5 duodenum: 2.2 DENND6B AFI1B, FAM116B, MGC33692 ENSG00000205593 DENN/MADD domain containing 6B 22 50309030-50327060 Predicted intracellular proteins Evidence at protein level HPA018934, HPA021653, HPA029570 Uncertain Uncertain Plasma membrane Endometrial cancer:5.93e-5 (favourable), Colorectal cancer:1.41e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 21.3 cerebral cortex: 12.0 APOBEC3G bK150C2.7, CEM15, dJ494G10.1, FLJ12740, MDS019 ENSG00000239713 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 22 39040961-39087743 Predicted intracellular proteins Evidence at protein level HPA001812, HPA073637 Approved Uncertain Nucleoplasm
Cytosol Renal cancer:8.66e-13 (unfavourable), Endometrial cancer:6.03e-5 (favourable), Cervical cancer:4.70e-4 (favourable), Breast cancer:4.78e-4 (favourable), Urothelial cancer:6.30e-4 (favourable) Expressed in all Mixed lymph node: 52.0 SORBS2 ARGBP2, KIAA0777 ENSG00000154556 Sorbin and SH3 domain containing 2 4 185585444-185956652 Predicted intracellular proteins Evidence at protein level HPA036754, HPA036755 Supported Supported Nucleoplasm Renal cancer:3.10e-6 (favourable), Liver cancer:1.47e-5 (favourable), Endometrial cancer:6.07e-5 (favourable) Expressed in all Tissue enhanced heart muscle: 359.9;thyroid gland: 459.9 parathyroid gland: 276.8 CCDC108 DKFZp434O0527, MGC35338 ENSG00000181378 Coiled-coil domain containing 108 2 219002846-219041527 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA055156 Uncertain Endometrial cancer:6.08e-5 (favourable) Tissue enhanced Group enriched 7 fallopian tube: 40.7;testis: 17.7 lung: 4.0 FNDC1 bA243O10.1, dJ322A24.1, FNDC2, KIAA1866 ENSG00000164694 Fibronectin type III domain containing 1 6 159169397-159272109 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030962, HPA030963 Approved Supported Nuclear speckles Renal cancer:1.93e-6 (unfavourable), Endometrial cancer:6.10e-5 (favourable) Tissue enhanced Tissue enhanced gallbladder: 23.0;thyroid gland: 33.8 smooth muscle: 16.3 NPDC1 CAB-, CAB1, DKFZp586J0523 ENSG00000107281 Neural proliferation, differentiation and control, 1 9 137039470-137046203 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008189 Approved Approved Nucleus
Cytosol Colorectal cancer:2.01e-5 (unfavourable), Endometrial cancer:6.19e-5 (favourable), Pancreatic cancer:3.18e-4 (favourable) Expressed in all Expressed in all prostate: 108.1 SRR ILV1, ISO1 ENSG00000167720 Serine racemase 17 2303383-2325260 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007529, CAB015343 Approved Approved Vesicles Renal cancer:2.45e-6 (favourable), Endometrial cancer:6.20e-5 (favourable), Pancreatic cancer:8.16e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 25.6 DPP9 ENSG00000142002 Dipeptidyl-peptidase 9 19 4675224-4724673 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036059 Approved Supported Cytosol Renal cancer:3.38e-8 (unfavourable), Endometrial cancer:6.21e-5 (favourable), Stomach cancer:7.72e-5 (favourable), Breast cancer:4.96e-4 (favourable) Expressed in all Expressed in all appendix: 34.2 C4BPA C4BP ENSG00000123838 Complement component 4 binding protein, alpha 1 207104262-207144972 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA000926, HPA001578 Supported Endometrial cancer:6.37e-5 (favourable), Liver cancer:2.24e-4 (favourable) Tissue enriched Group enriched 64 liver: 994.5;lung: 261.8 cervix, uterine: 9.7 DNAJC10 ERdj5, PDIA19 ENSG00000077232 DnaJ (Hsp40) homolog, subfamily C, member 10 2 182716041-182794464 Predicted membrane proteins Evidence at protein level HPA031111 Approved Renal cancer:2.19e-7 (unfavourable), Endometrial cancer:6.42e-5 (favourable), Thyroid cancer:7.27e-4 (unfavourable) Expressed in all Expressed in all epididymis: 152.2 PPP2R4 PR53, PTPA ENSG00000119383 Protein phosphatase 2A activator, regulatory subunit 4 9 129110950-129148946 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005695, CAB022068, CAB035999 Approved Validated Nucleoplasm
Cytosol Endometrial cancer:6.50e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 221.8 C6orf52 ENSG00000137434 Chromosome 6 open reading frame 52 6 10671418-10694797 Predicted intracellular proteins Evidence at transcript level HPA051142 Uncertain Approved Nuclear speckles Endometrial cancer:6.50e-5 (favourable) Mixed Tissue enhanced testis: 17.9 fallopian tube: 10.5 POLR3GL flj32422, MGC3200 ENSG00000121851 Polymerase (RNA) III (DNA directed) polypeptide G (32kD)-like 1 145964702-145978848 Predicted intracellular proteins, RNA polymerase related proteins Evidence at protein level HPA027288 Uncertain Approved Nucleoplasm
Golgi apparatus
Cytosol Endometrial cancer:6.52e-5 (favourable), Breast cancer:2.96e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 58.9 ARHGAP9 10C, MGC1295 ENSG00000123329 Rho GTPase activating protein 9 12 57472255-57488814 Predicted intracellular proteins Evidence at protein level Renal cancer:7.90e-9 (unfavourable), Endometrial cancer:6.61e-5 (favourable) Expressed in all Tissue enhanced bone marrow: 78.2 lymph node: 69.5 MADD DENN, KIAA0358, RAB3GEP ENSG00000110514 MAP-kinase activating death domain 11 47269161-47330031 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038568 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 104.2 ZNF77 pT1 ENSG00000175691 Zinc finger protein 77 19 2933218-2944971 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA023397 Uncertain Approved Nucleus
Nucleoli Lung cancer:6.79e-6 (favourable), Endometrial cancer:6.65e-5 (favourable), Cervical cancer:8.49e-4 (favourable) Expressed in all Mixed breast: 5.7 DNAH9 DNAH17L, Dnahc9, DNAL1, DYH9, HL-20, HL20, KIAA0357 ENSG00000007174 Dynein, axonemal, heavy chain 9 17 11598431-11969748 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA052641 Supported Endometrial cancer:6.79e-5 (favourable) Tissue enhanced Tissue enriched 5 fallopian tube: 55.6 testis: 11.1 ZNF79 pT7 ENSG00000196152 Zinc finger protein 79 9 127424374-127445372 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028977 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:6.04e-7 (favourable), Pancreatic cancer:5.42e-5 (favourable), Endometrial cancer:6.83e-5 (favourable), Lung cancer:5.96e-4 (favourable) Expressed in all Mixed testis: 11.4 TNIP1 ABIN-1, KIAA0113, NAF1, VAN ENSG00000145901 TNFAIP3 interacting protein 1 5 151029945-151093577 Predicted intracellular proteins Evidence at protein level HPA037893, HPA037894, HPA071950 Approved Supported Nucleoplasm
Cytosol Endometrial cancer:6.86e-5 (favourable), Breast cancer:5.69e-4 (favourable) Expressed in all Expressed in all adipose tissue: 132.2 ANXA2 ANX2, ANX2L4, CAL1H, LIP2, LPC2D ENSG00000182718 Annexin A2 15 60347134-60402883 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB004311 Approved Renal cancer:2.11e-6 (unfavourable), Pancreatic cancer:8.47e-6 (unfavourable), Liver cancer:2.54e-5 (unfavourable), Urothelial cancer:6.59e-5 (unfavourable), Endometrial cancer:6.88e-5 (favourable), Lung cancer:7.51e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1494.3 RUNDC1 DKFZp761H0421 ENSG00000198863 RUN domain containing 1 17 42980565-42993690 Predicted intracellular proteins Evidence at protein level HPA023726 Uncertain Approved Nuclear speckles
Cytosol Endometrial cancer:6.93e-5 (favourable) Expressed in all Expressed in all fallopian tube: 23.3 DNAJC8 SPF31 ENSG00000126698 DnaJ (Hsp40) homolog, subfamily C, member 8 1 28199456-28233025 Predicted intracellular proteins Evidence at protein level HPA026275, HPA026283 Approved Validated Nucleoplasm Endometrial cancer:6.95e-5 (favourable), Thyroid cancer:2.39e-4 (favourable), Liver cancer:4.71e-4 (unfavourable) Expressed in all Expressed in all lymph node: 94.7 SERPINA6 CBG ENSG00000170099 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 14 94304248-94323394 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA017864 Approved Endometrial cancer:6.96e-5 (favourable) Tissue enriched Tissue enriched 6 liver: 216.6 gallbladder: 34.1 WDR34 bA216B9.3, DIC5, FAP133, MGC20486 ENSG00000119333 WD repeat domain 34 9 128633661-128656787 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040764, HPA041091 Approved Approved Cytosol Endometrial cancer:7.01e-5 (favourable), Cervical cancer:1.63e-4 (favourable), Liver cancer:8.79e-4 (unfavourable) Expressed in all Expressed in all testis: 53.0 DPM3 MGC125904, MGC125905, MGC34275 ENSG00000179085 Dolichyl-phosphate mannosyltransferase polypeptide 3 1 155139891-155140595 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014667 Approved Endometrial cancer:7.09e-5 (favourable), Ovarian cancer:8.97e-5 (favourable), Urothelial cancer:8.64e-4 (favourable) Expressed in all Expressed in all adrenal gland: 78.8 C9orf152 bA470J20.2 ENSG00000188959 Chromosome 9 open reading frame 152 9 110190048-110208189 Predicted intracellular proteins Evidence at protein level HPA050769 Approved Supported Nucleus Endometrial cancer:7.22e-5 (favourable) Mixed Tissue enhanced rectum: 45.4 colon: 33.1 NME5 nm23-H5, RSPH23 ENSG00000112981 NME/NM23 family member 5 5 138115172-138139443 Predicted intracellular proteins Evidence at protein level HPA035648, HPA044555 Approved Approved Nucleoplasm
Nuclear bodies Endometrial cancer:7.24e-5 (favourable), Renal cancer:1.76e-4 (favourable) Mixed Tissue enhanced fallopian tube: 58.7;testis: 94.3 epididymis: 27.7 PIP5K1C KIAA0589, LCCS3, PIP5Kgamma ENSG00000186111 Phosphatidylinositol-4-phosphate 5-kinase, type I, gamma 19 3630183-3700479 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA017168 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:7.28e-5 (favourable), Cervical cancer:1.79e-4 (favourable), Pancreatic cancer:2.32e-4 (favourable), Renal cancer:3.00e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 53.0 MED15 Arc105, CAG7A, PCQAP, TIG-1, TNRC7 ENSG00000099917 Mediator complex subunit 15 22 20495913-20587632 Predicted intracellular proteins Evidence at protein level HPA003179 Approved Supported Nucleus Endometrial cancer:7.30e-5 (favourable), Renal cancer:1.61e-4 (unfavourable), Liver cancer:3.71e-4 (unfavourable), Pancreatic cancer:9.09e-4 (unfavourable) Expressed in all Expressed in all spleen: 44.4 PRR5L FLJ14213, PROTOR-2 ENSG00000135362 Proline rich 5 like 11 36296288-36465204 Predicted intracellular proteins Evidence at protein level HPA070174 Approved Cytokinetic bridge
Cytosol Renal cancer:7.71e-8 (unfavourable), Endometrial cancer:7.30e-5 (favourable), Stomach cancer:4.86e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 51.9 colon: 35.6 ANKRD54 LIAR ENSG00000100124 Ankyrin repeat domain 54 22 37830855-37849327 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA071287 Approved Approved Nucleoplasm
Microtubules
Midbody Endometrial cancer:7.38e-5 (favourable), Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.16e-4 (favourable) Expressed in all Expressed in all fallopian tube: 35.2 CCR5 CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22 ENSG00000160791 Chemokine (C-C motif) receptor 5 (gene/pseudogene) 3 46370854-46376206 CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:7.42e-5 (favourable), Head and neck cancer:9.33e-5 (favourable) Expressed in all Mixed appendix: 20.9 ERP29 C12orf8, ERp28, ERp29, ERp31, PDI-DB, PDIA9 ENSG00000089248 Endoplasmic reticulum protein 29 12 112013316-112023451 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039363, HPA039456 Supported Uncertain Nucleoplasm
Microtubules Endometrial cancer:7.43e-5 (favourable), Liver cancer:2.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 149.3 NUDT9 MGC3037 ENSG00000170502 Nudix (nucleoside diphosphate linked moiety X)-type motif 9 4 87422582-87459454 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036917, HPA044866, HPA078535 Approved Supported Nuclear membrane
Cell Junctions
Mitochondria Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 84.9 CAPS CAPS1, MGC126562 ENSG00000105519 Calcyphosine 19 5911707-5916208 Predicted intracellular proteins Evidence at protein level HPA043520 Supported Supported Nucleus
Plasma membrane
Cytosol Endometrial cancer:7.63e-5 (favourable), Head and neck cancer:8.60e-4 (favourable) Tissue enriched Tissue enriched 10 fallopian tube: 493.6 cervix, uterine: 51.4 CHD3 Mi-2a, Mi2-ALPHA, ZFH ENSG00000170004 Chromodomain helicase DNA binding protein 3 17 7884806-7912760 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043368, HPA076524 Supported Approved Nucleus
Nucleoli
Microtubule organizing center Endometrial cancer:7.68e-5 (favourable), Colorectal cancer:2.43e-4 (unfavourable), Pancreatic cancer:8.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 83.9 TMED6 MGC23911, p24g5, p24gamma5 ENSG00000157315 Transmembrane p24 trafficking protein 6 16 69343248-69351809 Predicted membrane proteins Evidence at protein level HPA012532 Approved Endometrial cancer:7.74e-5 (favourable) Mixed Tissue enhanced fallopian tube: 35.5;pancreas: 61.2;stomach: 36.5 epididymis: 21.9 C11orf63 FLJ23554 ENSG00000109944 Chromosome 11 open reading frame 63 11 122882528-122959798 Predicted intracellular proteins Evidence at protein level HPA039612, HPA040344 Supported Nucleoplasm
Golgi apparatus Endometrial cancer:7.94e-5 (favourable), Thyroid cancer:2.58e-4 (unfavourable), Renal cancer:8.77e-4 (favourable) Mixed Tissue enhanced testis: 63.4 parathyroid gland: 14.4 PLEKHH1 KIAA1200 ENSG00000054690 Pleckstrin homology domain containing, family H (with MyTH4 domain) member 1 14 67533301-67589612 Predicted intracellular proteins Evidence at protein level HPA047707, HPA051964 Uncertain Approved Centrosome Renal cancer:4.03e-7 (favourable), Endometrial cancer:8.03e-5 (favourable), Urothelial cancer:2.26e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 43.4;thyroid gland: 51.0 parathyroid gland: 15.4 RNF223 ENSG00000237330 Ring finger protein 223 1 1070966-1074307 Predicted membrane proteins Evidence at transcript level Endometrial cancer:8.08e-5 (favourable), Pancreatic cancer:6.53e-4 (unfavourable) Mixed Tissue enhanced esophagus: 5.3;stomach: 3.7 skin: 2.0 TPST2 TANGO13B ENSG00000128294 Tyrosylprotein sulfotransferase 2 22 26521983-26596717 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021054 Approved Renal cancer:2.34e-6 (unfavourable), Endometrial cancer:8.08e-5 (favourable) Expressed in all Expressed in all epididymis: 133.6 GOLM1 bA379P1.3, C9orf155, FLJ23608, GOLPH2, GP73 ENSG00000135052 Golgi membrane protein 1 9 86026146-86100173 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA010638, HPA011929, CAB015341 Supported Validated Golgi apparatus Endometrial cancer:8.14e-5 (favourable), Liver cancer:1.30e-4 (unfavourable) Expressed in all Expressed in all stomach: 406.6 NFE2L1 FLJ00380, LCR-F1, NRF1, TCF11 ENSG00000082641 Nuclear factor, erythroid 2-like 1 17 48048329-48061487 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA063384, HPA065424 Approved Approved Nucleus
Cytosol Renal cancer:5.79e-6 (favourable), Endometrial cancer:8.20e-5 (favourable), Head and neck cancer:2.73e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 468.1 NDUFC1 KFYI ENSG00000109390 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 4 139266880-139302551 Predicted membrane proteins Evidence at protein level HPA044556 Approved Supported Mitochondria Endometrial cancer:8.23e-5 (favourable), Urothelial cancer:7.25e-4 (favourable), Renal cancer:9.96e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 86.7 CROCC ROLT, rootletin ENSG00000058453 Ciliary rootlet coiled-coil, rootletin 1 16740273-16972979 Predicted intracellular proteins Evidence at protein level HPA021191, HPA021762 Supported Supported Plasma membrane
Centrosome Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable) Expressed in all Mixed skin: 11.7 MSX2 CRS2, FPP, HOX8, MSH, PFM, PFM1 ENSG00000120149 Msh homeobox 2 5 174724533-174730893 Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005652 Uncertain Supported Nuclear speckles Endometrial cancer:8.43e-5 (favourable), Lung cancer:6.93e-4 (unfavourable) Mixed Tissue enhanced placenta: 47.5 parathyroid gland: 16.4 ALG2 CDGIi, FLJ14511, hALPG2, NET38 ENSG00000119523 ALG2, alpha-1,3/1,6-mannosyltransferase 9 99216426-99221956 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041512, HPA041601 Approved Validated Actin filaments
Cytosol Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable) Expressed in all Expressed in all epididymis: 75.8 ZRSR2 U2AF1-RS2, U2AF1L2, URP, ZC3H22 ENSG00000169249 Zinc finger (CCCH type), RNA-binding motif and serine/arginine rich 2 X 15790472-15823260 Cancer-related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:4.87e-5 (unfavourable), Endometrial cancer:8.50e-5 (favourable), Urothelial cancer:2.97e-4 (favourable), Breast cancer:7.96e-4 (favourable) Expressed in all Expressed in all spleen: 34.8 SIRT3 SIR2L3 ENSG00000142082 Sirtuin 3 11 215458-236931 Predicted intracellular proteins Evidence at protein level HPA026809, CAB037142 Approved Renal cancer:4.85e-9 (favourable), Endometrial cancer:8.51e-5 (favourable), Pancreatic cancer:4.45e-4 (favourable), Glioma:9.21e-4 (unfavourable) Expressed in all Expressed in all epididymis: 49.8 C22orf15 FLJ36561, N27C7-3 ENSG00000169314 Chromosome 22 open reading frame 15 22 23763021-23765861 Predicted secreted proteins Evidence at transcript level HPA018006, HPA019494 Uncertain Endometrial cancer:8.53e-5 (favourable) Tissue enhanced Tissue enriched 15 fallopian tube: 29.0 testis: 1.9 SHH HHG1, HLP3, HPE3, MCOPCB5, SMMCI, TPT, TPTPS ENSG00000164690 Sonic hedgehog 7 155799986-155812273 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:8.62e-5 (favourable) Mixed Tissue enhanced adrenal gland: 12.0;stomach: 10.7;urinary bladder: 14.0 cervix, uterine: 6.7 TMEM50A SMP1 ENSG00000183726 Transmembrane protein 50A 1 25337917-25362361 Predicted membrane proteins Evidence at protein level HPA065192 Approved Plasma membrane
Actin filaments
Cytosol Endometrial cancer:8.64e-5 (favourable), Liver cancer:3.34e-4 (unfavourable) Expressed in all Expressed in all prostate: 71.1 ANAPC2 APC2, KIAA1406 ENSG00000176248 Anaphase promoting complex subunit 2 9 137174784-137188549 Predicted intracellular proteins Evidence at protein level CAB018692, HPA066539 Supported Validated Nucleoplasm Pancreatic cancer:1.07e-7 (favourable), Endometrial cancer:8.91e-5 (favourable), Stomach cancer:2.87e-4 (favourable), Renal cancer:3.67e-4 (favourable) Expressed in all Expressed in all testis: 27.1 CD5 LEU1, T1 ENSG00000110448 CD5 molecule 11 61102395-61127852 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015392, CAB020308, HPA043416, HPA060839 Supported Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable) Mixed Tissue enhanced appendix: 31.0;lymph node: 43.6 tonsil: 21.1 FAM174B LOC400451, MGC102891 ENSG00000185442 Family with sequence similarity 174, member B 15 92617443-92809884 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015306 Approved Approved Intermediate filaments Endometrial cancer:9.03e-5 (favourable) Expressed in all Mixed thyroid gland: 61.6 KIAA0930 bK268H5.C22.1, C22orf9 ENSG00000100364 KIAA0930 22 45190338-45240769 Predicted intracellular proteins Evidence at protein level HPA038091 Uncertain Approved Nuclear membrane
Mitochondria Liver cancer:6.90e-8 (unfavourable), Renal cancer:8.95e-7 (unfavourable), Endometrial cancer:9.22e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 76.4 SLC37A1 ENSG00000160190 Solute carrier family 37 (glucose-6-phosphate transporter), member 1 21 42496008-42581440 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030418, CAB034154 Approved Approved Nucleus Thyroid cancer:3.43e-5 (favourable), Endometrial cancer:9.22e-5 (favourable) Expressed in all Mixed duodenum: 46.9 TMEM107 MGC10744 ENSG00000179029 Transmembrane protein 107 17 8173237-8176399 Predicted membrane proteins Evidence at transcript level HPA052555, HPA059653 Approved Approved Nucleoplasm
Midbody
Midbody ring
Cytosol Endometrial cancer:9.39e-5 (favourable) Expressed in all Mixed fallopian tube: 71.3 PHF7 HSPC226, NYD-SP6 ENSG00000010318 PHD finger protein 7 3 52410561-52423641 Predicted intracellular proteins Evidence at protein level HPA036283, HPA070305 Supported Supported Nucleoplasm
Golgi apparatus Renal cancer:1.05e-6 (favourable), Breast cancer:7.38e-5 (favourable), Endometrial cancer:9.44e-5 (favourable) Expressed in all Tissue enriched 422 testis: 2170.2 rectum: 5.1 PDCD1 CD279, hSLE1, PD-1, PD1, SLEB2 ENSG00000188389 Programmed cell death 1 2 241849881-241858908 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035981, CAB038418 Supported Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable) Mixed Tissue enhanced lymph node: 12.2 appendix: 3.4 PCSK4 DKFZp434B217, MGC34749, PC4, SPC5 ENSG00000115257 Proprotein convertase subtilisin/kexin type 4 19 1481428-1490752 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA005572 Uncertain Endometrial cancer:9.45e-5 (favourable) Expressed in all Tissue enriched 9 testis: 41.3 fallopian tube: 4.7 CABIN1 KIAA0330, PPP3IN ENSG00000099991 Calcineurin binding protein 1 22 24011192-24178628 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043296 Approved Approved Nucleoplasm
Aggresome
Cytosol Endometrial cancer:9.57e-5 (favourable), Renal cancer:2.94e-4 (favourable) Expressed in all Expressed in all thyroid gland: 33.7 POC1B FLJ14923, TUWD12, WDR51B ENSG00000139323 POC1 centriolar protein B 12 89419718-89526024 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038841 Approved Renal cancer:3.45e-6 (favourable), Endometrial cancer:9.59e-5 (favourable) Expressed in all Expressed in all fallopian tube: 19.7 SLC39A3 ZIP3 ENSG00000141873 Solute carrier family 39 (zinc transporter), member 3 19 2732204-2740152 Predicted membrane proteins, Transporters Evidence at protein level HPA042139, HPA058526 Uncertain Approved Vesicles Endometrial cancer:9.76e-5 (favourable) Expressed in all Expressed in all testis: 109.9 ADH5 ADH-3, ADHX, FDH ENSG00000197894 Alcohol dehydrogenase 5 (class III), chi polypeptide 4 99070978-99088801 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044578, HPA061919 Approved Renal cancer:4.58e-10 (favourable), Endometrial cancer:9.90e-5 (favourable), Melanoma:3.54e-4 (unfavourable) Expressed in all Expressed in all endometrium: 197.0 LENG9 ENSG00000275183 Leukocyte receptor cluster (LRC) member 9 19 54461796-54463711 Predicted intracellular proteins Evidence at transcript level HPA051671, HPA053556 Approved Approved Nucleoli fibrillar center Endometrial cancer:9.99e-5 (favourable) Expressed in all Mixed duodenum: 5.4 CPM ENSG00000135678 Carboxypeptidase M 12 68842197-68971570 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002657, HPA077243 Uncertain Uncertain Vesicles Endometrial cancer:1.00e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 163.6 placenta: 100.2 TMEM259 ASBABP1, C19orf6, MBRL, MGC4022 ENSG00000182087 Transmembrane protein 259 19 1009648-1021179 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042669, HPA054801 Approved Approved Nuclear speckles
Endoplasmic reticulum Stomach cancer:8.92e-6 (favourable), Endometrial cancer:1.01e-4 (favourable) Expressed in all Expressed in all spleen: 132.3 FBXW5 DKFZP434B205, Fbw5, MGC20962 ENSG00000159069 F-box and WD repeat domain containing 5 9 136940435-136944696 Predicted intracellular proteins Evidence at protein level HPA046615 Approved Approved Mitochondria Endometrial cancer:1.02e-4 (favourable), Renal cancer:4.74e-4 (favourable) Expressed in all Expressed in all testis: 163.4 SLC9A3R2 E3KARP, NHERF-2, SIP-1, TKA-1 ENSG00000065054 Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 2 16 2025356-2039026 Predicted intracellular proteins, Transporters Evidence at protein level HPA001672 Approved Supported Plasma membrane Endometrial cancer:1.03e-4 (favourable) Expressed in all Mixed lung: 161.9 SPA17 CT22, SP17 ENSG00000064199 Sperm autoantigenic protein 17 11 124673798-124697518 Predicted intracellular proteins Evidence at protein level HPA037568 Supported Approved Vesicles Endometrial cancer:1.03e-4 (favourable) Expressed in all Group enriched 7 fallopian tube: 122.8;testis: 427.5 epididymis: 37.3 IGF1 IGF-I, IGF1A, IGFI ENSG00000017427 Insulin-like growth factor 1 (somatomedin C) 12 102395867-102480645 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA048946 Approved Endometrial cancer:1.04e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 126.3 smooth muscle: 97.4 ITGAE CD103, HUMINAE ENSG00000083457 Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide) 17 3714628-3801243 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026461, HPA036313 Approved Renal cancer:1.13e-8 (unfavourable), Endometrial cancer:1.04e-4 (favourable), Urothelial cancer:3.56e-4 (favourable), Pancreatic cancer:5.78e-4 (favourable) Expressed in all Tissue enhanced lung: 9.5 small intestine: 6.4 SGTA SGT ENSG00000104969 Small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha 19 2754714-2783371 Predicted intracellular proteins Evidence at protein level HPA056309 Approved Approved Nucleoplasm Endometrial cancer:1.04e-4 (favourable), Renal cancer:2.35e-4 (favourable), Cervical cancer:9.70e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 64.8 ACP2 LAP ENSG00000134575 Acid phosphatase 2, lysosomal 11 47239302-47248906 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:1.04e-4 (favourable) Expressed in all Expressed in all duodenum: 42.4 GREB1 KIAA0575 ENSG00000196208 Growth regulation by estrogen in breast cancer 1 2 11482341-11642788 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024616, HPA027843, HPA028416 Uncertain Approved Mitochondria
Cytosol Endometrial cancer:1.05e-4 (favourable) Tissue enhanced Tissue enhanced ovary: 156.7 prostate: 54.3 TTC23 FLJ12572, HCC-8 ENSG00000103852 Tetratricopeptide repeat domain 23 15 99136323-99251223 Predicted intracellular proteins Evidence at protein level HPA039806, HPA040369 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable) Expressed in all Mixed testis: 24.2 LY6G5C C6orf20, G5c, NG33 ENSG00000204428 Lymphocyte antigen 6 complex, locus G5C 6 31676684-31684040 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038690 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:1.07e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 1.5 testis: 1.0 VAMP2 SYB2, VAMP-2 ENSG00000220205 Vesicle-associated membrane protein 2 (synaptobrevin 2) 17 8159149-8163546 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB078785 Supported Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 485.0 C19orf25 FLJ36666 ENSG00000119559 Chromosome 19 open reading frame 25 19 1461143-1479556 Predicted intracellular proteins Evidence at protein level HPA050270, HPA067491 Approved Approved Intermediate filaments Renal cancer:9.20e-8 (favourable), Endometrial cancer:1.08e-4 (favourable), Pancreatic cancer:1.21e-4 (favourable), Liver cancer:3.81e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 21.7 C9orf69 bA83N9.1 ENSG00000238227 Chromosome 9 open reading frame 69 9 136114581-136118863 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066070 Supported Supported Nucleoplasm Endometrial cancer:1.09e-4 (favourable) Expressed in all Expressed in all skin: 23.8 FN3K ENSG00000167363 Fructosamine 3 kinase 17 82735575-82751197 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA059151, HPA061358 Supported Approved Mitochondria Renal cancer:1.39e-6 (favourable), Endometrial cancer:1.10e-4 (favourable), Pancreatic cancer:2.40e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 57.1 DLC1 ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12 ENSG00000164741 DLC1 Rho GTPase activating protein 8 13083361-13604610 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017753 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles Endometrial cancer:1.11e-4 (favourable) Expressed in all Expressed in all lung: 78.7 ANO10 FLJ10375, MGC47890, SCAR10, TMEM16K ENSG00000160746 Anoctamin 10 3 43354859-43691594 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051569 Approved Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable) Expressed in all Expressed in all duodenum: 64.3 G6PC3 UGRP ENSG00000141349 Glucose 6 phosphatase, catalytic, 3 17 44070735-44076344 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067052 Supported Endoplasmic reticulum Endometrial cancer:1.11e-4 (favourable), Liver cancer:9.61e-4 (unfavourable) Expressed in all Expressed in all epididymis: 82.8 ABCA7 ABCX ENSG00000064687 ATP-binding cassette, sub-family A (ABC1), member 7 19 1040101-1065572 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041564 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable) Expressed in all Mixed spleen: 25.8 TNIP2 ABIN-2, FLIP1, KLIP, MGC4289 ENSG00000168884 TNFAIP3 interacting protein 2 4 2741648-2756376 Predicted intracellular proteins Evidence at protein level CAB020818, HPA049886, HPA063197 Supported Validated Nucleoplasm
Cytosol Renal cancer:2.94e-5 (unfavourable), Endometrial cancer:1.13e-4 (favourable), Lung cancer:5.73e-4 (unfavourable) Expressed in all Expressed in all appendix: 22.2 ACSL5 ACS2, ACS5, FACL5 ENSG00000197142 Acyl-CoA synthetase long-chain family member 5 10 112374018-112428380 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007162, CAB062546 Supported Supported Nucleus
Mitochondria Endometrial cancer:1.13e-4 (favourable) Expressed in all Expressed in all small intestine: 469.9 CYB5R1 humb5R2, NQO3A2 ENSG00000159348 Cytochrome b5 reductase 1 1 202961869-202967280 Enzymes, Predicted intracellular proteins Evidence at protein level HPA010641, HPA014147 Supported Uncertain Nucleoli
Mitochondria
Cytosol Endometrial cancer:1.14e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 183.8 C6orf141 MGC46457 ENSG00000197261 Chromosome 6 open reading frame 141 6 49550646-49561907 Predicted intracellular proteins Evidence at protein level HPA036199 Uncertain Approved Nuclear membrane Breast cancer:3.92e-6 (favourable), Endometrial cancer:1.15e-4 (favourable) Mixed Tissue enhanced gallbladder: 9.3 duodenum: 6.4 GPER1 CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR ENSG00000164850 G protein-coupled estrogen receptor 1 7 1082208-1093815 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027052 Approved Endometrial cancer:1.17e-4 (favourable) Expressed in all Mixed placenta: 9.1 TGFBI BIGH3, CDB1, CDGG1, CSD1, CSD2, CSD3, LCD1 ENSG00000120708 Transforming growth factor, beta-induced, 68kDa 5 136028895-136063818 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008612, HPA017019 Supported Approved Cytosol Renal cancer:7.82e-10 (unfavourable), Cervical cancer:1.03e-5 (unfavourable), Ovarian cancer:1.14e-5 (unfavourable), Endometrial cancer:1.17e-4 (favourable) Expressed in all Expressed in all placenta: 606.0 NCLN NET59, NICALIN ENSG00000125912 Nicalin 19 3185563-3209575 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006625 Approved Uncertain Nucleoplasm
Lipid droplets Renal cancer:8.37e-5 (unfavourable), Stomach cancer:8.82e-5 (favourable), Endometrial cancer:1.19e-4 (favourable), Liver cancer:2.15e-4 (unfavourable) Expressed in all Expressed in all duodenum: 34.8 DDB2 DDBB, FLJ34321, UV-DDB2, XPE ENSG00000134574 Damage-specific DNA binding protein 2, 48kDa 11 47214465-47239240 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB025912, HPA058406 Supported Supported Nucleoplasm
Cell Junctions Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable) Expressed in all Expressed in all skin: 53.8 AMBP EDC1, HCP, HI30, IATIL, ITI, ITIL, ITILC, UTI ENSG00000106927 Alpha-1-microglobulin/bikunin precursor 9 114060127-114078472 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001497, CAB069436 Approved Endometrial cancer:1.20e-4 (favourable) Tissue enriched Tissue enriched 22 liver: 5152.3 gallbladder: 231.0 RAB11FIP3 eferin, KIAA0665, Rab11-FIP3 ENSG00000090565 RAB11 family interacting protein 3 (class II) 16 425619-523011 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028088, HPA028631, HPA030086 Approved Supported Vesicles
Cytokinetic bridge
Microtubule organizing center Pancreatic cancer:3.16e-5 (favourable), Liver cancer:9.87e-5 (unfavourable), Endometrial cancer:1.22e-4 (favourable), Renal cancer:7.99e-4 (favourable) Expressed in all Expressed in all kidney: 56.8 INTS10 C8orf35, FLJ10569, INT10 ENSG00000104613 Integrator complex subunit 10 8 19817140-19852083 Predicted intracellular proteins Evidence at protein level HPA039129, HPA050570 Uncertain Approved Nucleoplasm
Cytosol Endometrial cancer:1.22e-4 (favourable), Colorectal cancer:4.00e-4 (favourable) Expressed in all Expressed in all thyroid gland: 64.7 UQCR11 QCR10, UQCR ENSG00000127540 Ubiquinol-cytochrome c reductase, complex III subunit XI 19 1597172-1605490 Predicted membrane proteins Evidence at protein level Endometrial cancer:1.23e-4 (favourable), Renal cancer:1.65e-4 (favourable), Pancreatic cancer:1.86e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 111.9 ATP5D ENSG00000099624 ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 19 1241746-1244826 Predicted intracellular proteins Evidence at protein level HPA002865 Uncertain Renal cancer:3.46e-5 (favourable), Endometrial cancer:1.23e-4 (favourable), Pancreatic cancer:4.60e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 217.7 TIRAP Mal, wyatt ENSG00000150455 Toll-interleukin 1 receptor (TIR) domain containing adaptor protein 11 126283065-126298845 Predicted intracellular proteins Evidence at protein level HPA054431 Uncertain Approved Nucleoplasm
Cytokinetic bridge
Cytosol Endometrial cancer:1.24e-4 (favourable) Expressed in all Mixed parathyroid gland: 13.1 ZNF837 ENSG00000152475 Zinc finger protein 837 19 58367618-58381060 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA042833 Uncertain Approved Nucleoli Renal cancer:1.76e-5 (favourable), Endometrial cancer:1.27e-4 (favourable) Expressed in all Mixed skin,spleen: 1.4 SALL1 Hsal1, TBS, ZNF794 ENSG00000103449 Spalt-like transcription factor 1 16 51135975-51151367 Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049829 Uncertain Approved Nucleus
Cytosol Renal cancer:1.91e-7 (favourable), Endometrial cancer:1.28e-4 (favourable) Group enriched Tissue enhanced thyroid gland: 40.0 cerebral cortex: 30.4 TEKT4 MGC27019 ENSG00000163060 Tektin 4 2 94871433-94876829 Predicted intracellular proteins Evidence at protein level HPA048600, HPA053929 Uncertain Uncertain Intermediate filaments Endometrial cancer:1.29e-4 (favourable) Tissue enriched Group enriched 15 fallopian tube: 4.2;testis: 5.2 lung: 0.3 GPCPD1 GDE5, GDPD6, KIAA1434 ENSG00000125772 Glycerophosphocholine phosphodiesterase 1 20 5544404-5611026 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039556, HPA042987 Uncertain Approved Nucleoplasm Endometrial cancer:1.30e-4 (favourable), Renal cancer:3.73e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 46.6 BBC3 JFY1, PUMA ENSG00000105327 BCL2 binding component 3 19 47220822-47232766 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007752, HPA070403 Approved Approved Cytosol Urothelial cancer:2.62e-5 (favourable), Endometrial cancer:1.31e-4 (favourable) Expressed in all Mixed cerebral cortex,skin: 4.7 CYSTM1 C5orf32, ORF1-FL49 ENSG00000120306 Cysteine-rich transmembrane module containing 1 5 140174642-140282052 Predicted intracellular proteins Evidence at protein level HPA050930 Supported Renal cancer:9.69e-5 (favourable), Endometrial cancer:1.31e-4 (favourable), Liver cancer:1.71e-4 (unfavourable) Expressed in all Expressed in all stomach: 482.5 CADM1 BL2, IGSF4, IGSF4A, Necl-2, NECL2, RA175, ST17, SYNCAM, SYNCAM1, TSLC1 ENSG00000182985 Cell adhesion molecule 1 11 115169218-115504957 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037266 Supported Supported Cell Junctions Endometrial cancer:1.32e-4 (favourable) Expressed in all Mixed parathyroid gland: 119.5 CWH43 CWH43-C, FLJ21511 ENSG00000109182 Cell wall biogenesis 43 C-terminal homolog 4 48986247-49062081 Predicted membrane proteins Evidence at protein level HPA042814, HPA048140 Uncertain Renal cancer:2.29e-11 (favourable), Endometrial cancer:1.32e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 69.1 skin: 29.7 STT3A ITM1, MGC9042, STT3-A, TMC ENSG00000134910 STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 11 125591712-125625215 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA030735 Approved Uncertain Nucleoplasm
Vesicles
Cytosol Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable) Expressed in all Tissue enriched 6 parathyroid gland: 1111.5 epididymis: 173.1 VIMP AD-015, MGC2553, SBBI8, SELS, SEPS1 ENSG00000131871 VCP-interacting membrane selenoprotein 15 101270817-101277500 Predicted membrane proteins Evidence at protein level HPA010025 Approved Validated Endoplasmic reticulum Endometrial cancer:1.33e-4 (favourable), Ovarian cancer:5.19e-4 (favourable) Expressed in all Expressed in all testis: 141.3 IL32 NK4, TAIF, TAIFb, TAIFd ENSG00000008517 Interleukin 32 16 3065297-3082192 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA029397, CAB030029 Approved Endometrial cancer:1.33e-4 (favourable) Expressed in all Expressed in all small intestine: 632.5 STPG1 C1orf201, FLJ33340, MAPO2 ENSG00000001460 Sperm-tail PG-rich repeat containing 1 1 24356999-24416934 Predicted intracellular proteins Evidence at protein level HPA024301 Approved Nucleoplasm Endometrial cancer:1.33e-4 (favourable), Renal cancer:2.31e-4 (favourable) Mixed Tissue enhanced testis: 46.6 fallopian tube: 26.4 ZBTB18 C2H2-171, RP58, TAZ-1, ZNF238 ENSG00000179456 Zinc finger and BTB domain containing 18 1 244048939-244057476 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044652 Supported Nucleoplasm
Microtubules
Cytokinetic bridge Urothelial cancer:6.78e-6 (favourable), Endometrial cancer:1.34e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 76.5 TP53 LFS1, p53 ENSG00000141510 Tumor protein p53 17 7661779-7687550 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters Evidence at protein level CAB002973, CAB039238, CAB039239, HPA051244, CAB072876 Supported Validated Nucleoplasm Endometrial cancer:1.35e-4 (favourable), Prostate cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 50.3 ZNF652 KIAA0924 ENSG00000198740 Zinc finger protein 652 17 49289206-49362473 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044408 Uncertain Approved Nucleus Endometrial cancer:1.35e-4 (favourable) Expressed in all Mixed breast: 7.2 CIRBP CIRP ENSG00000099622 Cold inducible RNA binding protein 19 1259384-1274880 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA060537 Supported Nucleus
Nucleoli Renal cancer:3.65e-7 (favourable), Endometrial cancer:1.36e-4 (favourable), Lung cancer:2.50e-4 (favourable), Pancreatic cancer:2.69e-4 (favourable), Cervical cancer:3.63e-4 (favourable) Expressed in all Expressed in all ovary: 1040.0 C1orf194 ENSG00000179902 Chromosome 1 open reading frame 194 1 109105951-109113857 Predicted intracellular proteins Evidence at protein level HPA031144, HPA049684 Supported Uncertain Nuclear speckles
Cytosol Endometrial cancer:1.36e-4 (favourable) Group enriched Group enriched 30 fallopian tube: 195.3;testis: 197.5 lung: 6.5 OVGP1 CHIT5, MUC9 ENSG00000085465 Oviductal glycoprotein 1, 120kDa 1 111414314-111427777 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA062205 Supported Urothelial cancer:3.93e-5 (favourable), Endometrial cancer:1.36e-4 (favourable) Group enriched Tissue enriched 117 fallopian tube: 3120.0 endometrium: 26.6 IL17RC IL17-RL ENSG00000163702 Interleukin 17 receptor C 3 9917074-9933630 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019885, CAB026255, HPA048514 Approved Uncertain Microtubules
Centrosome Endometrial cancer:1.38e-4 (favourable) Expressed in all Expressed in all prostate: 21.3 ADAMTS8 ADAM-TS8, FLJ41712, METH2 ENSG00000134917 ADAM metallopeptidase with thrombospondin type 1 motif, 8 11 130404925-130428993 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at transcript level HPA066349 Approved Endometrial cancer:1.38e-4 (favourable) Tissue enhanced Tissue enhanced appendix: 11.2;lung: 15.6 seminal vesicle: 5.5 BFSP1 CP115, CP94, filensin, LIFL-H ENSG00000125864 Beaded filament structural protein 1, filensin 20 17493905-17569220 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040748, HPA042038 Supported Supported Plasma membrane
Cytosol Endometrial cancer:1.39e-4 (favourable) Mixed Mixed testis: 6.5 TRADD Hs.89862 ENSG00000102871 TNFRSF1A-associated via death domain 16 67154180-67160298 Predicted intracellular proteins Evidence at protein level CAB004602 Approved Approved Cytosol Endometrial cancer:1.40e-4 (favourable) Expressed in all Mixed spleen: 17.9 RRBP1 ES/130, hES ENSG00000125844 Ribosome binding protein 1 20 17613678-17682295 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009026, HPA011924 Supported Validated Endoplasmic reticulum Endometrial cancer:1.41e-4 (favourable), Urothelial cancer:9.38e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 219.5 DMBT1 GP340, muclin ENSG00000187908 Deleted in malignant brain tumors 1 10 122560665-122643736 Disease related genes, Predicted secreted proteins Evidence at protein level HPA040778 Supported Endometrial cancer:1.43e-4 (favourable) Group enriched Tissue enhanced duodenum: 876.2;small intestine: 299.5 salivary gland: 145.2 OSTC DC2 ENSG00000198856 Oligosaccharyltransferase complex subunit (non-catalytic) 4 108650584-108667820 Predicted membrane proteins Evidence at protein level HPA065174 Approved Nucleoplasm Renal cancer:2.31e-8 (unfavourable), Endometrial cancer:1.44e-4 (favourable), Lung cancer:2.84e-4 (unfavourable), Head and neck cancer:6.66e-4 (unfavourable) Expressed in all Expressed in all epididymis: 211.5 CFAP157 C9orf117 ENSG00000160401 Cilia and flagella associated protein 157 9 127706989-127716002 Predicted intracellular proteins Evidence at protein level HPA021474, HPA021786 Supported Validated Plasma membrane
Cytosol Endometrial cancer:1.45e-4 (favourable) Mixed Tissue enriched 8 fallopian tube: 93.9 lung: 12.2 MAPKBP1 KIAA0596 ENSG00000137802 Mitogen-activated protein kinase binding protein 1 15 41774434-41827855 Predicted intracellular proteins Evidence at protein level HPA030832, HPA030833 Approved Approved Nucleoli Endometrial cancer:1.47e-4 (favourable), Ovarian cancer:6.80e-4 (unfavourable) Expressed in all Mixed testis: 34.0 CNGA4 CNCA2, CNG5, CNGB2, OCNC2, OCNCb ENSG00000132259 Cyclic nucleotide gated channel alpha 4 11 6234765-6244429 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Endometrial cancer:1.48e-4 (favourable) Tissue enriched Group enriched 9 fallopian tube: 27.6;testis: 10.5 lung: 2.1 STOML3 Epb7.2l, SRO ENSG00000133115 Stomatin (EPB72)-like 3 13 38965925-38991066 Predicted membrane proteins Evidence at protein level HPA012892, CAB014880 Approved Endometrial cancer:1.49e-4 (favourable) Tissue enhanced Tissue enriched 17 fallopian tube: 49.7 lung: 2.8 SMIM6 C17orf110 ENSG00000259120 Small integral membrane protein 6 17 75646243-75647977 Predicted membrane proteins Evidence at transcript level HPA065721 Uncertain Approved Nucleus Endometrial cancer:1.49e-4 (favourable), Urothelial cancer:1.64e-4 (favourable), Renal cancer:4.09e-4 (favourable) Mixed Tissue enhanced fallopian tube: 39.8;stomach: 34.4 testis: 22.7 FAAH FAAH-1 ENSG00000117480 Fatty acid amide hydrolase 1 46394265-46413848 Enzymes, Predicted membrane proteins Evidence at protein level HPA007425 Approved Uncertain Cytosol Stomach cancer:3.63e-5 (favourable), Renal cancer:4.25e-5 (favourable), Endometrial cancer:1.51e-4 (favourable) Expressed in all Expressed in all prostate: 56.6 PTPN3 PTPH1 ENSG00000070159 Protein tyrosine phosphatase, non-receptor type 3 9 109375466-109498313 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038343, HPA046728 Approved Renal cancer:1.22e-15 (favourable), Endometrial cancer:1.52e-4 (favourable), Breast cancer:6.71e-4 (unfavourable) Mixed Mixed skin: 35.9 PTPN7 HEPTP, LC-PTP ENSG00000143851 Protein tyrosine phosphatase, non-receptor type 7 1 202147013-202161588 Enzymes, Predicted intracellular proteins Evidence at protein level CAB009530, HPA019118 Approved Renal cancer:2.42e-8 (unfavourable), Endometrial cancer:1.52e-4 (favourable), Head and neck cancer:1.84e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 25.2;lymph node: 24.6 tonsil: 20.1 ZNF69 Cos5 ENSG00000198429 Zinc finger protein 69 19 11887784-11914329 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047845 Uncertain Uncertain Nucleus Endometrial cancer:1.55e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 25.3 kidney: 10.3 CRIPAK FLJ34443 ENSG00000179979 Cysteine-rich PAK1 inhibitor 4 1391552-1395989 Predicted intracellular proteins Evidence at protein level Endometrial cancer:1.55e-4 (favourable), Head and neck cancer:4.37e-4 (favourable) Expressed in all Mixed skin: 15.0 DRG2 ENSG00000108591 Developmentally regulated GTP binding protein 2 17 18087886-18107971 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA007716 Approved Supported Nucleoplasm
Vesicles
Cytosol Endometrial cancer:1.56e-4 (favourable), Prostate cancer:7.34e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 29.0 TCTEX1D4 ENSG00000188396 Tctex1 domain containing 4 1 44805913-44806675 Predicted intracellular proteins Evidence at protein level HPA062652 Supported Endometrial cancer:1.58e-4 (favourable) Mixed Tissue enhanced fallopian tube: 5.8 epididymis: 1.6 FAM134C DKFZp686B1036, FLJ33806 ENSG00000141699 Family with sequence similarity 134, member C 17 42579513-42610623 Predicted membrane proteins Evidence at protein level HPA016492 Uncertain Approved Nucleoplasm
Nuclear membrane
Cytosol Endometrial cancer:1.61e-4 (favourable), Renal cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all testis: 48.6 ARL1 ARFL1 ENSG00000120805 ADP-ribosylation factor-like 1 12 101393120-101407820 Predicted intracellular proteins Evidence at protein level HPA062656, HPA073012 Approved Supported Golgi apparatus Endometrial cancer:1.61e-4 (favourable) Expressed in all Expressed in all thyroid gland: 141.5 PAM PAL, PHM ENSG00000145730 Peptidylglycine alpha-amidating monooxygenase 5 102753981-103031105 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026119, HPA042260 Supported Approved Golgi apparatus
Cytosol Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 1092.7 RANGRF HSPC165, HSPC236, MOG1, RANGNRF ENSG00000108961 RAN guanine nucleotide release factor 17 8288497-8290092 Predicted intracellular proteins Evidence at protein level HPA057280, HPA057888 Approved Supported Nucleoplasm Endometrial cancer:1.65e-4 (favourable), Pancreatic cancer:4.39e-4 (favourable) Expressed in all Expressed in all testis: 71.8 CORO1B coronin-2 ENSG00000172725 Coronin, actin binding protein, 1B 11 67435510-67443821 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017616, HPA040113, HPA070456 Supported Validated Plasma membrane
Cytosol Endometrial cancer:1.65e-4 (favourable) Expressed in all Expressed in all prostate: 77.2 MFNG ENSG00000100060 MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 22 37469063-37486401 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA048936, HPA056479 Approved Uncertain Actin filaments Renal cancer:3.31e-5 (unfavourable), Endometrial cancer:1.65e-4 (favourable), Colorectal cancer:5.12e-4 (unfavourable) Expressed in all Mixed lymph node: 69.5 MRAP2 bA51G5.2, C6orf117 ENSG00000135324 Melanocortin 2 receptor accessory protein 2 6 84033756-84090881 Disease related genes, Predicted membrane proteins Evidence at protein level Endometrial cancer:1.66e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 21.1 fallopian tube: 13.3 NHS ENSG00000188158 Nance-Horan syndrome (congenital cataracts and dental anomalies) X 17375420-17735994 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031497, HPA076257 Uncertain Supported Cell Junctions Endometrial cancer:1.68e-4 (favourable) Mixed Mixed endometrium: 7.8 ENKD1 C16orf48, DKFZP434A1319 ENSG00000124074 Enkurin domain containing 1 16 67662945-67667265 Predicted intracellular proteins Evidence at protein level HPA041163, HPA041478 Approved Supported Plasma membrane
Centrosome
Cytosol Endometrial cancer:1.68e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 32.0 DOT1L DOT1, KIAA1814, KMT4 ENSG00000104885 DOT1-like histone H3K79 methyltransferase 19 2164149-2232578 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA011875, HPA071217 Validated Nucleoplasm Endometrial cancer:1.69e-4 (favourable), Head and neck cancer:6.00e-4 (favourable) Expressed in all Tissue enriched 6 testis: 92.5 appendix: 14.5 STAT6 D12S1644, IL-4-STAT ENSG00000166888 Signal transducer and activator of transcription 6, interleukin-4 induced 12 57095408-57132139 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001861 Approved Validated Nucleoplasm
Cytosol Urothelial cancer:1.14e-4 (favourable), Endometrial cancer:1.69e-4 (favourable), Thyroid cancer:7.76e-4 (favourable) Expressed in all Expressed in all skin: 164.0 NANS SAS ENSG00000095380 N-acetylneuraminic acid synthase 9 98056739-98083075 Enzymes, Predicted intracellular proteins Evidence at protein level HPA019223 Approved Approved Nucleoplasm Endometrial cancer:1.71e-4 (favourable), Liver cancer:6.42e-4 (unfavourable) Expressed in all Expressed in all prostate: 149.7 AEN FLJ12484, FLJ12562, ISG20L1 ENSG00000181026 Apoptosis enhancing nuclease 15 88621296-88632282 Predicted intracellular proteins Evidence at protein level HPA048599 Supported Nucleus
Nuclear membrane
Nucleoli Endometrial cancer:1.72e-4 (favourable) Expressed in all Mixed gallbladder: 19.8 ABHD17A C19orf27, FAM108A1, MGC5244 ENSG00000129968 Abhydrolase domain containing 17A 19 1876810-1885547 Predicted intracellular proteins Evidence at protein level HPA043270, HPA047226 Uncertain Approved Vesicles Pancreatic cancer:1.76e-5 (favourable), Endometrial cancer:1.73e-4 (favourable), Head and neck cancer:6.46e-4 (favourable) Expressed in all Mixed cerebral cortex: 31.5 IL2RG CD132, CIDX, IMD4, SCIDX1 ENSG00000147168 Interleukin 2 receptor, gamma X 71107404-71112108 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046641, HPA049691 Supported Approved Vesicles Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable) Expressed in all Tissue enhanced lymph node: 277.4;tonsil: 290.2 appendix: 188.7 PARVA FLJ10793, FLJ12254, MXRA2 ENSG00000197702 Parvin, alpha 11 12377185-12530801 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA005964 Approved Supported Actin filaments
Focal adhesion sites
Cytosol Endometrial cancer:1.76e-4 (favourable), Lung cancer:8.19e-4 (unfavourable) Expressed in all Mixed smooth muscle: 143.9 SSR4 TRAPD ENSG00000180879 Signal sequence receptor, delta X 153793516-153798505 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA045209 Supported Renal cancer:5.51e-6 (unfavourable), Endometrial cancer:1.76e-4 (favourable) Expressed in all Expressed in all epididymis: 962.9 PHLDA3 TIH1 ENSG00000174307 Pleckstrin homology-like domain, family A, member 3 1 201464383-201469237 Predicted intracellular proteins Evidence at protein level HPA027601 Approved Endometrial cancer:1.77e-4 (favourable), Renal cancer:3.67e-4 (unfavourable) Expressed in all Mixed adipose tissue: 61.4 GCNT3 C2/4GnT, C2GnT-M, C2GnT2 ENSG00000140297 Glucosaminyl (N-acetyl) transferase 3, mucin type 15 59594875-59640239 Enzymes, Predicted membrane proteins Evidence at protein level HPA011154 Approved Approved Golgi apparatus
Vesicles Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable) Tissue enhanced Tissue enhanced colon: 144.6;gallbladder: 118.5;rectum: 136.6;small intestine: 141.0 duodenum: 100.5 HGD AKU, HGO ENSG00000113924 Homogentisate 1,2-dioxygenase 3 120628173-120682571 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA047374, HPA052359 Supported Approved Nucleus
Nucleoli Endometrial cancer:1.78e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 174.2;liver: 322.8 gallbladder: 87.5 SLC35E3 BLOV1 ENSG00000175782 Solute carrier family 35, member E3 12 68746106-68793964 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA049403 Uncertain Endometrial cancer:1.78e-4 (favourable) Expressed in all Mixed skin: 6.1 TTC21A IFT139A, STI2 ENSG00000168026 Tetratricopeptide repeat domain 21A 3 39107704-39138903 Predicted intracellular proteins Evidence at protein level HPA035510, HPA035511 Approved Supported Nucleoplasm Endometrial cancer:1.79e-4 (favourable) Mixed Tissue enriched 26 testis: 39.3 fallopian tube: 1.4 C10orf107 bA63A2.1, Em:AC022398.2, MGC44593 ENSG00000183346 Chromosome 10 open reading frame 107 10 61662961-61766766 Predicted intracellular proteins Evidence at protein level HPA041398 Supported Uncertain Nucleoplasm
Centrosome
Cytosol Endometrial cancer:1.79e-4 (favourable), Glioma:3.99e-4 (unfavourable) Mixed Tissue enhanced fallopian tube: 43.7;testis: 30.2 parathyroid gland: 12.4 TP73 P73 ENSG00000078900 Tumor protein p73 1 3652520-3736201 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002514, CAB003022, HPA027314, HPA044516 Supported Supported Nucleoplasm
Golgi apparatus Endometrial cancer:1.82e-4 (favourable), Cervical cancer:2.98e-4 (favourable), Head and neck cancer:9.50e-4 (favourable) Mixed Group enriched 5 fallopian tube: 11.0;skin: 8.1 prostate: 1.8 N6AMT2 ENSG00000150456 N-6 adenine-specific DNA methyltransferase 2 (putative) 13 20728731-20773958 Predicted intracellular proteins Evidence at protein level HPA040417, HPA042543 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:1.82e-4 (favourable) Expressed in all Expressed in all endometrium: 18.0 CST3 ENSG00000101439 Cystatin C 20 23626706-23638473 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000118, HPA013143 Supported Supported Golgi apparatus
Vesicles Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1269.6 CARS2 FLJ12118 ENSG00000134905 Cysteinyl-tRNA synthetase 2, mitochondrial (putative) 13 110641412-110713603 Enzymes, Predicted intracellular proteins Evidence at protein level HPA041776 Uncertain Approved Nucleoplasm
Mitochondria Renal cancer:2.49e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Endometrial cancer:1.84e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 28.3 WDR31 FLJ35921 ENSG00000148225 WD repeat domain 31 9 113313222-113340298 Predicted intracellular proteins Evidence at transcript level HPA019340, HPA019347 Approved Approved Nuclear bodies
Cytosol Renal cancer:1.90e-9 (favourable), Endometrial cancer:1.85e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 16.3 testis: 9.2 TTLL1 C22orf7 ENSG00000100271 Tubulin tyrosine ligase-like family member 1 22 43039644-43089428 Predicted intracellular proteins Evidence at transcript level HPA048392 Approved Approved Nucleoli
Mitochondria Liver cancer:2.34e-5 (unfavourable), Renal cancer:1.68e-4 (favourable), Endometrial cancer:1.85e-4 (favourable) Expressed in all Mixed testis: 20.2 SH3GL1 CNSA1, EEN, MGC111371, SH3D2B, SH3P8 ENSG00000141985 SH3-domain GRB2-like 1 19 4360370-4400547 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA021485 Approved Validated Cytosol Renal cancer:9.36e-8 (unfavourable), Liver cancer:1.10e-4 (unfavourable), Cervical cancer:1.50e-4 (favourable), Endometrial cancer:1.86e-4 (favourable) Expressed in all Expressed in all esophagus: 115.0 GZMM LMET1, MET1 ENSG00000197540 Granzyme M (lymphocyte met-ase 1) 19 544034-549924 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA015624 Supported Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable) Expressed in all Tissue enhanced lymph node: 21.3;spleen: 20.1 appendix: 13.4 UBXN11 SOC, SOCI, UBXD5 ENSG00000158062 UBX domain protein 11 1 26281328-26318363 Predicted intracellular proteins Evidence at protein level HPA028600, HPA031357 Approved Approved Nucleoli
Cytosol Liver cancer:5.90e-6 (unfavourable), Cervical cancer:2.54e-5 (favourable), Endometrial cancer:1.90e-4 (favourable), Head and neck cancer:4.90e-4 (favourable) Expressed in all Expressed in all fallopian tube: 49.6 DOCK5 FLJ21034 ENSG00000147459 Dedicator of cytokinesis 5 8 25184723-25418082 Predicted intracellular proteins Evidence at protein level HPA017719, HPA056837 Approved Validated Cytosol Renal cancer:1.18e-6 (unfavourable), Endometrial cancer:1.91e-4 (favourable) Expressed in all Mixed spleen: 18.9 IFT27 BBS19, RABL4, RAYL ENSG00000100360 Intraflagellar transport 27 22 36758202-36776256 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA018418 Uncertain Approved Nucleoplasm
Mitochondria Endometrial cancer:1.91e-4 (favourable), Urothelial cancer:5.55e-4 (favourable) Expressed in all Expressed in all fallopian tube: 56.6 SFN YWHAS ENSG00000175793 Stratifin 1 26863138-26864457 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB006268, HPA011105, CAB040552 Supported Supported Cytosol Renal cancer:7.45e-6 (unfavourable), Liver cancer:5.68e-5 (unfavourable), Endometrial cancer:1.92e-4 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Group enriched 8 esophagus: 1094.4;skin: 1158.9 tonsil: 137.8 NAAA ASAHL ENSG00000138744 N-acylethanolamine acid amidase 4 75913657-75941051 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026135 Approved Endometrial cancer:1.93e-4 (favourable), Pancreatic cancer:4.90e-4 (favourable) Expressed in all Expressed in all prostate: 112.5 PIK3R3 p55 ENSG00000117461 Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 1 46040140-46133036 Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA005751, HPA071988 Approved Approved Nucleoplasm
Vesicles Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable) Expressed in all Mixed testis: 46.2 GMEB1 P96PIF, PIF96 ENSG00000162419 Glucocorticoid modulatory element binding protein 1 1 28668732-28719353 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044811, HPA052975 Supported Validated Nucleoplasm Liver cancer:8.91e-7 (unfavourable), Endometrial cancer:1.94e-4 (favourable) Expressed in all Mixed bone marrow: 8.6 SND1 p100, TDRD11 ENSG00000197157 Staphylococcal nuclease and tudor domain containing 1 7 127652180-128092609 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002529, HPA002632, CAB019323 Supported Validated Cytosol Endometrial cancer:1.95e-4 (favourable) Expressed in all Expressed in all placenta: 121.5 GNA15 GNA16 ENSG00000060558 Guanine nucleotide binding protein (G protein), alpha 15 (Gq class) 19 3136193-3163769 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043113 Approved Renal cancer:4.26e-6 (unfavourable), Breast cancer:7.57e-5 (favourable), Endometrial cancer:2.01e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 48.8;esophagus: 61.5 skin: 25.9 UBXN10 FLJ25429, UBXD3 ENSG00000162543 UBX domain protein 10 1 20186085-20196048 Predicted intracellular proteins Evidence at protein level HPA028555, HPA028564 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable) Mixed Tissue enhanced fallopian tube: 78.2 testis: 25.4 SPON2 DIL1 ENSG00000159674 Spondin 2, extracellular matrix protein 4 1166932-1208962 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040170, HPA066095 Uncertain Approved Vesicles Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable) Tissue enriched Tissue enhanced endometrium: 105.3;prostate: 96.8 cervix, uterine: 53.6 PDIA3 ERp57, ERp60, ERp61, GRP57, GRP58, HsT17083, P58, PI-PLC ENSG00000167004 Protein disulfide isomerase family A, member 3 15 43746392-43773279 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002645, HPA003230, CAB011199, CAB015181 Supported Validated Endoplasmic reticulum Renal cancer:2.11e-8 (unfavourable), Head and neck cancer:8.95e-5 (unfavourable), Endometrial cancer:2.05e-4 (favourable) Expressed in all Expressed in all thyroid gland: 91.1 CD52 CDW52 ENSG00000169442 CD52 molecule 1 26317957-26320523 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable) Expressed in all Tissue enriched 34 epididymis: 43067.6 lymph node: 1271.7 CXCL9 CMK, crg-10, Humig, MIG, SCYB9 ENSG00000138755 Chemokine (C-X-C motif) ligand 9 4 76001275-76007488 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:5.15e-6 (unfavourable), Endometrial cancer:2.07e-4 (favourable), Breast cancer:6.36e-4 (favourable), Ovarian cancer:8.06e-4 (favourable) Expressed in all Tissue enhanced lymph node: 332.0 appendix: 89.3 AP1M2 AP1-mu2, HSMU1B, mu2 ENSG00000129354 Adaptor-related protein complex 1, mu 2 subunit 19 10572671-10587315 Predicted intracellular proteins Evidence at protein level HPA054999 Supported Vesicles Renal cancer:3.73e-6 (favourable), Endometrial cancer:2.07e-4 (favourable) Mixed Mixed thyroid gland: 98.0 PRF1 HPLH2, P1, PFP ENSG00000180644 Perforin 1 (pore forming protein) 10 70597348-70602775 Cancer-related genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB002436, HPA037940 Approved Approved Cytosol Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable) Expressed in all Tissue enhanced spleen: 54.5 lymph node: 21.2 LRRC46 MGC16309 ENSG00000141294 Leucine rich repeat containing 46 17 47831627-47837713 Predicted intracellular proteins Evidence at protein level HPA021882 Approved Cytosol Endometrial cancer:2.11e-4 (favourable) Tissue enhanced Group enriched 13 fallopian tube: 119.1;testis: 55.5 lung: 6.5 PLCB4 ENSG00000101333 Phospholipase C, beta 4 20 9068763-9481242 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007951 Approved Nucleoplasm
Microtubules Endometrial cancer:2.11e-4 (favourable) Tissue enhanced Tissue enhanced thyroid gland: 58.3 epididymis: 29.9 DNAAF1 CILD13, FLJ25330, LRRC50, ODA7 ENSG00000154099 Dynein, axonemal, assembly factor 1 16 84145287-84178767 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041166 Uncertain Approved Nuclear speckles
Plasma membrane
Cytosol Endometrial cancer:2.14e-4 (favourable) Tissue enhanced Group enriched 20 fallopian tube: 34.1;testis: 80.2 lung: 2.8 EIF3I eIF3-beta, eIF3-p36, eIF3i, EIF3S2, TRIP-1 ENSG00000084623 Eukaryotic translation initiation factor 3, subunit I 1 32221928-32231604 Predicted intracellular proteins Evidence at protein level HPA029939, HPA029940 Supported Uncertain Nucleoplasm
Cytosol Renal cancer:4.81e-6 (unfavourable), Endometrial cancer:2.14e-4 (favourable), Liver cancer:4.21e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 197.3 SPAG8 BS-84, CT142, HSD-1, hSMP-1, SPAG3 ENSG00000137098 Sperm associated antigen 8 9 35808045-35812272 Predicted intracellular proteins Evidence at protein level HPA068012 Supported Endometrial cancer:2.15e-4 (favourable) Mixed Group enriched 10 fallopian tube: 28.7;testis: 16.3 thyroid gland: 2.2 COASY CoASY, DPCK, NBP, PPAT ENSG00000068120 CoA synthase 17 42561467-42566277 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA022875, HPA022912, HPA023273 Approved Approved Nucleoplasm
Cytosol Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 58.9 CD4 ENSG00000010610 CD4 molecule 12 6786858-6820808 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000011, HPA004252, HPA004472, CAB068180 Supported Supported Plasma membrane Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 538.7 spleen: 224.0 ACOX3 ENSG00000087008 Acyl-CoA oxidase 3, pristanoyl 4 8366282-8440723 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035840, HPA035841 Uncertain Approved Peroxisomes Endometrial cancer:2.16e-4 (favourable) Expressed in all Expressed in all esophagus: 22.3 C22orf39 MGC74441 ENSG00000242259 Chromosome 22 open reading frame 39 22 19351368-19448232 Predicted intracellular proteins Evidence at protein level HPA073701 Approved Endoplasmic reticulum Renal cancer:1.44e-4 (favourable), Endometrial cancer:2.16e-4 (favourable) Expressed in all Expressed in all thyroid gland: 51.9 MLKL FLJ34389 ENSG00000168404 Mixed lineage kinase domain-like 16 74671855-74700960 Enzymes, Predicted intracellular proteins Evidence at protein level Endometrial cancer:2.16e-4 (favourable) Expressed in all Mixed spleen: 29.4 ARHGEF3 DKFZP434F2429, GEF3, STA3, XPLN ENSG00000163947 Rho guanine nucleotide exchange factor (GEF) 3 3 56727418-57079329 Predicted intracellular proteins Evidence at protein level HPA034715, HPA064945 Uncertain Approved Cytosol Renal cancer:1.96e-7 (favourable), Endometrial cancer:2.17e-4 (favourable), Head and neck cancer:2.61e-4 (favourable) Expressed in all Expressed in all endometrium: 64.6 MVD MPD ENSG00000167508 Mevalonate (diphospho) decarboxylase 16 88651935-88663161 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041404, HPA048250 Uncertain Approved Cell Junctions
Cytosol Endometrial cancer:2.17e-4 (favourable) Expressed in all Expressed in all duodenum: 34.8 DOK7 C4orf25, Dok-7, FLJ33718, FLJ39137 ENSG00000175920 Docking protein 7 4 3463311-3501473 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA059449 Approved Approved Nucleoplasm
Mitochondria Breast cancer:8.45e-5 (favourable), Urothelial cancer:1.28e-4 (favourable), Endometrial cancer:2.19e-4 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 6.5;heart muscle: 9.8 skeletal muscle: 4.2 DPM2 MGC111193, MGC21559 ENSG00000136908 Dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunit 9 127935099-127938484 Disease related genes, Predicted membrane proteins Evidence at protein level HPA064623 Approved Endometrial cancer:2.20e-4 (favourable), Liver cancer:7.08e-4 (unfavourable) Expressed in all Mixed stomach: 25.0 TRIM3 BERP, HAC1, RNF22, RNF97 ENSG00000110171 Tripartite motif containing 3 11 6448613-6474459 Predicted intracellular proteins Evidence at protein level HPA043396, HPA048233 Uncertain Approved Mitochondria Renal cancer:1.07e-5 (unfavourable), Pancreatic cancer:5.49e-5 (favourable), Endometrial cancer:2.20e-4 (favourable) Expressed in all Mixed duodenum: 17.7 GOLGA1 golgin-97, MGC33154 ENSG00000136935 Golgin A1 9 124878357-124948492 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013065, HPA044329, HPA050555 Supported Validated Golgi apparatus Endometrial cancer:2.21e-4 (favourable) Expressed in all Expressed in all testis: 28.7 RIN1 ENSG00000174791 Ras and Rab interactor 1 11 66330242-66336840 Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA035491 Uncertain Approved Nucleus
Nuclear membrane Renal cancer:9.34e-7 (unfavourable), Endometrial cancer:2.21e-4 (favourable) Expressed in all Tissue enhanced skin: 19.3 cerebral cortex,stomach: 5.2 TRNAU1AP FLJ20503, SECP43, TRSPAP1 ENSG00000180098 TRNA selenocysteine 1 associated protein 1 1 28553085-28578545 Predicted intracellular proteins Evidence at protein level HPA032068, HPA032069 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:1.16e-5 (unfavourable), Liver cancer:8.64e-5 (unfavourable), Endometrial cancer:2.22e-4 (favourable), Thyroid cancer:9.45e-4 (favourable) Expressed in all Mixed skin: 8.2 SPG7 CAR, CMAR, SPG5C ENSG00000197912 Spastic paraplegia 7 (pure and complicated autosomal recessive) 16 89490917-89557768 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable) Expressed in all Expressed in all thyroid gland: 52.3 TSNAXIP1 TXI1 ENSG00000102904 Translin-associated factor X interacting protein 1 16 67806765-67832148 Predicted intracellular proteins Evidence at protein level HPA053516 Approved Nucleus
Cytosol Endometrial cancer:2.22e-4 (favourable) Mixed Group enriched 10 fallopian tube: 15.4;testis: 40.0 parathyroid gland: 2.7 S1PR4 EDG6 ENSG00000125910 Sphingosine-1-phosphate receptor 4 19 3172346-3180332 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA060601, HPA067232 Uncertain Mitochondria Head and neck cancer:1.45e-6 (favourable), Cervical cancer:1.33e-4 (favourable), Endometrial cancer:2.22e-4 (favourable), Renal cancer:2.87e-4 (unfavourable), Breast cancer:3.13e-4 (favourable) Expressed in all Tissue enhanced lymph node: 18.3;spleen: 27.0 appendix: 14.5 SEPN1 MDRS1, RSMD1, RSS, selN ENSG00000162430 Selenoprotein N, 1 1 25800176-25818224 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA058076 Approved Supported Cytosol Liver cancer:3.40e-5 (unfavourable), Endometrial cancer:2.23e-4 (favourable) Expressed in all Expressed in all smooth muscle: 80.2 CASP3 apopain, CPP32, CPP32B, Yama ENSG00000164305 Caspase 3, apoptosis-related cysteine peptidase 4 184627696-184649509 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000091, HPA002643, CAB008381 Approved Supported Nucleoplasm
Mitochondria Renal cancer:2.30e-5 (unfavourable), Endometrial cancer:2.24e-4 (favourable) Expressed in all Expressed in all duodenum: 55.9 TPGS1 C19orf20, GTRGEO22, PGs1 ENSG00000141933 Tubulin polyglutamylase complex subunit 1 19 507497-519654 Predicted intracellular proteins Evidence at protein level Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:8.82e-4 (favourable) Expressed in all Mixed cerebral cortex: 6.6 DOHH HLRC1, MGC4293 ENSG00000129932 Deoxyhypusine hydroxylase/monooxygenase 19 3490821-3500940 Enzymes, Predicted intracellular proteins Evidence at protein level HPA041953 Approved Approved Nucleus
Cytosol Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable) Expressed in all Mixed duodenum: 18.3 FBXO36 Fbx36, FLJ37592 ENSG00000153832 F-box protein 36 2 229922302-230013109 Predicted intracellular proteins Evidence at protein level HPA053865 Approved Nucleus
Nucleoli Endometrial cancer:2.28e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 17.4 thyroid gland: 12.4 STXBP2 Hunc18b, UNC18B ENSG00000076944 Syntaxin binding protein 2 19 7636881-7647873 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA015564, HPA063868 Approved Validated Cytosol Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable) Expressed in all Mixed bone marrow: 125.6 PITPNA PITPN, VIB1A ENSG00000174238 Phosphatidylinositol transfer protein, alpha 17 1517718-1562816 Predicted intracellular proteins Evidence at protein level HPA000528 Uncertain Approved Vesicles
Cytosol Pancreatic cancer:1.80e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Renal cancer:9.35e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.3 MESDC2 BOCA, KIAA0081, MESD ENSG00000117899 Mesoderm development candidate 2 15 80946289-80989878 Predicted secreted proteins Evidence at protein level HPA039414, HPA041721 Approved Supported Nuclear bodies
Endoplasmic reticulum
Cytosol Ovarian cancer:1.12e-4 (favourable), Endometrial cancer:2.31e-4 (favourable) Expressed in all Expressed in all thyroid gland: 55.6 CCDC160 ENSG00000203952 Coiled-coil domain containing 160 X 134237047-134246207 Predicted intracellular proteins Evidence at transcript level HPA044684 Uncertain Ovarian cancer:7.62e-6 (favourable), Renal cancer:2.21e-4 (favourable), Endometrial cancer:2.31e-4 (favourable) Mixed Mixed parathyroid gland: 8.3 TPT1 fortilin, TCTP ENSG00000133112 Tumor protein, translationally-controlled 1 13 45333471-45341370 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008364, HPA039437 Approved Supported Cytosol Renal cancer:2.54e-5 (unfavourable), Thyroid cancer:4.31e-5 (favourable), Breast cancer:5.90e-5 (favourable), Endometrial cancer:2.35e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 8105.5 GLTSCR2 PICT-1 ENSG00000105373 Glioma tumor suppressor candidate region gene 2 19 47745522-47757058 Predicted intracellular proteins Evidence at protein level HPA018999, HPA049600 Approved Validated Nucleoli Endometrial cancer:2.35e-4 (favourable) Expressed in all Expressed in all ovary: 531.9 THOP1 ENSG00000172009 Thimet oligopeptidase 1 19 2785460-2815807 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025497, HPA035262 Uncertain Supported Cytosol Endometrial cancer:2.35e-4 (favourable), Stomach cancer:5.90e-4 (favourable) Expressed in all Expressed in all testis: 36.2 CRAT CAT1 ENSG00000095321 Carnitine O-acetyltransferase 9 129094810-129111189 Enzymes, Predicted intracellular proteins, Transporters Evidence at protein level HPA019230, HPA020260, HPA022815 Supported Approved Nucleoplasm
Nuclear membrane Renal cancer:0.00e+0 (favourable), Endometrial cancer:2.36e-4 (favourable) Expressed in all Expressed in all testis: 116.2 DEF6 IBP, SLAT, SWAP70L ENSG00000023892 DEF6 guanine nucleotide exchange factor 6 35297852-35321771 Predicted intracellular proteins Evidence at protein level HPA038975, HPA038976 Supported Validated Nucleoplasm Renal cancer:1.02e-8 (unfavourable), Breast cancer:3.02e-6 (favourable), Cervical cancer:1.08e-4 (favourable), Colorectal cancer:1.71e-4 (unfavourable), Endometrial cancer:2.37e-4 (favourable) Expressed in all Mixed lymph node: 56.9 AMPD3 ENSG00000133805 Adenosine monophosphate deaminase 3 11 10308313-10507579 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA038662, HPA047408 Uncertain Validated Nuclear membrane Endometrial cancer:2.37e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 53.6 bone marrow: 41.5 FDXR ADXR ENSG00000161513 Ferredoxin reductase 17 74862497-74873031 Enzymes, Predicted intracellular proteins Evidence at protein level CAB009818, HPA044393, HPA053673 Supported Validated Mitochondria Endometrial cancer:2.38e-4 (favourable) Expressed in all Tissue enriched 6 adrenal gland: 233.0 testis: 39.2 ZNF799 HIT-40, MGC71805, ZNF842 ENSG00000196466 Zinc finger protein 799 19 12390016-12401271 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003150, HPA018683 Supported Uncertain Nucleoplasm
Microtubule organizing center Endometrial cancer:2.39e-4 (favourable) Mixed Mixed ovary: 7.6 CD6 Tp120 ENSG00000013725 CD6 molecule 11 60971680-61020377 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002489, CAB016252 Supported Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable) Mixed Tissue enhanced appendix: 29.5;lymph node: 49.8 tonsil: 27.7 FUCA1 ENSG00000179163 Fucosidase, alpha-L- 1, tissue 1 23845077-23868294 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA046542, HPA056371 Supported Renal cancer:5.70e-13 (favourable), Endometrial cancer:2.45e-4 (favourable) Expressed in all Expressed in all lymph node: 188.2 HOXB6 HOX2, HOX2B ENSG00000108511 Homeobox B6 17 48595751-48604992 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA042063 Approved Nucleus
Golgi apparatus Endometrial cancer:2.46e-4 (favourable) Tissue enhanced Tissue enhanced epididymis: 48.4;seminal vesicle: 29.8 cervix, uterine: 26.3 RPS28 S28 ENSG00000233927 Ribosomal protein S28 19 8321158-8323340 Disease related genes, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA047132 Approved Approved Cytosol Endometrial cancer:2.47e-4 (favourable) Expressed in all Expressed in all ovary: 306.8 TLE2 ESG, ESG2, FLJ41188, GRG2 ENSG00000065717 Transducin-like enhancer of split 2 19 2997638-3047635 Predicted intracellular proteins Evidence at protein level HPA049103 Approved Supported Nuclear bodies
Focal adhesion sites Pancreatic cancer:2.39e-6 (favourable), Renal cancer:9.49e-6 (favourable), Endometrial cancer:2.51e-4 (favourable), Urothelial cancer:8.88e-4 (favourable) Expressed in all Mixed seminal vesicle: 39.1 HEXIM2 FLJ32384 ENSG00000168517 Hexamethylene bis-acetamide inducible 2 17 45160700-45170040 Predicted intracellular proteins Evidence at protein level HPA023323, HPA028455 Supported Supported Nucleoplasm
Nuclear speckles Endometrial cancer:2.53e-4 (favourable), Ovarian cancer:9.85e-4 (favourable) Expressed in all Expressed in all testis: 46.8 LSP1 WP34 ENSG00000130592 Lymphocyte-specific protein 1 11 1852970-1892267 Predicted intracellular proteins Evidence at protein level CAB017781, HPA019693, HPA071843 Supported Supported Plasma membrane Endometrial cancer:2.54e-4 (favourable), Cervical cancer:3.56e-4 (favourable), Glioma:9.00e-4 (unfavourable) Expressed in all Expressed in all spleen: 286.5 MMP9 CLG4B ENSG00000100985 Matrix metallopeptidase 9 20 46008908-46016561 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201 Supported Approved Cytosol Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 253.0;lymph node: 119.4 appendix: 85.4 NWD1 ENSG00000188039 NACHT and WD repeat domain containing 1 19 16719976-16817963 Predicted intracellular proteins Evidence at protein level Endometrial cancer:2.55e-4 (favourable) Tissue enriched Group enriched 7 cerebral cortex: 1.9;fallopian tube: 7.6;prostate: 5.8;seminal vesicle: 1.6 lung: 0.6 TMPRSS2 PRSS10 ENSG00000184012 Transmembrane protease, serine 2 21 41464551-41531116 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034493, HPA035787 Supported Supported Nucleoplasm
Cell Junctions Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable) Tissue enriched Tissue enhanced prostate: 495.7 stomach: 142.5 PIGR ENSG00000162896 Polymeric immunoglobulin receptor 1 206928518-206946466 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006154, CAB009454, HPA012012 Supported Uncertain Nucleus
Nucleoli
Cytosol Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable) Tissue enhanced Tissue enhanced colon: 1721.7;duodenum: 2732.8 rectum: 1357.3 SQRDL CGI-44 ENSG00000137767 Sulfide quinone reductase-like (yeast) 15 45631148-45691294 Predicted intracellular proteins Evidence at protein level HPA017079, HPA041589 Supported Validated Mitochondria Endometrial cancer:2.57e-4 (favourable), Lung cancer:8.80e-4 (unfavourable) Expressed in all Expressed in all colon: 196.9 BBS4 ENSG00000140463 Bardet-Biedl syndrome 4 15 72686179-72738476 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039418 Approved Supported Cytosol Endometrial cancer:2.57e-4 (favourable) Expressed in all Expressed in all testis: 37.3 FZR1 CDC20C, CDH1, FZR, FZR2, HCDH, HCDH1, KIAA1242 ENSG00000105325 Fizzy/cell division cycle 20 related 1 19 3506273-3538330 Predicted intracellular proteins Evidence at protein level HPA043536 Approved Supported Nucleoplasm
Nuclear membrane Cervical cancer:1.75e-4 (favourable), Endometrial cancer:2.57e-4 (favourable) Expressed in all Expressed in all testis: 33.1 HYOU1 Grp170, HSP12A, ORP150 ENSG00000149428 Hypoxia up-regulated 1 11 119044189-119057202 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA049296 Approved Renal cancer:5.10e-5 (unfavourable), Endometrial cancer:2.58e-4 (favourable), Thyroid cancer:5.00e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 111.5 CDK20 CCRK, p42 ENSG00000156345 Cyclin-dependent kinase 20 9 87966441-87974753 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007666, HPA027379, HPA027401 Approved Supported Nucleoplasm Renal cancer:2.12e-5 (favourable), Endometrial cancer:2.59e-4 (favourable) Expressed in all Mixed fallopian tube: 20.5 BSG CD147, EMMPRIN, OK ENSG00000172270 Basigin (Ok blood group) 19 571277-583493 Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB002427, HPA036048, HPA074870 Supported Approved Vesicles Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable) Expressed in all Expressed in all heart muscle: 585.9 SLC5A1 D22S675, NAGT, SGLT1 ENSG00000100170 Solute carrier family 5 (sodium/glucose cotransporter), member 1 22 32043032-32113029 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015467, HPA051805, HPA055106 Supported Approved Nucleoplasm
Vesicles Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable) Mixed Group enriched 10 duodenum: 518.9;small intestine: 320.2 gallbladder: 40.3 RARA NR1B1, RAR ENSG00000131759 Retinoic acid receptor, alpha 17 40309192-40357643 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058282 Supported Nucleus
Cytosol Endometrial cancer:2.60e-4 (favourable) Expressed in all Expressed in all gallbladder: 68.9 RDH11 ARSDR1, MDT1, SDR7C1 ENSG00000072042 Retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 14 67676801-67695814 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB046011 Supported Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 945.5 parathyroid gland: 123.3 PLIN3 M6PRBP1, PP17, TIP47 ENSG00000105355 Perilipin 3 19 4838341-4867768 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006427, HPA066538 Uncertain Validated Lipid droplets
Cytosol Renal cancer:9.15e-7 (unfavourable), Lung cancer:7.67e-6 (unfavourable), Liver cancer:3.27e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable) Expressed in all Expressed in all esophagus: 116.2 SMIM14 C4orf34, FLJ13289 ENSG00000163683 Small integral membrane protein 14 4 39546330-39639090 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051299 Uncertain Approved Mitochondria Head and neck cancer:3.00e-6 (favourable), Renal cancer:2.07e-4 (favourable), Endometrial cancer:2.63e-4 (favourable), Liver cancer:3.47e-4 (favourable) Expressed in all Expressed in all liver: 54.1 ALDH2 ENSG00000111275 Aldehyde dehydrogenase 2 family (mitochondrial) 12 111766887-111817529 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051065 Approved Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all liver: 440.7 APOBEC4 C1orf169, FLJ25691, MGC26594, RP1-127C7.4 ENSG00000173627 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 4 (putative) 1 183646404-183653316 Predicted intracellular proteins Evidence at transcript level HPA015636, HPA015637 Approved Endometrial cancer:2.65e-4 (favourable) Tissue enhanced Group enriched 10 fallopian tube: 19.3;testis: 18.4 lung: 1.9 SREBF1 bHLHd1, SREBP-1c, SREBP1 ENSG00000072310 Sterol regulatory element binding transcription factor 1 17 17810399-17837002 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB005406, HPA043343, HPA043878 Uncertain Supported Golgi apparatus
Cytosol Endometrial cancer:2.66e-4 (favourable), Pancreatic cancer:9.05e-4 (favourable) Expressed in all Expressed in all adrenal gland: 92.9 EAF2 BM040, TRAITS, U19 ENSG00000145088 ELL associated factor 2 3 121835183-121886526 Predicted intracellular proteins Evidence at protein level HPA008411 Supported Cervical cancer:2.25e-9 (favourable), Endometrial cancer:2.66e-4 (favourable) Expressed in all Tissue enhanced lymph node: 64.5 bone marrow: 47.9 RFX2 FLJ14226 ENSG00000087903 Regulatory factor X, 2 (influences HLA class II expression) 19 5993164-6199572 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA048969 Supported Approved Nucleoplasm
Golgi apparatus
Cytosol Endometrial cancer:2.67e-4 (favourable), Cervical cancer:2.80e-4 (favourable), Pancreatic cancer:7.36e-4 (favourable) Mixed Tissue enhanced testis: 93.2 fallopian tube: 32.5 GLT8D1 AD-017, FLJ14611 ENSG00000016864 Glycosyltransferase 8 domain containing 1 3 52694485-52706083 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010588 Approved Approved Mitochondria Endometrial cancer:2.76e-4 (favourable) Expressed in all Expressed in all testis: 116.6 SHISA8 C22orf17, Orf26 ENSG00000234965 Shisa family member 8 22 41909554-41914667 Predicted membrane proteins Evidence at transcript level HPA059173 Uncertain Endometrial cancer:2.76e-4 (favourable) Mixed Tissue enhanced adrenal gland: 4.4 lymph node,spleen: 1.4 SOX17 ENSG00000164736 SRY (sex determining region Y)-box 17 8 54457935-54460888 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB025594, HPA068399 Supported Approved Nucleoplasm Endometrial cancer:2.76e-4 (favourable) Group enriched Tissue enhanced cervix, uterine: 30.1;endometrium: 32.1;fallopian tube: 30.1 adipose tissue: 14.7 TDRD3 FLJ21007 ENSG00000083544 Tudor domain containing 3 13 60396457-60573878 Predicted intracellular proteins Evidence at protein level CAB034925 Approved Supported Nucleoplasm
Cytosol Endometrial cancer:2.77e-4 (favourable) Expressed in all Expressed in all testis: 22.7 BORCS6 C17orf59, FLJ20014 ENSG00000196544 BLOC-1 related complex subunit 6 17 8188333-8190907 Predicted intracellular proteins Evidence at protein level HPA045415, HPA060791 Uncertain Supported Centrosome
Cytosol Pancreatic cancer:2.60e-4 (favourable), Endometrial cancer:2.78e-4 (favourable) Expressed in all Expressed in all spleen: 7.1 PLLP PMLP, TM4SF11 ENSG00000102934 Plasmolipin 16 57248547-57284687 Predicted membrane proteins Evidence at protein level HPA041862 Supported Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.4 AIFM2 AMID, FLJ14497, PRG3 ENSG00000042286 Apoptosis-inducing factor, mitochondrion-associated, 2 10 70098223-70132934 Predicted intracellular proteins Evidence at protein level HPA028961, HPA042309 Approved Approved Cytosol Endometrial cancer:2.80e-4 (favourable), Urothelial cancer:2.92e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 42.6 thyroid gland: 17.9 RNMTL1 FLJ10581, HC90, MRM3, RMTL1 ENSG00000171861 RNA methyltransferase like 1 17 782273-792509 Predicted intracellular proteins Evidence at protein level HPA022534, HPA023031, HPA023292 Supported Supported Mitochondria Endometrial cancer:2.81e-4 (favourable), Renal cancer:3.00e-4 (favourable) Expressed in all Expressed in all testis: 31.5 ODF3B ENSG00000177989 Outer dense fiber of sperm tails 3B 22 50529710-50532580 Predicted intracellular proteins Evidence at protein level HPA062837 Approved Renal cancer:2.65e-5 (unfavourable), Endometrial cancer:2.84e-4 (favourable), Head and neck cancer:4.89e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 74.1 appendix: 37.8 BMPR1B ALK6, CDw293 ENSG00000138696 Bone morphogenetic protein receptor, type IB 4 94757968-95158448 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009634 Uncertain Endometrial cancer:2.84e-4 (favourable) Tissue enhanced Tissue enhanced cervix, uterine: 37.0;prostate: 36.4 seminal vesicle: 20.8 SIRT6 ENSG00000077463 Sirtuin 6 19 4174109-4182604 Predicted intracellular proteins Evidence at protein level HPA049729, HPA071776 Supported Supported Nucleoplasm Urothelial cancer:2.58e-4 (favourable), Endometrial cancer:2.85e-4 (favourable), Stomach cancer:9.13e-4 (favourable) Expressed in all Expressed in all colon: 13.5 PLA2G4A cPLA2-alpha, PLA2G4 ENSG00000116711 Phospholipase A2, group IVA (cytosolic, calcium-dependent) 1 186828953-186988981 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010050, HPA050062, HPA054206 Approved Supported Cytosol Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 196.9 seminal vesicle: 67.6 UBE2J1 CGI-76, HSPC153, NCUBE1, UBC6 ENSG00000198833 Ubiquitin-conjugating enzyme E2, J1 6 89326625-89352848 Enzymes, Predicted membrane proteins Evidence at protein level HPA003509, CAB073419 Supported Liver cancer:6.90e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:2.87e-4 (favourable), Ovarian cancer:7.43e-4 (favourable) Expressed in all Expressed in all lymph node: 103.6 SAT1 SAT, SSAT ENSG00000130066 Spermidine/spermine N1-acetyltransferase 1 X 23783173-23786226 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB047343, HPA055312 Approved Endometrial cancer:2.87e-4 (favourable) Expressed in all Expressed in all thyroid gland: 1264.0 TMEM144 FLJ11155 ENSG00000164124 Transmembrane protein 144 4 158201604-158255411 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043767, HPA063554 Uncertain Approved Mitochondria Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 90.8 testis: 46.6 CD27 S152, TNFRSF7, Tp55 ENSG00000139193 CD27 molecule 12 6444867-6451718 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002420, HPA038936 Supported Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable) Expressed in all Tissue enhanced lymph node: 142.5;tonsil: 90.3 spleen: 69.5 AKR1A1 ALR, DD3 ENSG00000117448 Aldo-keto reductase family 1, member A1 (aldehyde reductase) 1 45550543-45570049 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB006246, HPA017919, HPA019649, HPA027734 Approved Supported Nucleoplasm
Cytosol Cervical cancer:2.66e-6 (favourable), Endometrial cancer:2.92e-4 (favourable) Expressed in all Expressed in all kidney: 377.7 CCDC40 CILD15, FAP172, FLJ20753, FLJ32021, KIAA1640 ENSG00000141519 Coiled-coil domain containing 40 17 80036632-80100613 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA022974 Uncertain Approved Microtubules Renal cancer:2.45e-4 (unfavourable), Endometrial cancer:2.95e-4 (favourable) Mixed Tissue enhanced fallopian tube: 23.5 testis: 12.9 SERPINA4 KAL, kallistatin, KLST, KST, PI4 ENSG00000100665 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4 14 94561091-94569913 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003607 Approved Endometrial cancer:2.95e-4 (favourable) Group enriched Tissue enhanced gallbladder: 72.9;liver: 242.4 epididymis: 42.1 RBPJ CBF1, IGKJRB, IGKJRB1, KBF2, RBP-J, RBPJK, RBPSUH, SUH ENSG00000168214 Recombination signal binding protein for immunoglobulin kappa J region 4 26163455-26435131 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA060647 Supported Nucleoplasm Endometrial cancer:2.98e-4 (favourable) Expressed in all Expressed in all placenta: 76.7 TULP3 TUBL3 ENSG00000078246 Tubby like protein 3 12 2877223-2941140 Predicted intracellular proteins Evidence at protein level HPA015285, HPA018496 Uncertain Supported Nucleus
Nucleoli
Plasma membrane Liver cancer:7.97e-5 (unfavourable), Endometrial cancer:2.99e-4 (favourable), Renal cancer:7.18e-4 (unfavourable) Expressed in all Expressed in all ovary: 46.4 GAS8 DRC4, GAS11 ENSG00000141013 Growth arrest-specific 8 16 90019629-90044975 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041311, HPA048238 Approved Approved Plasma membrane
Cytosol Renal cancer:1.09e-7 (favourable), Endometrial cancer:3.01e-4 (favourable), Pancreatic cancer:7.67e-4 (favourable) Expressed in all Mixed fallopian tube: 22.6 CLUAP1 CFAP22, FAP22, FLJ13297, IFT38, KIAA0643 ENSG00000103351 Clusterin associated protein 1 16 3500924-3539048 Predicted intracellular proteins Evidence at protein level HPA036976, HPA044191 Uncertain Supported Nucleoplasm
Vesicles Endometrial cancer:3.01e-4 (favourable) Expressed in all Expressed in all testis: 71.7 CFAP161 C15orf26, FLJ38615 ENSG00000156206 Cilia and flagella associated protein 161 15 81007033-81149175 Predicted intracellular proteins Evidence at protein level HPA041807 Uncertain Endometrial cancer:3.05e-4 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 24.5;testis: 11.4 lung: 4.1 MARCH9 FLJ36578, RNF179 ENSG00000139266 Membrane-associated ring finger (C3HC4) 9 12 57755098-57760407 Predicted membrane proteins Evidence at protein level Lung cancer:1.54e-5 (favourable), Renal cancer:2.98e-5 (favourable), Ovarian cancer:1.59e-4 (favourable), Endometrial cancer:3.07e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 29.7 WDR66 CaM-IP4, MGC33630 ENSG00000158023 WD repeat domain 66 12 121917862-122003927 Predicted intracellular proteins Evidence at protein level HPA039902, HPA040005 Supported Uncertain Plasma membrane
Cytosol Endometrial cancer:3.11e-4 (favourable) Mixed Tissue enhanced fallopian tube: 32.2;testis: 30.6 thyroid gland: 7.4 GIMAP6 FLJ22690, IAN6 ENSG00000133561 GTPase, IMAP family member 6 7 150625375-150632648 Predicted intracellular proteins Evidence at protein level HPA026715, HPA050740 Uncertain Uncertain Nucleoplasm
Cytosol Liver cancer:1.56e-4 (favourable), Head and neck cancer:2.91e-4 (favourable), Endometrial cancer:3.12e-4 (favourable), Renal cancer:5.27e-4 (unfavourable) Expressed in all Mixed spleen: 89.4 NAA60 FLJ14154, NAT15 ENSG00000122390 N(alpha)-acetyltransferase 60, NatF catalytic subunit 16 3443611-3486963 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040916 Approved Uncertain Actin filaments
Cytosol Endometrial cancer:3.14e-4 (favourable), Pancreatic cancer:4.30e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 84.6 CARKD FLJ10769, LP3298 ENSG00000213995 Carbohydrate kinase domain containing 13 110615460-110639993 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA010551 Uncertain Renal cancer:4.63e-5 (favourable), Endometrial cancer:3.15e-4 (favourable) Expressed in all Expressed in all adrenal gland,seminal vesicle: 27.0 SASH3 753P9, CXorf9, HACS2, SH3D6C, SLY ENSG00000122122 SAM and SH3 domain containing 3 X 129779979-129795201 Predicted intracellular proteins Evidence at protein level HPA001085 Supported Renal cancer:6.51e-5 (unfavourable), Endometrial cancer:3.15e-4 (favourable) Expressed in all Tissue enhanced lymph node: 138.5;spleen: 100.9;tonsil: 101.1 appendix: 83.1 ADAM28 ADAM23, eMDCII, MDC-Lm, MDC-Ls ENSG00000042980 ADAM metallopeptidase domain 28 8 24294040-24359018 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074034 Approved Plasma membrane
Mitochondria Endometrial cancer:3.17e-4 (favourable) Mixed Tissue enhanced epididymis: 428.3 stomach: 104.5 AK7 FLJ32864 ENSG00000140057 Adenylate kinase 7 14 96392111-96489427 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003543 Approved Renal cancer:1.14e-4 (favourable), Endometrial cancer:3.18e-4 (favourable) Mixed Tissue enhanced fallopian tube: 38.5 parathyroid gland: 15.2 SLC43A1 PB39, POV1, R00504 ENSG00000149150 Solute carrier family 43 (amino acid system L transporter), member 1 11 57484534-57515786 Predicted membrane proteins, Transporters Evidence at protein level HPA018813, HPA018826 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable) Expressed in all Expressed in all liver: 50.0 GHDC LGP1 ENSG00000167925 GH3 domain containing 17 42188799-42194532 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA031650 Uncertain Renal cancer:2.00e-6 (favourable), Glioma:5.91e-5 (unfavourable), Endometrial cancer:3.21e-4 (favourable), Ovarian cancer:5.20e-4 (unfavourable) Expressed in all Expressed in all spleen: 29.8 APOBR APOB100R, APOB48R ENSG00000184730 Apolipoprotein B receptor 16 28494649-28498970 Predicted intracellular proteins Evidence at protein level HPA041667, HPA042093 Supported Endometrial cancer:3.26e-4 (favourable) Expressed in all Tissue enhanced spleen: 31.3 appendix: 28.3 C11orf16 ENSG00000176029 Chromosome 11 open reading frame 16 11 8920076-8933006 Predicted intracellular proteins Evidence at transcript level Endometrial cancer:3.32e-4 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 20.4;lung: 4.1 testis: 2.5 PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008719 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable) Expressed in all Expressed in all appendix: 61.3 HLA-DPB1 HLA-DP1B ENSG00000223865 Major histocompatibility complex, class II, DP beta 1 6 33075926-33087201 Predicted membrane proteins Evidence at protein level HPA011078, HPA058509 Approved Approved Nucleus
Cell Junctions Endometrial cancer:3.38e-4 (favourable) Expressed in all Expressed in all spleen: 174.2 AKAP17A 721P, CCDC133, CXYorf3, DXYS155E, MGC39904, SFRS17A, XE7, XE7Y ENSG00000197976 A kinase (PRKA) anchor protein 17A X 1591593-1602514 Predicted intracellular proteins Evidence at protein level HPA043247, HPA051020 Supported Supported Nuclear speckles
Cytosol Renal cancer:3.52e-7 (unfavourable), Urothelial cancer:1.11e-5 (favourable), Pancreatic cancer:2.42e-4 (favourable), Endometrial cancer:3.40e-4 (favourable) Expressed in all Expressed in all spleen: 61.7 CARD10 BIMP1, CARMA3 ENSG00000100065 Caspase recruitment domain family, member 10 22 37490362-37519542 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029359, HPA055612 Approved Approved Vesicles
Intermediate filaments
Cytosol Liver cancer:7.73e-6 (unfavourable), Endometrial cancer:3.47e-4 (favourable) Expressed in all Mixed small intestine: 40.7 PQLC2 FLJ20320 ENSG00000040487 PQ loop repeat containing 2 1 19312326-19329300 Predicted membrane proteins, Transporters Evidence at protein level HPA057810 Approved Validated Vesicles Liver cancer:2.64e-5 (unfavourable), Endometrial cancer:3.50e-4 (favourable) Expressed in all Expressed in all testis: 16.3 IDE ENSG00000119912 Insulin-degrading enzyme 10 92451684-92574076 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA063478 Approved Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable) Expressed in all Expressed in all skin: 63.5 IGFBP4 BP-4, HT29-IGFBP, IBP4, IGFBP-4 ENSG00000141753 Insulin-like growth factor binding protein 4 17 40443461-40457731 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA066240 Supported Renal cancer:2.72e-5 (unfavourable), Endometrial cancer:3.54e-4 (favourable), Liver cancer:5.49e-4 (favourable) Expressed in all Expressed in all smooth muscle: 923.3 CGNL1 FLJ14957, JACOP, KIAA1749, paracingulin ENSG00000128849 Cingulin-like 1 15 57375967-57550727 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB013500, HPA056911, HPA069214 Supported Approved Cell Junctions Renal cancer:1.37e-6 (favourable), Endometrial cancer:3.55e-4 (favourable), Liver cancer:5.58e-4 (favourable) Expressed in all Mixed kidney: 72.7 ARHGAP17 FLJ10308, FLJ13219, NADRIN, RICH1, WBP15 ENSG00000140750 Rho GTPase activating protein 17 16 24919385-25015666 Predicted intracellular proteins Evidence at protein level HPA041703 Approved Approved Nucleus
Cytosol Endometrial cancer:3.59e-4 (favourable), Urothelial cancer:3.76e-4 (unfavourable), Liver cancer:4.95e-4 (unfavourable) Expressed in all Expressed in all spleen: 71.6 PEX11G ENSG00000104883 Peroxisomal biogenesis factor 11 gamma 19 7476875-7497449 Predicted membrane proteins Evidence at protein level HPA069817 Uncertain Renal cancer:1.83e-9 (favourable), Liver cancer:3.27e-4 (favourable), Endometrial cancer:3.60e-4 (favourable) Expressed in all Mixed testis: 15.6 C9orf91 DKFZp547P234, FLJ38045 ENSG00000157693 Chromosome 9 open reading frame 91 9 114611206-114646422 Predicted membrane proteins Evidence at transcript level HPA017199 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 22.4 DRC7 C16orf50, CCDC135, CFAP50, DKFZp434I099, FAP50 ENSG00000159625 Dynein regulatory complex subunit 7 16 57694793-57731805 Predicted intracellular proteins Evidence at protein level HPA041521 Uncertain Endometrial cancer:3.61e-4 (favourable) Tissue enhanced Group enriched 17 fallopian tube: 32.4;testis: 81.1 parathyroid gland: 3.4 PGRMC2 DG6, PMBP ENSG00000164040 Progesterone receptor membrane component 2 4 128269237-128288829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041172, HPA058652 Approved Approved Nuclear bodies
Plasma membrane
Cytosol Endometrial cancer:3.62e-4 (favourable), Renal cancer:9.60e-4 (favourable) Expressed in all Expressed in all small intestine: 136.2 ANXA5 ANX5, ENX2 ENSG00000164111 Annexin A5 4 121667955-121697113 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003677, HPA035330 Approved Approved Nuclear membrane Renal cancer:9.29e-7 (unfavourable), Liver cancer:1.64e-5 (unfavourable), Head and neck cancer:3.01e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable), Endometrial cancer:3.64e-4 (favourable), Stomach cancer:7.19e-4 (unfavourable) Expressed in all Expressed in all placenta: 612.8 CCDC170 bA282P11.1, C6orf97, FLJ23305 ENSG00000120262 Coiled-coil domain containing 170 6 151494030-151621193 Predicted intracellular proteins Evidence at protein level HPA027114, HPA027185 Supported Approved Golgi apparatus
Cell Junctions Endometrial cancer:3.64e-4 (favourable) Mixed Tissue enriched 6 fallopian tube: 52.9 thyroid gland: 9.4 TSKU E2IG4, LRRC54, TSK ENSG00000182704 Tsukushi, small leucine rich proteoglycan 11 76782251-76798154 Predicted secreted proteins Evidence at protein level HPA008164 Approved Approved Nucleus
Nuclear bodies Renal cancer:2.80e-8 (unfavourable), Prostate cancer:1.66e-4 (favourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:3.66e-4 (favourable) Expressed in all Expressed in all liver: 114.5 COMT ENSG00000093010 Catechol-O-methyltransferase 22 19941607-19969975 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001169, CAB011233 Supported Approved Endoplasmic reticulum
Vesicles Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable) Expressed in all Expressed in all placenta: 172.0 TMCO4 DKFZp686C23231 ENSG00000162542 Transmembrane and coiled-coil domains 4 1 19682213-19799945 Predicted membrane proteins Evidence at protein level HPA014601, HPA014620 Uncertain Approved Endoplasmic reticulum Renal cancer:4.12e-11 (favourable), Liver cancer:1.12e-4 (unfavourable), Urothelial cancer:3.64e-4 (favourable), Endometrial cancer:3.71e-4 (favourable) Expressed in all Mixed parathyroid gland: 36.3 DNAJC25 bA16L21.2.1 ENSG00000059769 DnaJ (Hsp40) homolog, subfamily C , member 25 9 111631352-111654351 Predicted membrane proteins Evidence at protein level HPA019122 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:3.73e-4 (favourable) Expressed in all Tissue enhanced liver: 16.7 parathyroid gland: 7.8 TRAPPC2L HSPC176 ENSG00000167515 Trafficking protein particle complex 2-like 16 88856220-88862686 Predicted intracellular proteins Evidence at protein level HPA041714 Approved Supported Vesicles
Cytosol Endometrial cancer:3.75e-4 (favourable) Expressed in all Expressed in all adrenal gland: 91.9 KLK11 PRSS20, TLSP ENSG00000167757 Kallikrein-related peptidase 11 19 51022216-51028039 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026340 Approved Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable) Mixed Tissue enhanced esophagus: 226.6;skin: 214.5 prostate: 107.3 HSCB DNAJC20, HSC20, Jac1 ENSG00000100209 HscB mitochondrial iron-sulfur cluster co-chaperone 22 28742031-28757515 Predicted intracellular proteins Evidence at protein level HPA018447, HPA031518 Uncertain Supported Nucleus
Mitochondria
Cytosol Endometrial cancer:3.78e-4 (favourable), Urothelial cancer:8.38e-4 (favourable) Expressed in all Expressed in all adrenal gland: 13.3 DYNC1I1 DNCI1, DNCIC1 ENSG00000158560 Dynein, cytoplasmic 1, intermediate chain 1 7 95772506-96110322 Predicted intracellular proteins Evidence at protein level HPA061689 Supported Endometrial cancer:3.79e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 84.2 adrenal gland: 16.9 FANK1 ENSG00000203780 Fibronectin type III and ankyrin repeat domains 1 10 125896539-126009592 Predicted intracellular proteins Evidence at protein level HPA037557, HPA038413 Uncertain Supported Nucleoplasm Endometrial cancer:3.83e-4 (favourable) Mixed Group enriched 5 fallopian tube: 54.6;testis: 92.1 epididymis: 14.0 HES4 bHLHb42 ENSG00000188290 Hes family bHLH transcription factor 4 1 998962-1000172 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA062465 Approved Nucleoplasm
Vesicles
Cytosol Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:3.85e-4 (favourable), Renal cancer:6.27e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 7.5 NRTN NTN ENSG00000171119 Neurturin 19 5823802-5828324 Disease related genes, Predicted secreted proteins Evidence at protein level HPA065260 Approved Golgi apparatus Endometrial cancer:3.86e-4 (favourable), Head and neck cancer:7.23e-4 (favourable), Melanoma:9.92e-4 (favourable) Mixed Mixed heart muscle: 4.6 SMPD3 NSMASE2 ENSG00000103056 Sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 16 68358325-68448688 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033885, HPA065535, HPA069383 Approved Supported Endoplasmic reticulum Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable) Mixed Tissue enhanced duodenum: 62.7;small intestine: 64.1 stomach: 22.9 AES GRG5, TLE5 ENSG00000104964 Amino-terminal enhancer of split 19 3052910-3063107 Predicted intracellular proteins Evidence at protein level HPA049499 Approved Nucleoplasm Endometrial cancer:3.89e-4 (favourable), Renal cancer:7.74e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 332.3 CREB3L1 OASIS ENSG00000157613 CAMP responsive element binding protein 3-like 1 11 46277661-46321422 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA024069, CAB026151 Supported Uncertain Plasma membrane
Cytosol Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable) Expressed in all Mixed stomach: 66.1 MED18 FLJ20045, p28b ENSG00000130772 Mediator complex subunit 18 1 28329002-28335967 Predicted intracellular proteins Evidence at protein level HPA027429 Uncertain Approved Nucleoplasm Renal cancer:8.38e-5 (favourable), Liver cancer:1.52e-4 (unfavourable), Endometrial cancer:3.93e-4 (favourable), Stomach cancer:6.72e-4 (favourable) Expressed in all Expressed in all fallopian tube,lymph node: 13.0 SUMF2 DKFZp566I1024 ENSG00000129103 Sulfatase modifying factor 2 7 56064002-56080670 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024040, CAB025743, HPA074892 Supported Uncertain Vesicles
Plasma membrane Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 159.3 MRPL23 L23MRP, RPL23L ENSG00000214026 Mitochondrial ribosomal protein L23 11 1947278-1984522 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA050406 Approved Supported Nucleoli fibrillar center
Mitochondria Endometrial cancer:3.97e-4 (favourable) Expressed in all Expressed in all fallopian tube: 88.5 WDR38 ENSG00000136918 WD repeat domain 38 9 124853417-124857890 Predicted intracellular proteins Evidence at transcript level HPA056607 Uncertain Endometrial cancer:3.97e-4 (favourable) Tissue enhanced Tissue enriched 17 fallopian tube: 123.5 lung: 7.3 RABL6 bA216L13.9, C9orf86, FLJ10101, FLJ13045, Parf, pp8875, RBEL1 ENSG00000196642 RAB, member RAS oncogene family-like 6 9 136807943-136957733 Predicted intracellular proteins Evidence at protein level HPA044037, HPA050638 Uncertain Uncertain Nucleus
Centrosome
Cytosol Pancreatic cancer:1.46e-4 (favourable), Endometrial cancer:4.00e-4 (favourable), Stomach cancer:9.14e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 47.0 USP20 KIAA1003 ENSG00000136878 Ubiquitin specific peptidase 20 9 129834698-129881838 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006287, HPA007008 Uncertain Approved Approved Nucleus
Plasma membrane
Cytosol Pancreatic cancer:1.54e-7 (favourable), Renal cancer:5.65e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Endometrial cancer:4.01e-4 (favourable), Cervical cancer:8.01e-4 (favourable) Expressed in all Expressed in all thyroid gland: 22.1 CTBP1 BARS ENSG00000159692 C-terminal binding protein 1 4 1211448-1249953 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004217, HPA018987, HPA044971 Approved Validated Nucleoplasm Endometrial cancer:4.03e-4 (favourable), Urothelial cancer:8.94e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 142.1 WBP1L C10orf26, FLJ20154, OPAL1 ENSG00000166272 WW domain binding protein 1-like 10 102743970-102816267 Predicted membrane proteins Evidence at protein level HPA037635, HPA038371 Uncertain Approved Nucleoplasm
Microtubules Renal cancer:1.56e-6 (favourable), Endometrial cancer:4.03e-4 (favourable) Expressed in all Expressed in all thyroid gland: 69.6 CCDC96 FLJ90575 ENSG00000173013 Coiled-coil domain containing 96 4 7040849-7042939 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047546 Approved Renal cancer:3.80e-5 (favourable), Endometrial cancer:4.05e-4 (favourable), Pancreatic cancer:4.87e-4 (favourable) Expressed in all Group enriched 14 fallopian tube: 17.6;testis: 61.6 cerebral cortex,lung: 2.7 CCDC134 FLJ22349 ENSG00000100147 Coiled-coil domain containing 134 22 41800679-41826299 Predicted secreted proteins Evidence at protein level HPA003936 Approved Liver cancer:7.42e-7 (unfavourable), Renal cancer:1.36e-5 (favourable), Endometrial cancer:4.09e-4 (favourable) Expressed in all Mixed adrenal gland: 13.9 SERPIND1 D22S673, HC-II, HC2, HCF2, HLS2 ENSG00000099937 Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 22 20773879-20787720 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB008639, HPA055767 Supported Approved Vesicles Endometrial cancer:4.09e-4 (favourable) Tissue enriched Tissue enriched 16 liver: 584.7 parathyroid gland: 35.5 RPS6 S6 ENSG00000137154 Ribosomal protein S6 9 19375715-19380254 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level CAB004027, HPA031153 Supported Validated Endoplasmic reticulum
Cytosol Endometrial cancer:4.12e-4 (favourable) Expressed in all Expressed in all ovary: 4794.1 PPP1R32 C11orf66, FLJ32771, IIIG9 ENSG00000162148 Protein phosphatase 1, regulatory subunit 32 11 61481120-61490931 Predicted intracellular proteins Evidence at protein level HPA039067, HPA039068 Supported Endometrial cancer:4.13e-4 (favourable) Mixed Tissue enhanced fallopian tube: 64.0;testis: 87.4 epididymis: 15.2 ZNF653 Zip67 ENSG00000161914 Zinc finger protein 653 19 11483427-11505923 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA023631, HPA023635 Uncertain Approved Nucleus
Cytosol Endometrial cancer:4.15e-4 (favourable), Colorectal cancer:8.37e-4 (unfavourable), Urothelial cancer:8.74e-4 (favourable) Expressed in all Mixed testis: 19.0 TMEM261 C9orf123, MGC4730 ENSG00000137038 Transmembrane protein 261 9 7796490-7888380 Predicted membrane proteins Evidence at protein level HPA014585 Approved Renal cancer:1.96e-11 (favourable), Endometrial cancer:4.15e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.3 NAGLU NAG ENSG00000108784 N-acetylglucosaminidase, alpha 17 42536172-42544449 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038815 Supported Approved Renal cancer:2.58e-6 (favourable), Glioma:3.43e-4 (unfavourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:6.90e-4 (favourable) Expressed in all Expressed in all thyroid gland: 47.4 ZNF414 MGC15716, Zfp414 ENSG00000133250 Zinc finger protein 414 19 8509678-8514164 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053769 Approved Approved Nucleus
Cytosol Head and neck cancer:1.67e-6 (favourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:4.59e-4 (favourable), Urothelial cancer:8.71e-4 (favourable) Expressed in all Expressed in all spleen: 12.6 MYO1E HuncM-IC, MGC104638, MYO1C ENSG00000157483 Myosin IE 15 59132434-59372900 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA023886 Approved Lung cancer:1.57e-6 (unfavourable), Endometrial cancer:4.19e-4 (favourable), Pancreatic cancer:7.99e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 66.8 ALDH18A1 GSAS, P5CS, PYCS ENSG00000059573 Aldehyde dehydrogenase 18 family, member A1 10 95605929-95656706 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA008333, HPA012604 Approved Validated Mitochondria Renal cancer:3.60e-9 (unfavourable), Endometrial cancer:4.20e-4 (favourable) Expressed in all Expressed in all duodenum: 92.0 UQCRQ QCR8, QP-C, UQCR7 ENSG00000164405 Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa 5 132866560-132868031 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA046693, HPA053323 Approved Validated Mitochondria Endometrial cancer:4.23e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 376.1 CORO7 FLJ22021 ENSG00000262246 Coronin 7 16 4354542-4425705 Predicted intracellular proteins Evidence at protein level HPA041657, HPA053586 Uncertain Endometrial cancer:4.25e-4 (favourable), Cervical cancer:8.68e-4 (favourable) Expressed in all Mixed bone marrow: 24.5 TNK1 ENSG00000174292 Tyrosine kinase, non-receptor, 1 17 7380534-7389774 Enzymes, Predicted intracellular proteins Evidence at protein level HPA012065, HPA056452 Uncertain Approved Cell Junctions Urothelial cancer:1.52e-4 (favourable), Endometrial cancer:4.28e-4 (favourable), Renal cancer:6.40e-4 (favourable) Mixed Mixed skin: 10.3 C14orf159 FLJ39975 ENSG00000133943 Chromosome 14 open reading frame 159 14 91060333-91225632 Predicted intracellular proteins Evidence at protein level HPA041423, HPA052932 Approved Supported Cytosol Renal cancer:3.77e-15 (favourable), Lung cancer:9.48e-5 (favourable), Endometrial cancer:4.28e-4 (favourable), Ovarian cancer:7.28e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 81.0 TMEM101 FLJ23987, MGC4251 ENSG00000091947 Transmembrane protein 101 17 44011188-44023946 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039739 Approved Nucleoplasm
Plasma membrane Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 156.9 EXD3 FLJ20433, LOC54932, mut-7 ENSG00000187609 Exonuclease 3'-5' domain containing 3 9 137306896-137423262 Predicted intracellular proteins Evidence at transcript level HPA047395 Approved Approved Actin filaments
Focal adhesion sites Endometrial cancer:4.30e-4 (favourable) Expressed in all Mixed duodenum,small intestine,spleen: 10.2 LRRC29 FBL9, FBXL9 ENSG00000125122 Leucine rich repeat containing 29 16 67207139-67227048 Predicted intracellular proteins Evidence at protein level HPA034998 Uncertain Uncertain Nucleoplasm Endometrial cancer:4.33e-4 (favourable), Pancreatic cancer:5.20e-4 (favourable) Expressed in all Mixed testis: 4.7 SIL1 BAP, MSS, ULG5 ENSG00000120725 SIL1 nucleotide exchange factor 5 138946720-139293557 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA011949 Supported Glioma:3.77e-4 (unfavourable), Endometrial cancer:4.34e-4 (favourable) Expressed in all Expressed in all thyroid gland: 59.8 L3MBTL2 dJ756G23.3, DKFZP761I141, H-l(3)mbt-l ENSG00000100395 L(3)mbt-like 2 (Drosophila) 22 41205205-41231271 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000815 Approved Nucleoplasm Cervical cancer:6.39e-5 (favourable), Endometrial cancer:4.37e-4 (favourable) Expressed in all Expressed in all fallopian tube: 30.2 CCDC125 KENAE ENSG00000183323 Coiled-coil domain containing 125 5 69280175-69332809 Predicted intracellular proteins Evidence at protein level HPA041878 Approved Uncertain Nucleoplasm
Nuclear membrane
Intermediate filaments Urothelial cancer:2.51e-4 (favourable), Endometrial cancer:4.40e-4 (favourable), Breast cancer:8.06e-4 (unfavourable) Expressed in all Mixed prostate: 11.7 ZFAND5 ZA20D2, ZFAND5A, ZNF216 ENSG00000107372 Zinc finger, AN1-type domain 5 9 72351425-72365235 Predicted intracellular proteins Evidence at protein level HPA018129 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:4.43e-4 (favourable) Expressed in all Expressed in all adipose tissue: 309.5 KIZ C20orf19, HT013, NCRNA00153, PLK1S1 ENSG00000088970 Kizuna centrosomal protein 20 21125983-21246622 Disease related genes, Predicted intracellular proteins Evidence at protein level Renal cancer:4.11e-8 (unfavourable), Endometrial cancer:4.45e-4 (favourable) Expressed in all Expressed in all testis: 81.9 APOBEC3D APOBEC3DE, APOBEC3E, ARP6 ENSG00000243811 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 22 39014363-39033276 Predicted intracellular proteins Evidence at protein level HPA055116 Uncertain Renal cancer:3.76e-7 (unfavourable), Breast cancer:2.51e-5 (favourable), Cervical cancer:1.31e-4 (favourable), Urothelial cancer:3.01e-4 (favourable), Endometrial cancer:4.47e-4 (favourable) Expressed in all Mixed lymph node: 20.9 POLRMT APOLMT, h-mtRPOL, MTRNAP, MTRPOL ENSG00000099821 Polymerase (RNA) mitochondrial (DNA directed) 19 617224-633604 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006366 Uncertain Supported Mitochondria Endometrial cancer:4.50e-4 (favourable) Expressed in all Expressed in all testis: 46.6 CD37 TSPAN26 ENSG00000104894 CD37 molecule 19 49335171-49343335 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002492, HPA032120, HPA032121 Supported Endometrial cancer:4.51e-4 (favourable) Expressed in all Tissue enhanced lymph node: 244.2;spleen: 212.9 appendix: 133.5 CRB3 MGC17303 ENSG00000130545 Crumbs family member 3 19 6463777-6467221 Predicted membrane proteins Evidence at protein level HPA013835 Approved Supported Cell Junctions Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable) Mixed Mixed duodenum: 38.4 PDIA5 FLJ30401, PDIR ENSG00000065485 Protein disulfide isomerase family A, member 5 3 123067062-123225227 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030353, HPA030355 Approved Approved Nucleoplasm
Nucleoli fibrillar center
Golgi apparatus Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable) Expressed in all Mixed placenta: 70.2 C22orf46 CTA-216E10.6, FLJ23584 ENSG00000184208 Chromosome 22 open reading frame 46 22 41688939-41698136 Predicted secreted proteins Evidence at transcript level HPA052741, HPA057048 Uncertain Approved Nucleus
Nucleoli Endometrial cancer:4.70e-4 (favourable) Expressed in all Mixed parathyroid gland: 17.4 ACY3 ACY-3, HCBP1, MGC9740 ENSG00000132744 Aminoacylase 3 11 67642555-67650659 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039219, HPA048187 Supported Endometrial cancer:4.80e-4 (favourable) Mixed Tissue enhanced duodenum: 82.8;kidney: 53.1;small intestine: 80.3 cervix, uterine: 16.0 TICAM1 MGC35334, PRVTIRB, TICAM-1, TRIF ENSG00000127666 Toll-like receptor adaptor molecule 1 19 4815932-4831704 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA042460 Uncertain Approved Nucleus
Nucleoli
Plasma membrane Lung cancer:3.48e-4 (unfavourable), Endometrial cancer:4.81e-4 (favourable) Expressed in all Expressed in all esophagus: 22.1 MUM1 EXPAND1, MUM-1 ENSG00000160953 Melanoma associated antigen (mutated) 1 19 1285893-1378431 Predicted intracellular proteins Evidence at protein level HPA048063 Uncertain Approved Nucleus
Cytosol Pancreatic cancer:2.25e-6 (favourable), Endometrial cancer:4.82e-4 (favourable) Expressed in all Expressed in all testis: 60.9 MORN5 C9orf113, C9orf18, FLJ46909 ENSG00000185681 MORN repeat containing 5 9 122159908-122200088 Predicted intracellular proteins Evidence at transcript level Endometrial cancer:4.86e-4 (favourable) Tissue enhanced Group enriched 6 fallopian tube: 174.0;testis: 105.8 smooth muscle: 24.5 FBXW4 dactylin, Fbw4, SHFM3 ENSG00000107829 F-box and WD repeat domain containing 4 10 101610664-101695295 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA043496 Approved Approved Golgi apparatus Renal cancer:3.41e-5 (favourable), Pancreatic cancer:4.67e-4 (favourable), Endometrial cancer:4.91e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 79.6 TUBB4B Beta2, TUBB2C ENSG00000188229 Tubulin, beta 4B class IVb 9 137241213-137243707 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010880, HPA043640, HPA046280 Supported Validated Microtubules Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable) Expressed in all Expressed in all testis: 787.0 C2CD2L KIAA0285, TMEM24 ENSG00000172375 C2CD2-like 11 119102198-119118544 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011044 Approved Approved Nucleus
Nuclear membrane
Nucleoli
Cytosol Renal cancer:1.75e-4 (unfavourable), Endometrial cancer:4.92e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 29.7 ATPAF2 ATP12, Atp12p, LP3663, MGC29736 ENSG00000171953 ATP synthase mitochondrial F1 complex assembly factor 2 17 17977409-18039209 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA023329, HPA059422 Supported Validated Cytosol Renal cancer:6.00e-5 (favourable), Endometrial cancer:4.95e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 23.1 WAS IMD2, THC, WASP, WASPA ENSG00000015285 Wiskott-Aldrich syndrome X 48676596-48691427 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA002022, CAB004290 Supported Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable) Expressed in all Tissue enhanced appendix: 71.0;lymph node: 61.6;spleen: 70.8 bone marrow: 37.6 XAB2 HCNP, HCRN, NTC90, SYF1 ENSG00000076924 XPA binding protein 2 19 7619525-7629565 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048751 Approved Nucleus
Vesicles Cervical cancer:4.04e-4 (favourable), Endometrial cancer:4.96e-4 (favourable), Pancreatic cancer:7.47e-4 (favourable) Expressed in all Expressed in all testis: 39.3 NDUFA6 B14, CI-B14, LYRM6, NADHB14 ENSG00000184983 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14kDa 22 42085525-42090955 Predicted intracellular proteins Evidence at protein level Renal cancer:1.05e-6 (favourable), Cervical cancer:3.87e-4 (favourable), Endometrial cancer:4.96e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 39.5 C2orf88 MGC13057, smAKAP ENSG00000187699 Chromosome 2 open reading frame 88 2 189879609-190203484 Predicted intracellular proteins Evidence at protein level HPA049549 Approved Endometrial cancer:4.97e-4 (favourable), Renal cancer:7.79e-4 (favourable), Melanoma:9.39e-4 (unfavourable) Tissue enhanced Expressed in all testis: 92.3 FAM120A C9orf10, DNAPTP1, KIAA0183, OSSA ENSG00000048828 Family with sequence similarity 120A 9 93451722-93566107 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019734, HPA055800 Approved Validated Cytosol Renal cancer:1.08e-7 (favourable), Endometrial cancer:5.03e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 164.2 NR1H3 LXR-a, RLD-1 ENSG00000025434 Nuclear receptor subfamily 1, group H, member 3 11 47248300-47269032 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA036443, CAB037109 Approved Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:3.40e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Liver cancer:5.60e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 55.1 ACADS ACAD3, SCAD ENSG00000122971 Acyl-CoA dehydrogenase, C-2 to C-3 short chain 12 120725735-120740008 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA004799, CAB019284, HPA022271 Supported Supported Nucleoplasm
Mitochondria Renal cancer:3.33e-6 (favourable), Urothelial cancer:6.34e-5 (favourable), Liver cancer:2.43e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Glioma:9.94e-4 (unfavourable) Expressed in all Expressed in all duodenum: 83.5 C19orf18 MGC41906 ENSG00000177025 Chromosome 19 open reading frame 18 19 57958437-57974534 Predicted membrane proteins Evidence at transcript level HPA014527 Uncertain Approved Golgi apparatus Endometrial cancer:5.07e-4 (favourable) Mixed Tissue enhanced testis: 16.9 epididymis: 4.8 LCP2 SLP-76, SLP76 ENSG00000043462 Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa) 5 170246237-170298227 Predicted intracellular proteins Evidence at protein level CAB004574, HPA036396, HPA036397 Supported Renal cancer:6.22e-5 (unfavourable), Endometrial cancer:5.08e-4 (favourable) Expressed in all Expressed in all spleen: 127.7 MBD3 ENSG00000071655 Methyl-CpG binding domain protein 3 19 1573596-1592801 Predicted intracellular proteins Evidence at protein level CAB013265 Supported Supported Nucleoplasm Pancreatic cancer:1.76e-5 (favourable), Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:5.08e-4 (favourable) Expressed in all Expressed in all placenta: 45.7 ENDOG ENSG00000167136 Endonuclease G 9 128818474-128822677 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA021335, HPA021830 Approved Renal cancer:1.06e-7 (favourable), Endometrial cancer:5.12e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 45.8 AKIP1 BCA3, C11orf17 ENSG00000166452 A kinase (PRKA) interacting protein 1 11 8911139-8920084 Predicted intracellular proteins Evidence at protein level HPA061391 Supported Nucleoplasm Liver cancer:6.24e-9 (unfavourable), Endometrial cancer:5.15e-4 (favourable) Expressed in all Expressed in all adrenal gland: 30.7 FBP1 FBP ENSG00000165140 Fructose-1,6-bisphosphatase 1 9 94603133-94640249 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005857, HPA012513, CAB033869 Supported Uncertain Mitochondria Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable) Expressed in all Tissue enhanced duodenum: 338.7;liver: 442.9 small intestine: 286.0 BDH2 DHRS6, FLJ13261, PRO20933, SDR15C1, UCPA-OR, UNQ6308 ENSG00000164039 3-hydroxybutyrate dehydrogenase, type 2 4 103079435-103099883 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036028, HPA036029 Supported Supported Cytosol Renal cancer:4.45e-13 (favourable), Lung cancer:1.20e-4 (favourable), Endometrial cancer:5.21e-4 (favourable), Thyroid cancer:7.75e-4 (favourable) Expressed in all Expressed in all kidney: 452.1 ARSD ENSG00000006756 Arylsulfatase D X 2903970-2929351 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004694, HPA063835 Supported Approved Vesicles
Lipid droplets Renal cancer:1.97e-5 (favourable), Endometrial cancer:5.21e-4 (favourable) Expressed in all Mixed fallopian tube: 44.7 SERF2 4F5REL, FAM2C, H4F5rel, HsT17089 ENSG00000140264 Small EDRK-rich factor 2 15 43777087-43802589 Predicted intracellular proteins Evidence at protein level HPA056613 Uncertain Nucleus
Nucleoli Endometrial cancer:5.33e-4 (favourable) Expressed in all Expressed in all epididymis: 896.5 FBXL8 Fbl8 ENSG00000135722 F-box and leucine-rich repeat protein 8 16 67159931-67164570 Predicted intracellular proteins Evidence at protein level HPA035587, HPA035588 Uncertain Approved Golgi apparatus Endometrial cancer:5.39e-4 (favourable) Expressed in all Expressed in all prostate: 25.7 TFPI2 PP5, REF1, TFPI-2 ENSG00000105825 Tissue factor pathway inhibitor 2 7 93885397-93890991 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010142, HPA049158 Supported Breast cancer:8.33e-7 (favourable), Endometrial cancer:5.42e-4 (favourable), Renal cancer:8.53e-4 (unfavourable) Expressed in all Tissue enriched 23 placenta: 1205.5 ovary: 52.0 RIIAD1 C1orf230, FLJ36032, NCRNA00166 ENSG00000178796 Regulatory subunit of type II PKA R-subunit (RIIa) domain containing 1 1 151710433-151729805 Predicted intracellular proteins Evidence at protein level HPA045703 Supported Approved Nucleoplasm
Cytosol Endometrial cancer:5.46e-4 (favourable) Tissue enhanced Group enriched 8 fallopian tube: 69.8;testis: 22.4 cerebral cortex: 5.4 MED16 DRIP92, THRAP5, TRAP95 ENSG00000175221 Mediator complex subunit 16 19 867630-893218 Predicted intracellular proteins Evidence at protein level HPA030685, HPA046495 Uncertain Approved Nucleoli Renal cancer:1.11e-5 (favourable), Endometrial cancer:5.46e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 29.0 OXSM FASN2D, FLJ20604, KS ENSG00000151093 3-oxoacyl-ACP synthase, mitochondrial 3 25782917-25794534 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021293, HPA021300, HPA021337 Supported Approved Mitochondria
Cytosol Renal cancer:4.18e-9 (favourable), Colorectal cancer:1.35e-4 (favourable), Endometrial cancer:5.51e-4 (favourable) Expressed in all Expressed in all testis: 17.3 CFAP73 CCDC42B, MIA2 ENSG00000186710 Cilia and flagella associated protein 73 12 113149858-113159276 Predicted intracellular proteins Evidence at protein level HPA048539 Supported Cervical cancer:1.29e-4 (favourable), Endometrial cancer:5.52e-4 (favourable) Tissue enhanced Tissue enriched 8 fallopian tube: 59.6 lung: 7.0 CXCL13 ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13 ENSG00000156234 Chemokine (C-X-C motif) ligand 13 4 77511753-77611834 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA052613 Uncertain Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable) Expressed in all Group enriched 7 appendix: 170.3;lymph node: 606.7;spleen: 430.3;tonsil: 411.9 urinary bladder: 60.1 MCAT fabD, FASN2C, MCT, MT, NET62 ENSG00000100294 Malonyl CoA:ACP acyltransferase (mitochondrial) 22 43132206-43143394 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003122, HPA035471 Approved Supported Mitochondria Renal cancer:2.18e-4 (favourable), Stomach cancer:3.89e-4 (favourable), Endometrial cancer:5.53e-4 (favourable) Expressed in all Expressed in all fallopian tube: 22.7 RABL2B ENSG00000079974 RAB, member of RAS oncogene family-like 2B 22 50767501-50783663 Predicted intracellular proteins Evidence at protein level HPA042700, HPA044007 Approved Uncertain Plasma membrane
Cytosol Liver cancer:4.58e-5 (unfavourable), Endometrial cancer:5.58e-4 (favourable) Expressed in all Expressed in all epididymis: 109.0 BCL2L15 Bfk, C1orf178, FLJ22588 ENSG00000188761 BCL2-like 15 1 113878168-113887547 Predicted intracellular proteins Evidence at protein level HPA029732, HPA029733 Approved Endometrial cancer:5.63e-4 (favourable) Tissue enhanced Tissue enhanced colon: 48.1;duodenum: 68.4;rectum: 52.8;small intestine: 65.6 stomach: 24.2 ALAD ALADH, PBGS ENSG00000148218 Aminolevulinate dehydratase 9 113386317-113401333 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021023, HPA022124 Supported Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable) Expressed in all Expressed in all adrenal gland: 147.9 TFF1 BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2 ENSG00000160182 Trefoil factor 1 21 42362282-42366594 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002170, HPA003425 Supported Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable) Group enriched Tissue enriched 32 stomach: 6481.5 gallbladder: 204.1 BBS12 C4orf24, FLJ35630, FLJ41559 ENSG00000181004 Bardet-Biedl syndrome 12 4 122732702-122744943 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA061856 Approved Renal cancer:9.89e-6 (favourable), Endometrial cancer:5.69e-4 (favourable) Mixed Mixed thyroid gland: 15.9 ZNF557 MGC4054 ENSG00000130544 Zinc finger protein 557 19 7069444-7087968 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003151, HPA029291 Uncertain Approved Nucleus
Intermediate filaments
Cytosol Head and neck cancer:3.67e-6 (favourable), Pancreatic cancer:1.51e-4 (favourable), Lung cancer:2.62e-4 (favourable), Endometrial cancer:5.70e-4 (favourable) Expressed in all Mixed testis: 5.6 HSBP1 ENSG00000230989 Heat shock factor binding protein 1 16 83807843-83819737 Predicted intracellular proteins Evidence at protein level Ovarian cancer:2.96e-4 (favourable), Endometrial cancer:5.73e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 59.0 PSMD13 p40.5, Rpn9 ENSG00000185627 Proteasome 26S subunit, non-ATPase 13 11 236546-252984 Predicted intracellular proteins Evidence at protein level HPA038691, HPA038692 Approved Approved Nuclear speckles
Cytosol Renal cancer:1.52e-13 (unfavourable), Liver cancer:4.76e-5 (unfavourable), Endometrial cancer:5.74e-4 (favourable) Expressed in all Expressed in all thyroid gland: 41.6 DDIT4L REDD2, Rtp801L ENSG00000145358 DNA-damage-inducible transcript 4-like 4 100185870-100190782 Predicted intracellular proteins Evidence at protein level HPA050903 Uncertain Nucleoplasm
Plasma membrane
Actin filaments Endometrial cancer:5.77e-4 (favourable) Tissue enhanced Tissue enhanced skeletal muscle: 113.3 cervix, uterine: 33.1 TCTN3 C10orf61, DKFZP564D116, JBTS18, TECT3 ENSG00000119977 Tectonic family member 3 10 95663396-95694143 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026987 Approved Approved Microtubules Endometrial cancer:5.77e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 135.3 ADCYAP1R1 PAC1, PAC1R, PACAPR ENSG00000078549 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I 7 31052461-31111479 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA049877 Approved Uncertain Vesicles Endometrial cancer:5.78e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 137.5;fallopian tube: 46.5 cervix, uterine: 20.6 MRVI1 IRAG, JAW1L ENSG00000072952 Murine retrovirus integration site 1 homolog 11 10573091-10693988 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008704 Uncertain Approved Nuclear bodies
Cytosol Endometrial cancer:5.78e-4 (favourable), Renal cancer:9.70e-4 (unfavourable) Mixed Mixed endometrium: 98.6 TMEM219 ENSG00000149932 Transmembrane protein 219 16 29940885-29973052 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059185 Approved Endometrial cancer:5.79e-4 (favourable) Expressed in all Expressed in all fallopian tube: 196.0 PKP4 p0071 ENSG00000144283 Plakophilin 4 2 158456964-158682879 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037334, HPA066647, HPA070648 Approved Validated Plasma membrane
Cell Junctions Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable) Expressed in all Expressed in all kidney: 65.1 ING1 p24ING1c, p33, p33ING1, p33ING1b, p47, p47ING1a ENSG00000153487 Inhibitor of growth family, member 1 13 110712736-110723339 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB016136, CAB017773, HPA052591 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:5.81e-4 (favourable) Expressed in all Expressed in all ovary: 20.9 CYP4V2 CYP4AH1 ENSG00000145476 Cytochrome P450, family 4, subfamily V, polypeptide 2 4 186191520-186213456 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA029122 Approved Approved Nuclear speckles Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 63.8 liver: 47.3 GMDS GMD, SDR3E1 ENSG00000112699 GDP-mannose 4,6-dehydratase 6 1623806-2245692 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031528 Approved Endometrial cancer:5.89e-4 (favourable), Renal cancer:5.93e-4 (favourable) Expressed in all Mixed duodenum: 109.2 UBE2D2 UBC4, UbcH5B ENSG00000131508 Ubiquitin-conjugating enzyme E2D 2 5 139526431-139628433 Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable) Expressed in all Expressed in all testis: 237.4 IQCE KIAA1023 ENSG00000106012 IQ motif containing E 7 2558972-2614734 Predicted intracellular proteins Evidence at protein level HPA019515 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:5.91e-4 (favourable) Expressed in all Tissue enhanced testis: 51.4 fallopian tube: 23.6 VLDLR CARMQ1, CHRMQ1, VLDLRCH ENSG00000147852 Very low density lipoprotein receptor 9 2621834-2660053 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB032462, HPA051312 Uncertain Approved Vesicles
Cytokinetic bridge
Microtubule organizing center Endometrial cancer:5.95e-4 (favourable) Expressed in all Tissue enhanced ovary: 109.9;parathyroid gland: 123.5 heart muscle: 44.5 APBA3 mint3, X11L2 ENSG00000011132 Amyloid beta (A4) precursor protein-binding, family A, member 3 19 3750819-3761699 Predicted intracellular proteins Evidence at protein level HPA045577 Approved Approved Vesicles Pancreatic cancer:1.51e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Head and neck cancer:4.91e-4 (favourable), Endometrial cancer:5.97e-4 (favourable) Expressed in all Mixed spleen: 6.8 GPSM3 AGS4, C6orf9, G18, G18.1a, G18.1b, G18.2, NG1 ENSG00000213654 G-protein signaling modulator 3 6 32190766-32195523 Predicted intracellular proteins Evidence at protein level Renal cancer:6.92e-9 (unfavourable), Endometrial cancer:5.98e-4 (favourable) Expressed in all Tissue enhanced appendix: 25.7;lymph node: 27.9;spleen: 29.8 tonsil: 16.1 DDOST KIAA0115, OST, OST48, WBP1 ENSG00000244038 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit (non-catalytic) 1 20651767-20661544 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009746, HPA046841, HPA052867 Supported Supported Endoplasmic reticulum Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable) Expressed in all Expressed in all thyroid gland: 307.5 MCF2L ARHGEF14, DBS, KIAA0362, OST ENSG00000126217 MCF.2 cell line derived transforming sequence-like 13 112894378-113099739 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Renal cancer:9.14e-6 (favourable), Urothelial cancer:2.63e-5 (favourable), Pancreatic cancer:4.36e-5 (favourable), Endometrial cancer:6.01e-4 (favourable) Expressed in all Mixed cerebral cortex: 62.6 HMHA1 ARHGAP45, HA-1, KIAA0223 ENSG00000180448 Histocompatibility (minor) HA-1 19 1065923-1086628 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA019816 Supported Endometrial cancer:6.02e-4 (favourable), Head and neck cancer:7.82e-4 (favourable) Expressed in all Tissue enhanced appendix: 58.4;lymph node: 67.5;spleen: 79.4 bone marrow: 44.1 CFAP57 FLJ32000, WDR65 ENSG00000243710 Cilia and flagella associated protein 57 1 43172149-43254358 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002736, HPA028623 Supported Uncertain Cytosol Endometrial cancer:6.02e-4 (favourable) Mixed Group enriched 8 fallopian tube: 35.3;testis: 27.6 liver: 3.8 TEKT1 ENSG00000167858 Tektin 1 17 6789133-6831761 Predicted intracellular proteins Evidence at protein level HPA044444, HPA062285 Supported Endometrial cancer:6.08e-4 (favourable) Group enriched Group enriched 7 fallopian tube: 79.4;testis: 18.3 lung: 7.0 ALG12 ECM39 ENSG00000182858 ALG12, alpha-1,6-mannosyltransferase 22 49900229-49918458 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003076, HPA051665 Approved Approved Endoplasmic reticulum Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.1 STK16 MPSK, PKL12 ENSG00000115661 Serine/threonine kinase 16 2 219245455-219250337 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029450 Approved Approved Cytosol Endometrial cancer:6.09e-4 (favourable) Expressed in all Expressed in all testis,thyroid gland: 28.6 MPND FLJ14981 ENSG00000008382 MPN domain containing 19 4343527-4360086 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043274, HPA045475 Approved Approved Nucleus
Nucleoli Lung cancer:1.55e-4 (favourable), Cervical cancer:2.99e-4 (favourable), Endometrial cancer:6.12e-4 (favourable), Renal cancer:7.04e-4 (favourable) Expressed in all Expressed in all duodenum: 31.8 CDYL2 FLJ38866 ENSG00000166446 Chromodomain protein, Y-like 2 16 80597906-80804329 Predicted intracellular proteins Evidence at protein level HPA041016 Approved Endometrial cancer:6.13e-4 (favourable) Expressed in all Mixed testis: 21.3 NFAM1 CNAIP ENSG00000235568 NFAT activating protein with ITAM motif 1 22 42380410-42432395 Predicted membrane proteins Evidence at protein level HPA031812 Uncertain Endometrial cancer:6.16e-4 (favourable) Expressed in all Tissue enhanced appendix: 17.6;bone marrow: 20.3 spleen: 14.8 CYB5D2 MGC32124 ENSG00000167740 Cytochrome b5 domain containing 2 17 4143168-4187310 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042299 Approved Approved Nuclear membrane
Nucleoli
Centrosome Renal cancer:2.03e-10 (favourable), Liver cancer:4.98e-6 (favourable), Pancreatic cancer:7.76e-5 (favourable), Endometrial cancer:6.19e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.5 RPL13 BBC1, D16S444E, L13 ENSG00000167526 Ribosomal protein L13 16 89560657-89566828 Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA051702 Approved Validated Nucleoli
Endoplasmic reticulum
Cytosol Endometrial cancer:6.26e-4 (favourable), Renal cancer:6.64e-4 (unfavourable) Expressed in all Expressed in all ovary: 3867.8 HOXB5 HOX2, HOX2A ENSG00000120075 Homeobox B5 17 48591257-48593961 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA074454 Supported Nucleus Urothelial cancer:8.59e-5 (favourable), Lung cancer:4.61e-4 (unfavourable), Endometrial cancer:6.28e-4 (favourable) Tissue enhanced Tissue enhanced epididymis: 20.8 fallopian tube: 11.0 TLR4 ARMD10, CD284, hToll, TLR-4 ENSG00000136869 Toll-like receptor 4 9 117704332-117716871 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB004025, HPA049174 Approved Approved Golgi apparatus
Cytosol Testis cancer:3.79e-4 (unfavourable), Endometrial cancer:6.29e-4 (favourable) Expressed in all Mixed spleen: 49.0 SERPINA11 ENSG00000186910 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 11 14 94442464-94452790 Plasma proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:6.30e-4 (favourable) Tissue enriched Tissue enriched 30 liver: 255.3 cervix, uterine: 8.6 RGS10 ENSG00000148908 Regulator of G-protein signaling 10 10 119499828-119542708 Predicted intracellular proteins Evidence at protein level CAB004559, HPA021305, HPA058485 Supported Supported Nucleus
Plasma membrane Renal cancer:4.20e-10 (unfavourable), Endometrial cancer:6.32e-4 (favourable), Cervical cancer:6.81e-4 (favourable) Expressed in all Expressed in all lymph node: 139.8 BBOF1 C14orf45, CCDC176 ENSG00000119636 Basal body orientation factor 1 14 74019353-74082863 Predicted intracellular proteins Evidence at protein level HPA003090, HPA003136 Uncertain Approved Nucleus
Plasma membrane
Microtubule organizing center Endometrial cancer:6.34e-4 (favourable) Expressed in all Tissue enhanced testis: 69.7 fallopian tube: 35.6 BIN2 BRAP-1 ENSG00000110934 Bridging integrator 2 12 51281038-51324668 Predicted intracellular proteins Evidence at protein level HPA038666, HPA038667 Supported Cervical cancer:1.33e-4 (favourable), Endometrial cancer:6.34e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 65.9 spleen: 53.9 LFNG SCDO3 ENSG00000106003 LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 7 2512529-2529177 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA069130 Approved Endometrial cancer:6.36e-4 (favourable) Expressed in all Expressed in all skin: 68.6 B3GALT5 B3GalT-V, B3T5, beta3Gal-T5, GLCT5 ENSG00000183778 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 21 39556442-39673137 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054092, HPA054684 Approved Endometrial cancer:6.36e-4 (favourable) Mixed Group enriched 5 colon: 23.1;duodenum: 28.2;gallbladder: 8.6;rectum: 41.3;small intestine: 37.9 stomach: 5.1 PRR15 ENSG00000176532 Proline rich 15 7 29563811-29567295 Predicted intracellular proteins Evidence at protein level HPA040996, HPA048121 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable) Mixed Tissue enhanced cervix, uterine: 91.8 colon,small intestine: 80.6 APCDD1 B7323 ENSG00000154856 Adenomatosis polyposis coli down-regulated 1 18 10454628-10489948 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:6.39e-4 (favourable) Expressed in all Tissue enhanced skin: 153.5 cerebral cortex: 60.8 IL4R CD124 ENSG00000077238 Interleukin 4 receptor 16 27313668-27364778 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004451, HPA050124 Supported Approved Cytosol Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable) Expressed in all Expressed in all lymph node: 139.5 CTDP1 FCP1 ENSG00000060069 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 18 79679801-79756623 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB032641, HPA040394 Supported Supported Nuclear speckles
Actin filaments Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable) Expressed in all Expressed in all testis: 19.6 CTDNEP1 DULLARD, HSA011916, NET56 ENSG00000175826 CTD nuclear envelope phosphatase 1 17 7243591-7252491 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037439 Uncertain Pancreatic cancer:1.81e-4 (favourable), Endometrial cancer:6.45e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 190.2 SHQ1 FLJ10539, Shq1p ENSG00000144736 SHQ1, H/ACA ribonucleoprotein assembly factor 3 72749277-72861914 Predicted intracellular proteins Evidence at protein level HPA042792 Uncertain Supported Nucleoplasm Colorectal cancer:2.83e-4 (favourable), Endometrial cancer:6.49e-4 (favourable) Expressed in all Expressed in all testis: 18.0 MIOS FLJ20323 ENSG00000164654 Missing oocyte, meiosis regulator, homolog (Drosophila) 7 7566872-7608929 Predicted intracellular proteins Evidence at protein level HPA042928, HPA052223 Approved Validated Nucleoplasm
Cytosol Renal cancer:3.28e-6 (favourable), Endometrial cancer:6.51e-4 (favourable), Liver cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 53.8 C1orf115 FLJ14146 ENSG00000162817 Chromosome 1 open reading frame 115 1 220689845-220699157 Predicted intracellular proteins Evidence at transcript level Ovarian cancer:5.12e-5 (favourable), Endometrial cancer:6.52e-4 (favourable) Expressed in all Mixed small intestine: 113.1 EHMT1 bA188C12.1, Eu-HMTase1, FLJ12879, KIAA1876, KMT1D ENSG00000181090 Euchromatic histone-lysine N-methyltransferase 1 9 137618963-137870016 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA060022 Supported Nucleoplasm
Nuclear bodies Endometrial cancer:6.56e-4 (favourable), Head and neck cancer:8.91e-4 (favourable) Expressed in all Expressed in all testis: 75.6 SLC22A23 C6orf85, FLJ22174 ENSG00000137266 Solute carrier family 22, member 23 6 3268962-3457022 Predicted membrane proteins, Transporters Evidence at protein level HPA014697 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:2.39e-4 (unfavourable), Endometrial cancer:6.57e-4 (favourable) Expressed in all Expressed in all stomach: 28.2 DPCD DKFZP566F084, RP11-529I10.4 ENSG00000166171 Deleted in primary ciliary dyskinesia homolog (mouse) 10 101570560-101609668 Predicted intracellular proteins Evidence at protein level HPA036603, HPA036604 Supported Approved Nuclear speckles Endometrial cancer:6.57e-4 (favourable) Expressed in all Expressed in all testis: 152.7 CCDC149 DKFZp761B107 ENSG00000181982 Coiled-coil domain containing 149 4 24806117-24980204 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044158, HPA047913 Uncertain Supported Nucleoli Endometrial cancer:6.63e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 24.1 SYCE1L MRP2 ENSG00000205078 Synaptonemal complex central element protein 1-like 16 77199397-77213215 Predicted intracellular proteins Evidence at protein level HPA062464, HPA066691 Validated Intermediate filaments Renal cancer:2.11e-5 (unfavourable), Endometrial cancer:6.65e-4 (favourable) Mixed Tissue enriched 6 testis: 23.7 prostate: 3.9 PTPN6 HCP, HCPH, PTP-1C, SHP-1, SHP1 ENSG00000111679 Protein tyrosine phosphatase, non-receptor type 6 12 6946468-6961316 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001466, CAB004572, CAB072845 Supported Supported Nucleus
Nucleoli Urothelial cancer:2.64e-8 (favourable), Cervical cancer:1.87e-4 (favourable), Colorectal cancer:5.42e-4 (unfavourable), Endometrial cancer:6.65e-4 (favourable) Expressed in all Mixed lymph node: 163.5 NOG SYM1, SYNS1 ENSG00000183691 Noggin 17 56593699-56595590 Disease related genes, Predicted secreted proteins Evidence at protein level HPA061318 Approved Pancreatic cancer:6.86e-5 (unfavourable), Endometrial cancer:6.66e-4 (favourable) Mixed Group enriched 5 cerebral cortex: 7.3;placenta: 15.8 lymph node: 2.2 MROH1 HEATR7A, KIAA1833 ENSG00000179832 Maestro heat-like repeat family member 1 8 144148016-144261940 Predicted intracellular proteins Evidence at protein level HPA044465 Approved Renal cancer:3.65e-6 (favourable), Endometrial cancer:6.74e-4 (favourable) Expressed in all Expressed in all thyroid gland: 14.9 CHID1 FLJ42707, MGC3234 ENSG00000177830 Chitinase domain containing 1 11 867860-915058 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039374 Uncertain Uncertain Nucleoplasm
Intermediate filaments Endometrial cancer:6.76e-4 (favourable) Expressed in all Expressed in all epididymis: 108.1 LMLN Gp63, Msp ENSG00000185621 Leishmanolysin-like (metallopeptidase M8 family) 3 197960200-198043720 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016481, HPA028844 Uncertain Supported Focal adhesion sites
Cytosol Endometrial cancer:6.77e-4 (favourable) Expressed in all Tissue enhanced testis: 18.7 epididymis: 12.7 CCNO CCNU, FLJ22422, UDG2, UNG2 ENSG00000152669 Cyclin O 5 55231152-55233680 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA050090 Uncertain Stomach cancer:5.10e-4 (favourable), Endometrial cancer:6.78e-4 (favourable), Lung cancer:7.60e-4 (favourable) Expressed in all Tissue enhanced testis: 6.9 fallopian tube,seminal vesicle: 1.6 MTFR1L FAM54B ENSG00000117640 Mitochondrial fission regulator 1-like 1 25818640-25832942 Predicted intracellular proteins Evidence at protein level HPA027124, HPA027130 Approved Approved Cell Junctions
Mitochondria Renal cancer:5.89e-12 (favourable), Endometrial cancer:6.81e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 155.3 ZNF764 MGC13138 ENSG00000169951 Zinc finger protein 764 16 30553764-30558498 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003203 Uncertain Approved Cytosol Endometrial cancer:6.84e-4 (favourable) Expressed in all Mixed testis: 6.0 ANG RAA1, RNASE5 ENSG00000214274 Angiogenin, ribonuclease, RNase A family, 5 14 20684177-20698971 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Liver cancer:7.83e-5 (favourable), Endometrial cancer:6.85e-4 (favourable) Tissue enriched Tissue enriched 27 liver: 1557.7 prostate: 58.5 SLC38A7 FLJ10815 ENSG00000103042 Solute carrier family 38, member 7 16 58665109-58685104 Predicted membrane proteins, Transporters Evidence at protein level HPA041777 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable) Expressed in all Mixed testis: 34.8 OSCP1 C1orf102, NOR1 ENSG00000116885 Organic solute carrier partner 1 1 36415827-36450451 Predicted intracellular proteins, Transporters Evidence at protein level HPA028436, HPA052655 Uncertain Approved Nucleus
Nucleoli
Plasma membrane Renal cancer:2.18e-6 (favourable), Endometrial cancer:6.88e-4 (favourable) Expressed in all Expressed in all testis: 126.0 CTSH ACC-4, ACC-5, ACC4, ACC5, CPSB ENSG00000103811 Cathepsin H 15 78921058-78949574 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000458, HPA003524 Supported Supported Vesicles
Cytosol
Cytoplasmic bodies Endometrial cancer:6.90e-4 (favourable) Expressed in all Expressed in all lung: 570.4 MON1B HSRG1, KIAA0872, SAND2 ENSG00000103111 MON1 secretory trafficking family member B 16 77190835-77202405 Predicted intracellular proteins Evidence at protein level HPA046285 Approved Approved Cytosol Renal cancer:9.42e-5 (favourable), Endometrial cancer:6.90e-4 (favourable) Expressed in all Expressed in all thyroid gland: 30.2 CLEC11A CLECSF3, LSLCL, P47, SCGF ENSG00000105472 C-type lectin domain family 11, member A 19 50723329-50725718 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042690 Approved Approved Centrosome Renal cancer:1.02e-5 (unfavourable), Endometrial cancer:6.91e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 81.6 cervix, uterine: 18.9 CORO1A coronin-1, HCORO1, p57 ENSG00000102879 Coronin, actin binding protein, 1A 16 30182827-30189076 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB046473, HPA051132 Supported Approved Cytosol Renal cancer:5.74e-7 (unfavourable), Head and neck cancer:4.42e-4 (favourable), Endometrial cancer:6.91e-4 (favourable) Expressed in all Expressed in all lymph node: 601.3 C11orf71 FLJ20010 ENSG00000180425 Chromosome 11 open reading frame 71 11 114391443-114400550 Predicted intracellular proteins Evidence at transcript level HPA063943, HPA074787 Approved Nucleoplasm Renal cancer:7.01e-9 (favourable), Endometrial cancer:6.94e-4 (favourable) Expressed in all Tissue enriched 518 testis: 53.6 liver: 0.1 TCF25 KIAA1049, Nulp1 ENSG00000141002 Transcription factor 25 (basic helix-loop-helix) 16 89873586-89911384 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA041699, HPA041786 Uncertain Endometrial cancer:6.95e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 124.9 COG7 ENSG00000168434 Component of oligomeric golgi complex 7 16 23388493-23453180 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040758, HPA064645 Uncertain Validated Golgi apparatus Renal cancer:3.14e-4 (favourable), Endometrial cancer:6.95e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 30.4 SLC15A2 PEPT2 ENSG00000163406 Solute carrier family 15 (oligopeptide transporter), member 2 3 121894089-121944102 Predicted membrane proteins, Transporters Evidence at protein level Cervical cancer:2.37e-4 (favourable), Lung cancer:6.74e-4 (favourable), Endometrial cancer:6.96e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 77.7;prostate: 66.0 epididymis: 47.2 LIN7B LIN-7B, MALS-2, VELI2 ENSG00000104863 Lin-7 homolog B (C. elegans) 19 49114324-49118460 Predicted intracellular proteins Evidence at protein level Endometrial cancer:7.00e-4 (favourable) Expressed in all Mixed cerebral cortex: 18.2 GAS2L2 GAR17 ENSG00000270765 Growth arrest-specific 2 like 2 17 35744511-35752878 Predicted intracellular proteins Evidence at protein level HPA044370 Supported Endometrial cancer:7.00e-4 (favourable) Tissue enhanced Tissue enriched 11 fallopian tube: 27.8 epididymis,lung: 2.6 CCDC113 DKFZp434N1418, HSPC065 ENSG00000103021 Coiled-coil domain containing 113 16 58231157-58283836 Predicted intracellular proteins Evidence at protein level HPA040759, HPA040869 Uncertain Approved Nucleoplasm
Cytosol Endometrial cancer:7.01e-4 (favourable), Colorectal cancer:8.65e-4 (favourable) Mixed Tissue enhanced fallopian tube: 49.6;testis: 32.7 parathyroid gland: 16.1 FOXP3 AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID ENSG00000049768 Forkhead box P3 X 49250436-49264826 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB026301, HPA045943 Supported Approved Nucleoplasm Cervical cancer:1.91e-4 (favourable), Head and neck cancer:4.90e-4 (favourable), Endometrial cancer:7.02e-4 (favourable) Mixed Tissue enhanced appendix: 9.0 lymph node: 6.1 GADD45G CR6, DDIT2, GADD45gamma, GRP17 ENSG00000130222 Growth arrest and DNA-damage-inducible, gamma 9 89605013-89606555 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023606 Approved Approved Nucleus Pancreatic cancer:3.80e-5 (favourable), Endometrial cancer:7.06e-4 (favourable) Expressed in all Mixed adrenal gland: 47.4 IZUMO4 C19orf36 ENSG00000099840 IZUMO family member 4 19 2096429-2099593 Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA045099, HPA048496 Approved Uncertain Nucleoplasm
Vesicles Pancreatic cancer:1.69e-4 (favourable), Endometrial cancer:7.08e-4 (favourable) Mixed Tissue enriched 52 testis: 341.4 ovary: 6.5 SPRED1 FLJ33903, PPP1R147 ENSG00000166068 Sprouty-related, EVH1 domain containing 1 15 38252326-38357249 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042193, HPA061805 Approved Supported Nucleus Renal cancer:7.37e-5 (unfavourable), Stomach cancer:8.29e-5 (unfavourable), Endometrial cancer:7.08e-4 (favourable) Expressed in all Mixed thyroid gland: 48.1 FKBP11 FKBP19 ENSG00000134285 FK506 binding protein 11, 19 kDa 12 48921518-48926474 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041709 Approved Approved Centrosome Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable) Expressed in all Mixed pancreas: 60.7 SAFB2 KIAA0138 ENSG00000130254 Scaffold attachment factor B2 19 5586999-5624046 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA050894 Approved Supported Nucleoplasm
Nuclear bodies
Vesicles Urothelial cancer:2.12e-4 (favourable), Pancreatic cancer:2.53e-4 (favourable), Endometrial cancer:7.10e-4 (favourable) Expressed in all Expressed in all ovary: 40.2 SAR1B SARA2 ENSG00000152700 Secretion associated, Ras related GTPase 1B 5 134601144-134649271 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006923, HPA048368 Supported Approved Endoplasmic reticulum Liver cancer:6.59e-4 (favourable), Endometrial cancer:7.11e-4 (favourable) Expressed in all Expressed in all testis: 117.9 ABI3 NESH, SSH3BP3 ENSG00000108798 ABI family, member 3 17 49210227-49223225 Predicted intracellular proteins Evidence at protein level HPA017345 Approved Endometrial cancer:7.13e-4 (favourable) Expressed in all Tissue enhanced spleen: 63.1 lymph node: 30.4 CCDC92 FLJ22471 ENSG00000119242 Coiled-coil domain containing 92 12 123918660-123972831 Predicted intracellular proteins Evidence at protein level HPA038560, HPA057580 Approved Supported Nucleoplasm
Centrosome Pancreatic cancer:4.59e-5 (favourable), Endometrial cancer:7.15e-4 (favourable) Expressed in all Mixed testis: 18.0 PSMB8 beta5i, D6S216E, LMP7, PSMB5i, RING10 ENSG00000204264 Proteasome subunit beta 8 6 32840717-32844703 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046995, HPA050327 Supported Approved Vesicles
Cytokinetic bridge Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable) Expressed in all Mixed lymph node: 23.3 SELK ENSG00000113811 Selenoprotein K 3 53884410-53891988 Predicted membrane proteins Evidence at protein level HPA008196 Uncertain Approved Nucleoplasm
Cytosol Lung cancer:3.76e-4 (favourable), Endometrial cancer:7.18e-4 (favourable) Expressed in all Expressed in all epididymis: 74.5 DUSP6 MKP-3, PYST1 ENSG00000139318 Dual specificity phosphatase 6 12 89347232-89353271 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB017566, HPA053188 Approved Uncertain Nucleoplasm
Cytosol Endometrial cancer:7.21e-4 (favourable) Expressed in all Expressed in all adipose tissue: 140.8 CREB3L4 AIbZIP, ATCE1, CREB3, CREB4, hJAL ENSG00000143578 CAMP responsive element binding protein 3-like 4 1 153967534-153974363 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA038122 Supported Approved Nucleoplasm
Nuclear membrane
Mitochondria Endometrial cancer:7.21e-4 (favourable) Group enriched Expressed in all prostate: 171.5 DERL2 CGI-101, derlin-2, F-LAN-1, F-LANa, FLANa ENSG00000072849 Derlin 2 17 5471251-5486811 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037287, HPA048957, HPA056551 Supported Supported Endoplasmic reticulum Renal cancer:6.49e-4 (unfavourable), Endometrial cancer:7.26e-4 (favourable) Expressed in all Expressed in all thyroid gland: 41.3 MZB1 HSPC190, MEDA-7, MGC29506, PACAP, pERp1 ENSG00000170476 Marginal zone B and B1 cell-specific protein 5 139387480-139390081 Predicted secreted proteins Evidence at protein level HPA043745, HPA052694 Supported Renal cancer:1.15e-8 (unfavourable), Head and neck cancer:4.60e-5 (favourable), Endometrial cancer:7.27e-4 (favourable) Mixed Mixed lymph node: 163.6 SLC26A2 DTD, DTDST ENSG00000155850 Solute carrier family 26 (anion exchanger), member 2 5 149960737-149993455 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041957, HPA058090 Supported Approved Vesicles Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable) Expressed in all Tissue enhanced colon: 215.9;rectum: 209.8 parathyroid gland: 81.4 VCP IBMPFD, p97 ENSG00000165280 Valosin containing protein 9 35056064-35073249 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level CAB005593, HPA012728, HPA012814 Supported Validated Nucleoplasm
Cytosol Renal cancer:9.63e-7 (favourable), Endometrial cancer:7.30e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 92.6 CFAP77 C9orf171, FLJ46082 ENSG00000188523 Cilia and flagella associated protein 77 9 132410043-132573317 Predicted intracellular proteins Evidence at protein level HPA021329, HPA024647 Uncertain Approved Cytosol Endometrial cancer:7.31e-4 (favourable) Tissue enhanced Group enriched 10 fallopian tube: 48.2;testis: 22.8 lung: 3.4 GALK2 GK2 ENSG00000156958 Galactokinase 2 15 49155656-49367869 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043564, HPA048267 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:1.88e-5 (favourable), Endometrial cancer:7.31e-4 (favourable) Expressed in all Expressed in all kidney: 31.7 ZFYVE19 ANCHR, FLJ14840 ENSG00000166140 Zinc finger, FYVE domain containing 19 15 40807086-40815084 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040283, HPA041946 Uncertain Endometrial cancer:7.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 27.7 OCIAD2 MGC45416 ENSG00000145247 OCIA domain containing 2 4 48885019-48906937 Predicted intracellular proteins Evidence at protein level HPA040979, HPA041090 Supported Validated Mitochondria Renal cancer:2.67e-5 (favourable), Urothelial cancer:2.34e-4 (favourable), Ovarian cancer:6.56e-4 (favourable), Pancreatic cancer:6.89e-4 (unfavourable), Endometrial cancer:7.37e-4 (favourable) Expressed in all Expressed in all kidney: 150.6 LRRC56 DKFZp761L1518, FLJ00101 ENSG00000161328 Leucine rich repeat containing 56 11 537527-554916 Predicted intracellular proteins Evidence at transcript level HPA038728 Uncertain Lung cancer:6.19e-4 (favourable), Pancreatic cancer:6.32e-4 (favourable), Endometrial cancer:7.39e-4 (favourable) Expressed in all Tissue enhanced testis: 3.9 epididymis,fallopian tube: 1.5 OTUD7B CEZANNE, ZA20D1 ENSG00000264522 OTU deubiquitinase 7B 1 149937812-150010676 Enzymes, Predicted intracellular proteins Evidence at protein level HPA027045 Supported Approved Nucleoplasm
Microtubules Melanoma:5.09e-5 (favourable), Endometrial cancer:7.47e-4 (favourable) Expressed in all Mixed testis: 23.5 APBB1IP INAG1, RIAM ENSG00000077420 Amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 10 26438203-26567803 Predicted intracellular proteins Evidence at protein level HPA017009, HPA063903 Supported Validated Plasma membrane
Cytosol Endometrial cancer:7.48e-4 (favourable) Expressed in all Mixed appendix: 63.1 GLE1 GLE1L, hGLE1, LCCS1 ENSG00000119392 GLE1 RNA export mediator 9 128504700-128542288 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA041689, HPA043538, HPA061560 Supported Supported Nuclear membrane
Nucleoli Stomach cancer:7.04e-4 (favourable), Endometrial cancer:7.49e-4 (favourable) Expressed in all Expressed in all testis: 58.6 C16orf71 DKFZp686H2240, FLJ43261 ENSG00000166246 Chromosome 16 open reading frame 71 16 4734272-4749396 Predicted intracellular proteins Evidence at protein level HPA049468 Supported Uncertain Nuclear speckles Endometrial cancer:7.49e-4 (favourable) Mixed Group enriched 16 fallopian tube: 36.2;testis: 113.1 epididymis: 4.5 ACAA1 ENSG00000060971 Acetyl-CoA acyltransferase 1 3 38103129-38137242 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006764, HPA007244 Supported Validated Peroxisomes Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable) Expressed in all Expressed in all liver: 327.6 MAN2B2 KIAA0935 ENSG00000013288 Mannosidase, alpha, class 2B, member 2 4 6575175-6623362 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA037005 Uncertain Endometrial cancer:7.59e-4 (favourable) Expressed in all Expressed in all thyroid gland: 37.6 PKHD1L1 ENSG00000205038 Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 8 109362477-109530330 Predicted membrane proteins Evidence at protein level HPA044458 Uncertain Endometrial cancer:7.61e-4 (favourable) Group enriched Group enriched 6 cervix, uterine: 21.2;fallopian tube: 19.5;thyroid gland: 56.9 endometrium: 5.4 GIMAP4 FLJ11110, HIMAP4, IAN1, IMAP4 ENSG00000133574 GTPase, IMAP family member 4 7 150567277-150573955 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019135, HPA019137, HPA027198 Supported Renal cancer:1.13e-4 (unfavourable), Endometrial cancer:7.63e-4 (favourable) Expressed in all Expressed in all spleen: 150.0 DESI1 D15Wsu75e, FAM152B, PPPDE2 ENSG00000100418 Desumoylating isopeptidase 1 22 41598028-41621096 Predicted intracellular proteins Evidence at protein level HPA053415 Approved Approved Cytokinetic bridge
Cytosol Endometrial cancer:7.70e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 29.6 LRTOMT CFAP111, COMT2, DFNB63, LRRC51 ENSG00000184154 Leucine rich transmembrane and O-methyltransferase domain containing 11 72080331-72110782 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039949 Approved Approved Nucleoli
Microtubules Ovarian cancer:5.36e-4 (favourable), Endometrial cancer:7.70e-4 (favourable) Expressed in all Expressed in all testis: 137.8 SERPINA5 PAI3, PCI, PLANH3, PROCI ENSG00000188488 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 14 94561442-94593120 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA056919 Approved Mitochondria Endometrial cancer:7.72e-4 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 516.7;liver: 406.5;testis: 816.1 gallbladder: 251.6 HS3ST1 3OST1 ENSG00000002587 Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 4 11393150-11429765 Enzymes, Predicted secreted proteins Evidence at protein level HPA002237 Approved Approved Vesicles Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable) Mixed Tissue enhanced gallbladder: 14.0;ovary: 23.1 urinary bladder: 5.8 GPX1 ENSG00000233276 Glutathione peroxidase 1 3 49357176-49358600 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011582, HPA044758 Approved Supported Cytosol Endometrial cancer:7.78e-4 (favourable) Expressed in all Expressed in all adipose tissue: 275.5 SEC61A1 ENSG00000058262 Sec61 translocon alpha 1 subunit 3 128051641-128071683 Predicted membrane proteins, Transporters Evidence at protein level CAB022076 Supported Endoplasmic reticulum Renal cancer:6.84e-9 (unfavourable), Liver cancer:1.07e-6 (unfavourable), Endometrial cancer:7.82e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 217.0 HN1L C16orf34, FLJ13092, KIAA1426, L11 ENSG00000206053 Hematological and neurological expressed 1-like 16 1678256-1702280 Predicted intracellular proteins Evidence at protein level HPA041888, HPA041908 Approved Validated Plasma membrane
Cytosol Endometrial cancer:7.85e-4 (favourable), Liver cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 100.6 HLA-DRB5 ENSG00000198502 Major histocompatibility complex, class II, DR beta 5 6 32517343-32530287 Predicted membrane proteins Evidence at protein level HPA043151 Supported Endometrial cancer:7.89e-4 (favourable) Expressed in all Tissue enhanced lung: 532.0 lymph node: 405.2 HMOX2 HO-2 ENSG00000103415 Heme oxygenase 2 16 4474690-4510347 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025464, HPA040611 Supported Approved Vesicles
Cytosol Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable) Expressed in all Expressed in all testis: 97.3 SLAIN2 FLJ21611, KIAA1458 ENSG00000109171 SLAIN motif family, member 2 4 48341322-48426212 Predicted intracellular proteins Evidence at protein level HPA035824, HPA063599 Approved Validated Centrosome
Cytosol Renal cancer:1.50e-4 (favourable), Colorectal cancer:5.77e-4 (favourable), Pancreatic cancer:6.71e-4 (unfavourable), Endometrial cancer:7.98e-4 (favourable) Expressed in all Expressed in all testis: 72.6 ADRA2A ADRA2, ADRA2R, ADRAR ENSG00000150594 Adrenoceptor alpha 2A 10 111077163-111080907 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:8.06e-4 (favourable) Expressed in all Mixed cervix, uterine: 33.1 FAM181B LOC220382, MGC33846 ENSG00000182103 Family with sequence similarity 181, member B 11 82729941-82733864 Predicted intracellular proteins Evidence at transcript level HPA066861 Approved Approved Nuclear membrane
Mitochondria Endometrial cancer:8.07e-4 (favourable) Tissue enriched Tissue enriched 20 cerebral cortex: 17.5 adrenal gland,fallopian tube: 0.8 VWA3A FLJ40941, FLJ46765 ENSG00000175267 Von Willebrand factor A domain containing 3A 16 22092538-22156966 Predicted intracellular proteins Evidence at protein level HPA041696, HPA042044 Uncertain Endometrial cancer:8.15e-4 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 52.4 lung: 11.6 P4HTM EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4 ENSG00000178467 Prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) 3 48989886-49007154 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007199 Supported Uncertain Vesicles
Cytosol Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable) Expressed in all Expressed in all fallopian tube: 49.9 LRRC4 NAG14 ENSG00000128594 Leucine rich repeat containing 4 7 128027071-128032107 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051100 Uncertain Golgi apparatus Renal cancer:6.98e-4 (favourable), Endometrial cancer:8.19e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 53.0 parathyroid gland: 13.0 ADCY4 AC4 ENSG00000129467 Adenylate cyclase 4 14 24318349-24335093 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB005070, HPA048344 Approved Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable) Expressed in all Tissue enhanced placenta: 20.9 lung: 11.6 CSK ENSG00000103653 C-src tyrosine kinase 15 74782057-74803198 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011203, HPA026488, HPA028425 Approved Approved Vesicles
Cytosol Cervical cancer:5.14e-5 (favourable), Stomach cancer:1.07e-4 (favourable), Renal cancer:1.74e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable) Expressed in all Expressed in all lymph node: 197.7 TNFRSF1A CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60 ENSG00000067182 Tumor necrosis factor receptor superfamily, member 1A 12 6328757-6342114 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004102, CAB010309 Approved Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable) Expressed in all Expressed in all gallbladder: 140.8 POLR2G hRPB19, hsRPB7, RPB7 ENSG00000168002 Polymerase (RNA) II (DNA directed) polypeptide G 11 62761544-62766710 Predicted intracellular proteins, RNA polymerase related proteins Evidence at protein level HPA053000 Approved Supported Nucleoplasm Liver cancer:6.02e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:8.23e-4 (favourable) Expressed in all Expressed in all fallopian tube: 98.6 SEC23B CDA-II, CDAII, CDAN2, HEMPAS ENSG00000101310 Sec23 homolog B, COPII coat complex component 20 18507493-18561415 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008216, HPA069974 Uncertain Supported Vesicles Endometrial cancer:8.25e-4 (favourable) Expressed in all Expressed in all thyroid gland: 85.5 GTF2F1 BTF4, RAP74, TF2F1, TFIIF ENSG00000125651 General transcription factor IIF, polypeptide 1, 74kDa 19 6379569-6393981 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022793, HPA028707 Approved Validated Nucleus
Cell Junctions Endometrial cancer:8.39e-4 (favourable), Renal cancer:9.80e-4 (favourable) Expressed in all Expressed in all ovary: 93.6 CTSV CTSL2, CTSU ENSG00000136943 Cathepsin V 9 97029679-97039643 Enzymes, Predicted secreted proteins Evidence at protein level CAB017112 Uncertain Approved Nucleus
Nucleoli fibrillar center
Plasma membrane
Cytosol Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 68.9;skin: 64.3;testis: 131.2 placenta: 25.7 BNIP2 BNIP-2, Nip2 ENSG00000140299 BCL2/adenovirus E1B 19kDa interacting protein 2 15 59659146-59689534 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026843 Approved Renal cancer:2.19e-5 (unfavourable), Endometrial cancer:8.42e-4 (favourable) Expressed in all Expressed in all bone marrow: 84.4 DOK1 p62dok ENSG00000115325 Docking protein 1, 62kDa (downstream of tyrosine kinase 1) 2 74549026-74557554 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004224, HPA048561 Approved Supported Cytosol Renal cancer:3.16e-6 (unfavourable), Lung cancer:4.64e-4 (favourable), Endometrial cancer:8.42e-4 (favourable) Expressed in all Mixed appendix: 9.0 GCNT1 C2GNT, NACGT2, NAGCT2 ENSG00000187210 Glucosaminyl (N-acetyl) transferase 1, core 2 9 76419850-76507416 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003522, HPA003523, HPA031151 Uncertain Supported Nuclear speckles Urothelial cancer:4.96e-4 (unfavourable), Endometrial cancer:8.44e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 183.3 duodenum: 51.5 CSF3 C17orf33, G-CSF, GCSF, MGC45931 ENSG00000108342 Colony stimulating factor 3 (granulocyte) 17 40015361-40017813 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001412, CAB016131 Approved Endometrial cancer:8.45e-4 (favourable) Mixed Tissue enhanced appendix: 19.4;cervix, uterine: 38.0 adipose tissue: 10.2 GNPTAB GNPTA, KIAA1208, MGC4170 ENSG00000111670 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 12 101745497-101830938 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017754, HPA042343 Approved Approved Vesicles Endometrial cancer:8.48e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 64.0 SRPR Sralpha, SRP-alpha ENSG00000182934 Signal recognition particle receptor (docking protein) 11 126262919-126269144 Plasma proteins, Predicted intracellular proteins Evidence at protein level Endometrial cancer:8.56e-4 (favourable) Expressed in all Expressed in all epididymis: 167.7 ITPK1 ENSG00000100605 Inositol-tetrakisphosphate 1-kinase 14 92936914-93116320 Enzymes, Predicted intracellular proteins Evidence at protein level HPA055230 Approved Approved Mitochondria Endometrial cancer:8.56e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 93.4 PAPSS1 ATPSK1, PAPSS ENSG00000138801 3'-phosphoadenosine 5'-phosphosulfate synthase 1 4 107590276-107720452 Enzymes, Predicted intracellular proteins Evidence at protein level HPA049781 Approved Approved Nucleus
Nucleoli Liver cancer:2.70e-5 (unfavourable), Endometrial cancer:8.58e-4 (favourable), Colorectal cancer:9.14e-4 (favourable) Expressed in all Expressed in all endometrium: 73.3 SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 66.4 RIC8A synembryn, synembryn-A ENSG00000177963 RIC8 guanine nucleotide exchange factor A 11 207511-215113 Predicted intracellular proteins Evidence at protein level HPA041491, CAB046012 Approved Supported Cytosol Liver cancer:1.11e-6 (unfavourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all smooth muscle: 71.5 GAD1 GAD ENSG00000128683 Glutamate decarboxylase 1 (brain, 67kDa) 2 170813213-170861151 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004415, HPA031949, HPA058412, CAB078176 Supported Supported Approved Vesicles Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable) Tissue enhanced Tissue enriched 6 cerebral cortex: 75.5 parathyroid gland: 11.7 C9orf9 Mast ENSG00000165698 Chromosome 9 open reading frame 9 9 132878027-132890201 Predicted intracellular proteins Evidence at protein level HPA022243, HPA051600 Supported Approved Mitochondria Renal cancer:8.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable) Expressed in all Group enriched 5 epididymis: 88.9;fallopian tube: 62.4;testis: 129.6 thyroid gland: 17.9 C1orf228 MGC33556, NCRNA00082, p40 ENSG00000198520 Chromosome 1 open reading frame 228 1 44674692-44725591 Predicted intracellular proteins Evidence at protein level HPA034769 Uncertain Uncertain Cytosol Endometrial cancer:8.64e-4 (favourable) Mixed Tissue enhanced fallopian tube: 13.4;testis: 21.5 epididymis: 5.1 PPFIA3 KIAA0654, LPNA3, MGC126567, MGC126569 ENSG00000177380 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 3 19 49119389-49151026 Predicted intracellular proteins Evidence at protein level HPA043567, HPA050340 Supported Uncertain Nucleoli fibrillar center
Vesicles Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable) Expressed in all Group enriched 5 cerebral cortex: 21.6;skin: 20.2 parathyroid gland: 3.9 PRKAB1 ENSG00000111725 Protein kinase, AMP-activated, beta 1 non-catalytic subunit 12 119667753-119681630 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA004247, CAB005058 Supported Approved Nucleoplasm
Cytosol Renal cancer:5.40e-9 (favourable), Endometrial cancer:8.66e-4 (favourable) Expressed in all Expressed in all kidney: 53.7 TMEM63A KIAA0792 ENSG00000196187 Transmembrane protein 63A 1 225845536-225882369 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066504, HPA066936, HPA068918 Validated Vesicles
Microtubule organizing center Endometrial cancer:8.79e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 77.4 CDK2AP2 DOC-1R, p14 ENSG00000167797 Cyclin-dependent kinase 2 associated protein 2 11 67506497-67508649 Predicted intracellular proteins Evidence at protein level HPA047599 Uncertain Approved Nucleoplasm Renal cancer:5.20e-4 (unfavourable), Endometrial cancer:8.80e-4 (favourable) Expressed in all Expressed in all epididymis: 49.8 LPXN LDPL ENSG00000110031 Leupaxin 11 58526871-58578220 Predicted intracellular proteins Evidence at protein level HPA043741, CAB046478, HPA061441 Supported Validated Nuclear speckles
Focal adhesion sites
Cytosol Endometrial cancer:8.81e-4 (favourable) Expressed in all Expressed in all tonsil: 111.2 TMEM167B AD-020, C1orf119, FLJ90710 ENSG00000215717 Transmembrane protein 167B 1 109089803-109096934 Predicted membrane proteins Evidence at transcript level Endometrial cancer:8.86e-4 (favourable) Expressed in all Expressed in all thyroid gland: 49.3 C21orf59 C21orf48, CILD26, FBB18, FLJ20467 ENSG00000159079 Chromosome 21 open reading frame 59 21 32592079-32612866 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA018453, HPA019055, HPA028849, CAB034170 Supported Supported Approved Rods & Rings Renal cancer:1.54e-5 (unfavourable), Endometrial cancer:8.90e-4 (favourable) Expressed in all Expressed in all testis: 78.2 COA3 CCDC56, HSPC009, MITRAC12 ENSG00000183978 Cytochrome c oxidase assembly factor 3 17 42795147-42798704 Predicted membrane proteins Evidence at protein level HPA031966 Approved Supported Mitochondria Cervical cancer:3.40e-4 (favourable), Renal cancer:6.62e-4 (favourable), Endometrial cancer:8.93e-4 (favourable) Expressed in all Expressed in all epididymis: 210.1 SSNA1 N14, NA14 ENSG00000176101 Sjogren syndrome nuclear autoantigen 1 9 137188647-137190370 Predicted intracellular proteins Evidence at protein level Endometrial cancer:8.94e-4 (favourable) Expressed in all Expressed in all testis: 101.3 TUBG1 TUBG, TUBGCP1 ENSG00000131462 Tubulin, gamma 1 17 42609676-42615234 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004608 Approved Liver cancer:1.08e-8 (unfavourable), Renal cancer:6.48e-5 (unfavourable), Endometrial cancer:8.99e-4 (favourable) Expressed in all Tissue enriched 6 testis: 242.4 smooth muscle: 39.7 DALRD3 FLJ10496 ENSG00000178149 DALR anticodon binding domain containing 3 3 49015488-49022293 Predicted intracellular proteins Evidence at protein level HPA036862 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:2.79e-5 (favourable), Endometrial cancer:9.03e-4 (favourable) Expressed in all Expressed in all fallopian tube: 58.8 FPGS ENSG00000136877 Folylpolyglutamate synthase 9 127794597-127814327 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA050488 Approved Endometrial cancer:9.08e-4 (favourable) Expressed in all Expressed in all ovary: 26.1 CYTIP B3-1, CASP, CYBR, CYTHIP, HE, PSCDBP ENSG00000115165 Cytohesin 1 interacting protein 2 157414619-157488961 Predicted intracellular proteins Evidence at protein level HPA007191 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:9.12e-4 (favourable) Expressed in all Tissue enhanced lymph node: 103.1;tonsil: 106.0 appendix: 95.3 LDLRAD1 ENSG00000203985 Low density lipoprotein receptor class A domain containing 1 1 54007299-54018186 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052489 Approved Uncertain Nucleoplasm
Golgi apparatus Endometrial cancer:9.21e-4 (favourable) Tissue enhanced Tissue enriched 21 fallopian tube: 253.3 lung: 11.8 KATNB1 ENSG00000140854 Katanin p80 (WD repeat containing) subunit B 1 16 57735730-57757250 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041165, HPA041839 Supported Supported Plasma membrane
Microtubules
Cytosol Liver cancer:3.93e-4 (unfavourable), Pancreatic cancer:8.44e-4 (favourable), Endometrial cancer:9.24e-4 (favourable) Expressed in all Expressed in all testis: 45.4 FBLN1 FBLN ENSG00000077942 Fibulin 1 22 45502238-45601135 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001612, HPA001613, CAB004393, CAB068187 Supported Approved Endoplasmic reticulum Renal cancer:3.02e-10 (unfavourable), Endometrial cancer:9.28e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 1317.9 TRPM2 EREG1, KNP3, LTRPC2, NUDT9H, NUDT9L1, TRPC7 ENSG00000142185 Transient receptor potential cation channel, subfamily M, member 2 21 44350163-44443081 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030976, HPA035260 Approved Approved Nuclear membrane Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:7.59e-4 (favourable), Endometrial cancer:9.28e-4 (favourable) Expressed in all Mixed bone marrow: 18.9 C11orf1 FLJ23499 ENSG00000137720 Chromosome 11 open reading frame 1 11 111878935-111885975 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038410, HPA057519 Uncertain Validated Nucleoplasm Renal cancer:1.39e-4 (favourable), Endometrial cancer:9.32e-4 (favourable) Expressed in all Expressed in all testis: 103.8 UFM1 bA131P10.1, C13orf20 ENSG00000120686 Ubiquitin-fold modifier 1 13 38349849-38363619 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039758 Approved Head and neck cancer:1.08e-4 (unfavourable), Endometrial cancer:9.35e-4 (favourable) Expressed in all Expressed in all endometrium: 101.0 STAT5B ENSG00000173757 Signal transducer and activator of transcription 5B 17 42199168-42276707 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004298, HPA042128, HPA049883, HPA051156 Approved Renal cancer:2.39e-5 (favourable), Pancreatic cancer:1.63e-4 (favourable), Endometrial cancer:9.37e-4 (favourable) Expressed in all Expressed in all endometrium: 70.8 SRD5A3 FLJ13352, SRD5A2L, SRD5A2L1 ENSG00000128039 Steroid 5 alpha-reductase 3 4 55346109-55373096 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027006 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable) Expressed in all Expressed in all gallbladder: 28.3 PALMD C1orf11, FLJ20271, PALML ENSG00000099260 Palmdelphin 1 99645943-99694541 Predicted intracellular proteins Evidence at protein level HPA017959, HPA030549 Approved Supported Plasma membrane
Actin filaments
Focal adhesion sites Head and neck cancer:5.90e-5 (favourable), Endometrial cancer:9.42e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 140.7 placenta: 60.0 INTS9 CPSF2L, FLJ10871, RC-74 ENSG00000104299 Integrator complex subunit 9 8 28767661-28890242 Predicted intracellular proteins Evidence at protein level HPA051615, HPA066822 Validated Nucleoplasm Renal cancer:1.91e-5 (favourable), Lung cancer:7.71e-4 (favourable), Endometrial cancer:9.45e-4 (favourable) Expressed in all Expressed in all testis: 19.8 SH2D3C NSP3 ENSG00000095370 SH2 domain containing 3C 9 127738317-127778741 Predicted intracellular proteins Evidence at protein level HPA047586 Approved Head and neck cancer:1.98e-4 (favourable), Endometrial cancer:9.47e-4 (favourable) Expressed in all Mixed spleen: 50.6 ERICH2 ENSG00000204334 Glutamate-rich 2 2 170783786-170798971 Predicted intracellular proteins Evidence at protein level HPA061010 Approved Nucleoli fibrillar center
Vesicles Renal cancer:8.98e-7 (unfavourable), Endometrial cancer:9.49e-4 (favourable) Expressed in all Tissue enriched 8 testis: 232.3 thyroid gland: 30.5 SLAMF6 CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000 ENSG00000162739 SLAM family member 6 1 160485030-160523262 CD markers, Predicted membrane proteins Evidence at protein level HPA051363, HPA051903 Uncertain Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable) Mixed Tissue enhanced lymph node: 71.8;spleen: 44.1;tonsil: 46.5 appendix: 28.3 KCTD11 C17orf36, KCASH1, REN ENSG00000213859 Potassium channel tetramerization domain containing 11 17 7351889-7354944 Predicted intracellular proteins Evidence at protein level HPA052035 Approved Approved Nucleoplasm Ovarian cancer:5.02e-4 (unfavourable), Endometrial cancer:9.55e-4 (favourable) Expressed in all Mixed esophagus: 40.0 TEP1 p240, TLP1, TP1, TROVE1, VAULT2 ENSG00000129566 Telomerase-associated protein 1 14 20365667-20413429 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029206 Supported Nucleoplasm
Vesicles Endometrial cancer:9.58e-4 (favourable) Expressed in all Mixed parathyroid gland: 46.0 HLA-A ENSG00000206503 Major histocompatibility complex, class I, A 6 29941260-29945884 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB078470 Supported Golgi apparatus
Plasma membrane Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable) Expressed in all Mixed gallbladder: 342.4 TYK2 JTK1 ENSG00000105397 Tyrosine kinase 2 19 10350529-10380676 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005157 Uncertain Approved Cytosol Head and neck cancer:1.05e-5 (favourable), Pancreatic cancer:1.02e-4 (favourable), Urothelial cancer:4.16e-4 (favourable), Renal cancer:4.43e-4 (unfavourable), Endometrial cancer:9.62e-4 (favourable) Expressed in all Expressed in all spleen: 101.6 CHP1 CHP, p22, p24, Sid470p, SLC9A1BP ENSG00000187446 Calcineurin-like EF-hand protein 1 15 41230839-41281890 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006616 Approved Approved Vesicles Renal cancer:2.79e-6 (favourable), Liver cancer:4.07e-6 (favourable), Endometrial cancer:9.63e-4 (favourable) Expressed in all Expressed in all colon: 113.0 RIBC1 FLJ32783 ENSG00000158423 RIB43A domain with coiled-coils 1 X 53422690-53431120 Predicted intracellular proteins Evidence at protein level HPA001150, HPA021613 Uncertain Approved Nuclear bodies Cervical cancer:1.90e-5 (favourable), Endometrial cancer:9.66e-4 (favourable) Mixed Group enriched 7 fallopian tube: 44.6;testis: 41.6 thyroid gland: 6.1 ZC3H12A FLJ23231, MCPIP1 ENSG00000163874 Zinc finger CCCH-type containing 12A 1 37474552-37484379 Predicted intracellular proteins Evidence at protein level HPA032052, HPA032053 Uncertain Supported Nucleoplasm
Cytoplasmic bodies Renal cancer:5.95e-5 (unfavourable), Endometrial cancer:9.67e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 114.3 gallbladder: 76.1 CD38 ENSG00000004468 CD38 molecule 4 15778275-15853230 Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002493, HPA022132, CAB025255, HPA052381 Supported Approved Plasma membrane Endometrial cancer:9.68e-4 (favourable) Expressed in all Mixed lymph node,seminal vesicle: 27.3 SLCO2A1 MATR1, OATP2A1, PGT, SLC21A2 ENSG00000174640 Solute carrier organic anion transporter family, member 2A1 3 133932696-134052184 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA013742 Supported Liver cancer:9.24e-5 (favourable), Stomach cancer:3.25e-4 (unfavourable), Endometrial cancer:9.69e-4 (favourable) Expressed in all Tissue enhanced seminal vesicle: 113.4 thyroid gland: 71.0 PLA2G2D sPLA2S ENSG00000117215 Phospholipase A2, group IID 1 20111939-20119566 Enzymes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Cervical cancer:8.15e-5 (favourable), Breast cancer:4.35e-4 (favourable), Endometrial cancer:9.74e-4 (favourable) Tissue enriched Tissue enhanced lymph node: 120.2;tonsil: 56.0 appendix: 21.3 TAPT1 FLJ90013 ENSG00000169762 Transmembrane anterior posterior transformation 1 4 16160505-16227410 Predicted membrane proteins Evidence at protein level HPA042567, HPA048658 Approved Approved Vesicles Urothelial cancer:4.18e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable), Renal cancer:8.52e-4 (favourable), Endometrial cancer:9.75e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 21.6 FAM216B C13orf30, FLJ40919 ENSG00000179813 Family with sequence similarity 216, member B 13 42781550-42791549 Predicted intracellular proteins Evidence at transcript level HPA040118 Uncertain Endometrial cancer:9.77e-4 (favourable) Group enriched Tissue enriched 8 fallopian tube: 121.7 lung: 15.2 GALNT6 GalNAc-T6 ENSG00000139629 Polypeptide N-acetylgalactosaminyltransferase 6 12 51351247-51392867 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA011762, HPA017086 Supported Approved Nucleoplasm
Golgi apparatus Ovarian cancer:5.40e-4 (favourable), Endometrial cancer:9.85e-4 (favourable) Mixed Tissue enhanced stomach: 61.9 cervix, uterine: 49.2 FERMT3 KIND3, MGC10966, MIG-2, MIG2B, UNC112C, URP2 ENSG00000149781 Fermitin family member 3 11 64206678-64223886 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA065231 Approved Vesicles Renal cancer:2.12e-5 (unfavourable), Endometrial cancer:9.89e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 114.4 lymph node: 102.9 PPP1R26 KIAA0649 ENSG00000196422 Protein phosphatase 1, regulatory subunit 26 9 135479079-135488893 Predicted intracellular proteins Evidence at protein level HPA044686, HPA063817 Uncertain Validated Nucleoplasm Renal cancer:6.20e-13 (favourable), Colorectal cancer:3.98e-4 (unfavourable), Pancreatic cancer:6.93e-4 (favourable), Endometrial cancer:9.91e-4 (favourable) Expressed in all Mixed parathyroid gland: 27.2 VPS28 ENSG00000160948 Vacuolar protein sorting 28 homolog (S. cerevisiae) 8 144423601-144428563 Predicted intracellular proteins Evidence at protein level HPA024688, HPA024745 Supported Endometrial cancer:9.93e-4 (favourable) Expressed in all Expressed in all fallopian tube: 234.2